Hepatitus A virus vaccines

ABSTRACT

A live hepatitis A virus adapted to growth in MRC-5 cells, which HAV is preferably characterized by suitable attenuation for effective vaccine administration to humans and animals without inactivation, methods for adapting HAV to growth in MRC-5, vaccine compositions and method of vaccinating humans against HAV infection.

CROSS-REFERENCE TO RELATED PATENT APPLICATIONS

This application claims the benefit of priority and is a continuation of U.S. patent application Ser. No. 09/653,499, filed on August 31, 2000, now U.S. Pat. No. 6,423,318, which claims the benefit of priority and is a divisional of U.S. patent application Ser. No. 08/475,886, filed on Jun. 7, 1995, now U.S. Pat. No. 6,113,912, which claims the benefit of priority and is a continuation-in-part of U.S. patent application Ser. No. 08/397,232, filed on Apr. 17, 1995, now U.S. Pat. No. 6,180,110, which is a U.S. National Phase of International Application No. PCT/US93/08610, filed on Sep. 17, 1993, designating the United States of America and published in English, which claims the benefit of priority and is a continuation-in-part of U.S. patent application Ser. No. 07/947,338, filed on Sep. 18, 1992, now abandoned.

This invention was made with government support under certain Collaborative Research and Development Agreements awarded by the Department of Health and Human Services. The government has certain rights in this invention.

FIELD OF THE INVENTION

The present invention relates generally to the field of vaccinal compositions useful in the prophylaxis of hepatitis A. More specifically, the invention provides a novel live hepatitis A virus (HAV), and recombinant and chimeric HAVs, the genomes of which are modified from that of their parental strain HM-175 to provide them with the ability to propagate in MRC-5 cells and retain appropriate attenuation for use as live vaccines in humans and other primates.

BACKGROUND OF THE INVENTION

In the United States, hepatitis A virus is the cause of approximately 25% of all clinical hepatitis cases, accounting for approximately 150,000 such cases. Populations at high risk of acquiring hepatitis A in industrialized countries include the socially disadvantaged, medical personnel, military personnel, staff and adult contacts of children in day-care centers, male homosexuals, drug addicts, and travelers to endemic areas.

In developing countries, virtually the entire population is infected with hepatitis A virus at an early age. Much of this infection results in subclinical and inapparent infection, but, as countries improve their hygienic conditions, infection with hepatitis A virus occurs at progressively older ages, resulting in a higher proportion of clinical disease. Thus, there is a paradoxical increase in clinical hepatitis A as the overall rate of infection diminishes. To successfully immunize against hepatitis A in the United States and in other industrialized countries as well as in developing countries, it will be necessary to vaccinate the entire pediatric population. There will be an increasing need for hepatitis A vaccines in such countries for the foreseeable future.

Research in HAV vaccines has focused on inactivated, or killed, viruses. However, in vaccine therapy there are several advantages to a live vaccine, rather than an inactivated, vaccine. With a live vaccine, one can use a lower dosage and smaller number of doses, because a live vaccine replicates in the vaccinee to produce more antigen and can stimulate the immune system of the vaccinee to make both IgA and IgM. Inactivated vaccines, such as the Salk polio vaccine which stimulates production of IgG only in vaccinees, do not protect against infection by ingested virus, only against disease.

A major obstacle to the development of live, attenuated vaccine has been the difficulty in adapting HAV to a cell line that supports rapid viral growth and is licensed for vaccine production. Wild type hepatitis A virus (HAV) grows poorly in cell culture.

U.S. Pat. Nos. 4,532,215 and 4,636,469 describe, respectively, a strain of wild-type HAV, designated HM-175 [see FIG. 6 below; also SEQ ID NOS: 1 and 2], initially isolated from human feces of a patient in Melbourne, Australia, and adapted to passage in vitro in African green monkey kidney (AGMK) culture cells and methods for obtaining same by serial passaging. U.S. Pat. No. 4,620,978 describes a vaccine employing the HAV HM-175, triply cloned in AGMK cell culture and attenuated. U.S. Pat. No. 4,894,228 describes the HAV strain, HM-175, Pass 35, passaged 35 times in AGMK, which differs from wild-type HM-175 by nucleotide changes in the genome, is attenuated for chimpanzees, elicits serum neutralizing antibodies, and is suitable for use as an attenuated HAV vaccine. It discloses the complete nucleotide sequence of clone 7 of the HAV, designated HM-175/7 or pHAV/7. See FIG. 6 below; the nucleotide changes in pHAV/7 from wt HM-175 appear above the wt sequence; the amino acid changes in pHAV/7 from wt HM-175 appear below the wt amino acid. See, also, B. C. Ross et al, J. Gen. Virol., 70:2805-2810 (1989); R. W. Jansen et al, Virol., 163:299-307 (1988); and Tedeschi et al, J. Med. Virol., 39:16-22 (1993). The disclosures of these patents and articles are incorporated by reference herein.

N. Fineschi et al, J. Hepatol., 13(4):S146-S151 (1991) describes an HAV isolate, LSH/S, which is a candidate for an inactivated vaccine. It was adapted to grow in human diploid MRC-5 cells, a preferred licensed cell for vaccine development. This document compares only a small part of its nucleotide sequence to that of wild-type HM-175.

Provost et al, J. Med. Virol., 20:165-175 (1986) described the F and F′ variants of the CR326 hepatitis A virus strain. While it is reported to be immunogenic in volunteer vaccinees, the F variant also caused abnormal serum ALT levels in a substantial proportion of individuals.

Another publication from this group of investigators has described further work with the F′ variant [K. Midthun et al, J. Infect. Dis., 163:735-739 (1991)]. They observed that the immunogenicity of the F′ vaccine product is dose dependent, i.e., a 10^(7.3) TCID₅₀ evoked an antibody response in 100% of volunteers within 9 weeks after immunization whereas lower doses were immunogenic in a smaller percentage of volunteers, and anti-HAV was observed 4 to 6 months after immunization. Chinese investigators have also described studies of a potential live attenuated hepatitis A vaccine prepared from the H2 strain of HAV [J. S. Mao et al, J. Infect. Dis., 159:621-624 (1989)]. Twelve volunteers received the vaccine by the subcutaneous route.

A live attenuated hepatitis A vaccine could have a significant impact on the eradication of the disease. It could be anticipated that a live attenuated vaccine which requires minimal purification and no adjuvant would be less costly than presently available inactivated hepatitis A vaccines.

There is a need in the art for methods and compositions for effective vaccination of humans and animals against hepatitis A.

SUMMARY OF THE INVENTION

In one aspect, the present invention provides a live hepatitis A virus adapted to growth in MRC-5 cells. This virus is preferably characterized by attenuation. The attenuated virus may be recombinant or chimeric. More preferably, the HAV is characterized by suitable attenuation for effective vaccine administration to primates or humans, without inactivation. The HAV may be characterized by containing one or more of sixteen specific nucleotides which differ from nucleotides in the same position in the genome of HAV HM-175, Pass 35.

In another aspect, the invention provides a vaccine useful for protecting humans or other primates against hepatitis A which vaccine contains at least one above-described HAV adapted to growth in MRC-5 cells. Preferably, the vaccine is effective in inducing a protective antibody response without adjuvant.

In still another aspect, the invention provides a method for protecting humans against hepatitis A virus infection which comprises administering to the human patient an effective amount of a vaccine composition of this invention.

In a further aspect, the invention provides a method for preparing a live HAV adapted to growth in MRC-5 cells by incorporating into a selected area of the genome of an HAV one or more of thirteen specific nucleotides. The HAV genome so modified is preferably HAV HM-175, Pass 35 [SEQ ID NO: 3] or a related cell culture-adapted mutant.

In another embodiment, the HAV may be constructed using another HAV cDNA clone and inserting appropriate nucleotides into its genome. According to this method an attenuated, MRC-5-adapted HAV is provided without requiring further passaging in MRC-5 or other primate cell lines.

In still another aspect, the invention provides polynucleotide sequences encoding the recombinant or chimeric HAVs described above. Preferably these sequences are cDNAs useful as master seeds for vaccine preparation.

Other aspects and advantages of the present invention are described further in the following detailed description of the preferred embodiments thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graph plotting anti-HAV antibody production vs. time (weeks) vs. ALT and ICD levels for the chimpanzee studies with HAV virus 4380 and subsequent challenge with wild-type HAV, as described in Example 1. These results were obtained from a chimpanzee that was infected with the attenuated HAV at time 0 and challenged with virulent virus at week 28.

FIG. 2 is a graph plotting anti-HAV antibody production vs. time (weeks) vs. ALT and ICD levels for the chimpanzee studies with HAV virus 4380 and subsequent challenge with wild-type HAV, as described in Example 1. The conditions were the same as for FIG. 1.

FIG. 3 is a graph plotting anti-HAV antibody production vs. time (weeks) vs. ALT and ICD levels for the chimpanzee studies with HAV virus 4380 and subsequent challenge with wild-type HAV, as described in Example 1. The conditions were the same as for FIG. 1.

FIG. 4 is a graph plotting anti-HAV antibody production vs. time (weeks) vs. ALT and ICD levels for the chimpanzee studies with HAV virus 4380 and subsequent challenge with wild-type HAV, as described in Example 1. These results were obtained from the chimpanzee that was not infected with the attenuated HAV, and therefore developed hepatitis following challenge with the virulent virus. The conditions were the same as for FIG. 1.

FIG. 5 is a bar graph of endpoint dilutions of several of the chimeric viruses, Viruses #2, 3, 4, 5, and 6, listed in Table VI.

FIG. 6 illustrates the nucleotide sequence of wt HM-175 [SEQ ID NO: 1] and its amino acid sequence [SEQ ID NO: 2]. Appearing above the nucleotides are the nucleotide changes of HM-175/7 (pHAV/7) [SEQ ID NO: 3]and appearing below the amino acids of wt HM-175 are the amino acid residues which are characteristic of pHAV/7 [SEQ ID NO: 4]. The dashes represent nucleotides present in wt HM-175 which do not appear in pHAV/7.

FIG. 7 provides the genomic map of the mutations that occurred during passage in AGMK cells and MRC-5 cells (both MRC5/9, which is HAV 4380; and the clone MR8 described in Example 5 below), and shows those mutations which differentiate the MR8 clone from the HAV 4380 (MRC5/9) virus. Mutations noted in each successive bar diagram represent only newly acquired mutations and resulting amino acid changes, if any, with absent mutations designed by dotted lines.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides hepatitis A virus (HAV) adapted to growth in the human fibroblast-like cell line, MRC-5, a cell substrate suitable for commercial production and licensing of inactivated and live, attenuated hepatitis A vaccines. In addition to such adapted HAVs, the invention provides a method for adapting a selected HAV to growth in that human cell line and preparing an MRC-5-adapted, attenuated HAV without passaging in other primate cells. The HAV of this invention and the preparative method also preferably provides the HAV with sufficient attenuation to enable its efficacy as a vaccine for humans and animals.

Although the prior art discloses other candidate vaccine strains of hepatitis A virus which have been adapted to growth in human diploid fibroblasts, the genetic changes in the virus genome necessary and sufficient for such adaptation have not been characterized. Thus, these strains cannot be manipulated in vitro to assure a reproducible and fully-characterized vaccine product.

The present invention is based on the wild-type HAV, strain HM-175, which is described in detail in the above-cited and incorporated art [Cohen et al., J. Virol., 61:50-59 (1987); SEQ ID NOS: 1 and 2]. Briefly described, the wild type, infectious HAV HM-175 virus was previously adapted to growth in primary African green monkey kidney (AGMK) cells at 37°C. After 26 passages in AGMK, the virus was cloned three times in AGMK cells by serial dilution, then passaged three more times to provide passage 32 (P-32). P-32 was found to be attenuated as described in R. A. Karron et al, J. Infec. Dis., 157:338-345 (1988).

The P-32 virus described above was passaged three more times in AGMK, and molecularly cloned. The virus that was cloned was called P-35 and the full-length clone was referred to as-pHAV/7 [SEQ ID NOS: 3 and 4]. pHAV/7 is an infectious-cDNA clone of the virus that can be maintained in a monoclonal state and amplified at will with diminished risk of spontaneous mutations. The resulting P-35 virus grew well in fetal rhesus monkey kidney (FRhK) cells and minimally in human fibroblastoid lung cells (MRC-5).

U.S. Pat. No. 4,894,228 and Cohen et al., Proc. Natl. Acad. Sci., USA, 84:2497-2501 (1987) provide the HAV nucleotide sequence of wild-type HAV strain HM-175 (see, FIG. 1 of the patent; SEQ ID NO: 1) and the nucleotide differences between HAV HM-175, Pass 35, clone pHAV/7 [SEQ ID NO: 3], and the wild-type sequence. Thus, these documents, incorporated by reference, provide the nucleotide sequence of pHAV/7, P-35 [SEQ ID NO: 3]. The nucleotide numbers used herein to which the mutations of this invention correspond (Tables I and VI below) are the nucleotide numbers assigned to positions of the wild-type sequence of FIG. 6 [SEQ ID NOS: 1 AND 2] from U.S. Pat. No. 4,894,228 containing the mutations for P-35. Note that the nucleotides which are deleted from wild-type virus to P-35 are assigned the nucleotide position of the wild-type sequence and appear above the wt sequence of FIG. 6 as dashes (—). Thus, for example, nucleotide position 131 represents a nucleotide that was deleted between wild-type and P-35.

The P-35 cDNA, i.e., HAV/HM-175/7, is on deposit at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. under Accession No. 67495, deposited Aug. 7, 1987. One of skill in the art can readily construct the nucleotide and amino acid sequences of P-35 by use of the above-cited art and its deposit. See, also, SEQ ID NOS: 3 and 4.

Yet another HAV virus was provided as follows. The P-32 AGMK cell-adapted and attenuated virus was manipulated to enable it to be adapted for growth in MRC-5 cells, so that it is available for large scale vaccine production. Passage 32 was double plaque cloned in MRC-5 to form Passage 37. A selected clone 25-4-21 of Passage 37 was passaged once in MRC-5. The resulting Passage 38 was passaged three times in MRC-5 cells, resulting in Passage 41, the master seed, designated 87J19. This master seed virus stock is also referred to as HAV 4380 or MRC5/9 (the latter term reflects its ability to grow in MRC5 cell, as well as the fact that it is 9 passages from P32). This virus is referred to throughout this disclosure by the name HAV 4380.

Live attenuated virus HAV 4380, was deposited on Apr. 4, 1990 at the Collection Nationale de Cultures de Microorganismes, Institut Pasteur, 25, rue du Docteur Roux, 75724, Paris CEDEX 15 under Accession No. 1936, which deposited HAV 4380 virus has a nucleic acid sequence shown in SEQ ID NO:5. This deposit was made under the Budapest Treaty on the International Recognition of the Deposit of Microorganisms and has not been publicly disseminated. HAV 4380 is a cell culture-adapted and attenuated strain of hepatitis A virus strain HM-175, adapted to growth in a human fibroblast cell line (MRC-5) suitable for vaccine development by incubation at a reduced temperature of 32-35° C. Growth of the virus is determined by detection of viral antigen in a serological assay. The adapted virus is purified by plaque-purification, using an accepted method (radioimmunofocus assay).

As stated above, after a total of nine passages in MRC-5 cells at reduced temperature, the resultant virus was examined for its biological characteristics in cell culture and in two primate species that are considered to be surrogates for man, i.e., marmosets and chimpanzees. See, e.g., Example 1 below. The HAV 4380 virus was found to be temperature-sensitive (i.e., only grew at reduced temperatures) in MRC-5 cells but was still capable of growing at 37° C. in primary African green monkey kidney cells. The virus was further attenuated in virulence, compared to the parent virus HM-175, P-32, when tested in chimpanzees and marmoset monkeys, in which species the virus replicated poorly or not at all. This reduced capacity for replication in primates was further confirmed in human volunteers, as described in Example 2.

A candidate inactivated hepatitis A vaccine was prepared from the HAV 4380 and demonstrated to be safe (i.e., it does not produce hepatitis or other serious adverse effects) and immunogenic in humans. It was also found to induce antibody production without adjuvant. HAV 4380, as it currently exists, grows well in a cell substrate suitable for commercial vaccine production. It also does not infect human beings when administered by the oral or intravenous route at doses of up to 10⁷ tissue culture infectious doses, even when not inactivated. HAV 4380 is suitable for use as a live HAV vaccine in humans. However, as indicated in Example 2, vaccine 4380 is believed to be somewhat over-attenuated, because it is not infectious, which characteristic reduces its efficiency when used as an attenuated vaccine.

In order to produce other vaccine candidates which are maximized for desirable levels of attenuation and good growth in MRC-5 cells, the inventors determined the genetic changes that occurred in the genome of the MRC-5-adapted HAV 4380 virus that altered its growth characteristics and made it more suitable for vaccine production than the related AGMK-adapted virus HM-175, Passage 35 [SEQ ID NO: 3]. The discovery of the following mutations in the nucleotide sequences in HAV 4380, when compared to HM-175 Pass 35 [SEQ ID NO: 3; Cohen et al, cited above; and U.S. Pat. No. 4,894,228, FIG. 1], permit the manipulation of the HAV genome by genetic engineering techniques.

Thus, knowledge of the genomic differences between the AGMK-adapted passages of HM-175 and the more attenuated 4380 permit the construction of chimeric viruses having the improved growth characteristics, i.e., rapid and efficient growth in MRC-5 cell culture, but with a level of attenuation of virulence for primate species, including man, that will permit the virus to replicate efficiently without producing hepatitis or other untoward effects. This invention permits the design of a chimeric HAV that can achieve the optimum characteristics for a candidate live-attenuated hepatitis A vaccine. Such a virus will also permit the design of preferred inactivated vaccine candidates, if desired. The present invention identifies the mutations that are believed to have occurred during adaptation to growth of the HM-175 HAV, passage 32, strain in MRC-5 cells. One or a combination of these mutations are responsible for MRC-5 cell adaptation and overattenuation in HAV 4380.

The nucleotide sequence of the MRC-5 cell-adapted virus HAV 4380 was compared with that of the AGMK-adapted, HM-175 virus, passage 35, clone 7 [SEQ ID NO: 3]. Nucleotide consensus sequences were determined directly from polymerase chain reaction products.

The inventors have discovered that there are at least sixteen unique nucleotide differences between the Pass-35 HM-175/7 virus and the MRC-5-adapted virus 4380. Table I lists these sixteen mutations by nucleotide differences and resulting amino acid (AA) differences, if any, acquired by the MRC-5-adapted virus HAV 4380. Note that the partial sequence of LSH/S HAV of Fineschi et al., cited above, overlaps with only the mutation observed at position 5145.

In the Table, A represents adenine, G represents guanine, C represents cytosine, and T represents thymine; Leu represents leucine, Phe represents phenylalanine, Ile represents isoleucine, Val represents valine, Ser represents serine, Lys represents lysine, Asn represents asparagine, Thr represents threonine and Arg represents arginine. Note that the nucleotide positions in Table I correspond with the nucleotide positions of wt HM-175; see FIG. 6. This is true for all nucleotide positions referred to throughout this specification.

TABLE 1 Difference in Nucleotide Sequence of MRC-5-Adapted Hepatitis A Virus: Comparison with sequence of HM-175/7 (P-35) Nucleotide Region of Change Genome AA Change 591 A to G 5′ nc NA 646 G to A 5′ nc NA 669 C to T 5′ nc NA 687 T to G 5′ nc NA 2750 C to T VP1 No change 3027 T to A 2A Ser to Thr 3196 G to A 2A Ser to Asn 3934 A to G 2B Lys to Arg 4418 A to T 2C Leu to Phe 4563 A to G 2C Ile to Val 4643 A to T 2C No Change 5145 A to G 3A Ile to Val 5745 A to T 3C Thr to Ser 6908 T to C 3D No change 7032 C to T 3D No change 7255 A to T 3D Asn to Ile

Note that two previously reported changes at nucleotide position 2864 from U to A in VP1, resulting in no amino acid change, and at nucleotide position 6216 from U to C in 3D, resulting in no amino acid change, are nucleotides that were actually present in a subset of HM175 wild-type cDNA clones made from virus before passage in cell culture. These changes occur due to microheterogeneity in some wild-type subpopulations of HM-175/7, as reported in Cohen, Proc. Natl. Acad. Sci., USA, 84:2497 (1987) and Cohen, J. Virol., 61:50 (1987), cited above. These nucleotides were present in the wt HM-175 sequence used to prepare HAV 4380.

The nucleotide changes at positions 2750, 3027 and 7255 were previously unreported. However, all of these nucleotide changes are contained in the HAV 4380 deposited virus.

A nucleotide change at nucleotide position 6383 from a C to a U in region 3D of the HAV genome, which would cause no change in amino acid sequence, has also been detected in some clones. This change is also believed to occur in some HAV strains due to microheterogeneity in the Virus 4380, since it was not present in a PCR consensus sequence, but was present in a subclone used to make a full length virus cDNA.

New HAV vaccine candidates are designed by introducing one or more of the nucleotides mentioned in Table 1 and discussed above into an HAV at a nucleotide position homologous to the nucleotide position in the genomic sequence of the wt HM-175 [SEQ ID NO:1 ] or the AGMK-adapted virus HM-175, Pass 35 [SEQ ID NO: 1]. These nucleotides identified in Table I may be introduced at analogous and/or homologous nucleotide positions to those of P-35 in the genomic sequences of other HAV strains and variants to produce a recombinant or chimeric HAV of this invention. By the phrase “analogous or homologous nucleotide position” is meant a nucleotide in an HAV other than HAV HM-175, Pass 35 which is present in the same viral region, e.g., 2C, 3D and the like, at a position in that region similar to that of the nucleotide of Table I. In other words, the nucleotide position may differ in position number due to deletions in other regions of the virus; but one of skill in the art can readily determine its functional similarity to the nucleotide position in HM-175 [SEQ ID NO: 1] or in HM-175, Pass 35 [SEQ ID NO: 3].

While such nucleotide positions may not have the identical nucleotide position numbers corresponding to the wild-type HM-175 [SEQ ID NO: 1], it is anticipated that these analogous and/or homologous positions can be readily identified to enable HAVs other than strain HM-175 derivatives to be modified to create novel HAVs according to this invention.

Similarly, the inventors are able to manipulate the genome of a progenitor or intermediate of HAV 4380 with resort to this knowledge and can thereby ‘reverse’ certain mutations in 4380 to create new chimeric HAV viruses. One or more of these nucleotides, or varying combinations thereof, can be incorporated, by chimera formation or oligonucleotide-directed mutagenesis, into an HAV strain, most readily the cDNA clone HAV/HM-175/7, to produce new viable virus which has acquired the ability to grow in MRC-5 cells. Other EM-175 HAV derivatives are available from the American Type Culture Collection under ATCC designation numbers VR 2089, VR 2090, VR 2091, VR 2092, VR 2093, VR 2097, VR 2098, and VR 2099. These and other HAVs may be employed to derive desired HAVs of this invention. Since there are indications that the MRC-5-adapted virus 4380 may be over-attenuated for humans, it is important to be able to remove or introduce selected mutations into HM-175. The construction of nine exemplary chimeric viruses containing one or more such mutations is described in detail in Example 3 below.

The mutagenic and genetic engineering techniques employed to construct chimeric or recombinant HAVs which incorporate one or more of these mutations are conventional and known to those of skill in the art [see, for example, Sambrook et al., Molecular Cloning. A Laboratory Manual, 2d edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., (1989)]. Other conventional techniques, including polymerase chain reactions and chemical synthetic techniques may also be used to design HAVs of this invention. Similarly, it is anticipated that homologous mutations may be made using other HM-175 passages. It also may be possible to adapt similar changes to HAV strains other than HM-175 by introducing these nucleotides into homologous regions.

Chimeric and recombinant viruses of this invention may be designed by application of similar techniques and selecting one or more different combinations of the nucleotides (mutations) appearing in Tables I and VI. For example, data from growth analyses of the chimeric viruses of Example 3 demonstrate that one or more of the four MRC-5 specific mutations in the 5′ non-coding region (mutations at nucleotide positions 591, 646, 669, and 687 of HM-175/7) and one or both of the MRC-5 specific mutations in the 2C region (mutations at nucleotide positions 4418 and 4643 of HM-175/7) are desirable for optimal growth of the virus in MRC-5 cells.

Additional viruses employing other combinations of these mutations were prepared by conventional cloning and PCR techniques. When acting together and in the presence of the 5′ non-coding and 2C mutations of Table I, MCR-5- specific mutations in P3 and VP1/2AB in every instance increased growth efficiency in MRC-5 cells. Similarly it was noted that the mutations in the 5′ non-coding region increased growth efficiency in every virus and in different background genotypes. Studies have shown that the 5′ non-coding mutations can reduce biochemical evidence of hepatitis. Other mutations may also be involved.

Specific exemplary chimeric HAVs of this invention are characterized by the mutations in the genome of HAV HM-175/7 that appear in viruses designated #2 through #10 in Table VI of Example 3 below. However, other chimeric HAVs may be readily prepared by application of the same methods known to those of skill in the art.

HAVs of this invention may be characterized by the presence of one or more of these nucleotides of Tables I or VI in analogous genomic positions of HAV HM-175 derivatives or other HAV strains. HAVs of this invention may also be characterized by two or more such nucleotides, where one nucleotide in the HAV parent strain is a guanine (G) at position 5145 of pHAV/7 or the analogous position of another HAV strain.

It is further anticipated that additional mutations may appear in a few regions of HAV that have yet to be sequenced. The mutations appearing in Table I may be incorporated in any combination, and/or with other mutations yet to be identified to construct a number of chimeric or recombinant HAVs with desired characteristics for use as live HAV vaccines.

Additional chimeras and recombinant viruses constructed by oligonucleotide-directed mutagenesis may be designed and evaluated for assessment of the individual effects of the mutations and combinations thereof on viral growth in MRC-5 cells and on adaptation to growth in selected cell culture. The attenuation phenotype of these chimeric viruses may be evaluated in marmosets or chimpanzees by techniques such as described below in Example 1 for HAV 4380.

Also provided by this invention are the polynucleotide sequences encoding the HAVs of this invention. Such polynucleotide sequences are preferably cDNA sequences, which can form a master seed for the HAV vaccine. A cDNA sequence of this invention comprises a DNA sequence encoding a selected HAV genome characterized by the presence of one or more of the nucleotides identified as the thirteen mutations in Table I in any desired combination which imparts desired characteristics to the novel HAV. Such cDNAs may be obtained by conventional techniques known to those of skill in the art. See, e.g., Sambrook et al, cited above, and U.S. Pat. No. 4,894,228.

Thus, the present invention provides a live vaccine composition useful in protecting against HAV infection and a prophylactic method entailing administering to a primate, preferably a human, an effective amount of such a composition. This vaccine composition may contain one or more of the HAVs of the invention, including HAV 4380, as well as the chimeric and recombinant HAVs described herein. The vaccine composition may also contain mixtures of two or more of the HAVs, if desired.

A vaccinal composition may be formulated to contain a carrier or diluent and one or more of the HAVs of the invention. Suitable pharmaceutically acceptable carriers facilitate administration of the viruses but are physiologically inert and/or nonharmful. Carriers may be selected by one of skill in the art. Exemplary carriers include sterile saline, lactose, sucrose, calcium phosphate, gelatin, dextrin, agar, pectin, peanut oil, olive oil, sesame oil, and water. Additionally, the carrier or diluent may include a time delay material, such as glycerol monostearate or glycerol distearate alone or with a wax. In addition, slow release polymer formulations can be used.

Optionally, the vaccine composition may further contain preservatives, chemical stabilizers, other antigenic proteins, and conventional pharmaceutical ingredients. Suitable ingredients which may be used in a vaccinal composition in conjunction with the viruses include, for example, casamino acids, sucrose, gelatin, phenol red, N-Z amine, monopotassium diphosphate, lactose, lactalbumin hydrolysate, and dried milk. Typically, stabilizers, adjuvants, and preservatives are optimized to determine the best formulation for efficacy in the target human or animal. Suitable preservatives include chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, the parabens, ethyl vanillin, glycerin, phenol, parachlorophenol.

A vaccine composition of this invention is most preferably produced without an adjuvant. However, where necessary, one or more of the above described vaccine components may be admixed or adsorbed with a conventional adjuvant. The adjuvant is used as a non-specific irritant to attract leukocytes or enhance an immune response. Such adjuvants include, among others, mineral oil and water, aluminum hydroxide, Amphigen, Avridine, L121/squalene, D-lactide-polylactide/glycoside, pluronic plyois, muramyl dipeptide, killed Bordetella, saponins, and Quil A.

Alternatively, or in addition to the HAV of the invention, other agents useful in treating HAV infection, e.g., immunostimulatory agents, are expected to be useful in reducing and eliminating disease symptoms. The development of vaccine or therapeutic compositions containing these agents is within the skill of one of skill in the art in view of the teaching of this invention.

According to the method of the invention, a human or an animal may be vaccinated against HAV infection by administering an effective amount of a vaccine composition described above. An effective amount is defined as that amount of HAV vaccine capable of inducing protection in the vaccinee against HAV infection and/or against hepatitis. The vaccine may be administered by any suitable route. Such a composition may be administered parenterally, preferably intramuscularly or subcutaneously. However, it may also be formulated to be administered by any other suitable route, including orally.

Suitable effective amounts of the HAVs of this invention can be determined by one of skill in the art based upon the level of immune response desired. Such a composition may be administered once, and/or a booster may also be administered. However, suitable dosage adjustments may be made by the attending physician or veterinarian depending upon the age, sex, weight and general health of the human or animal patient.

Similarly, suitable doses of the vaccine composition of the invention can be readily determined by one of skill in the art. The dosage can be adjusted depending upon the human patient or the animal species being treated, i.e. its weight, age, and general health.

The following examples illustrate the preferred methods for obtaining HAVs of the invention and using them as vaccine compositions. These examples are not intended to limit the scope thereof.

EXAMPLE 1 TEST OF MRC-5-ADAPTED HAV 4380 VACCINE In MARMOSETS AND CHIMPANZEES

The attenuation of hepatitis A virus (HAV), strain HM-175, by serial passage in cell culture has previously been demonstrated. Following 32 passages in primary AGMK cells, the virus was completely attenuated for chimpanzees and almost completely attenuated for marmosets. Subsequently, according to this invention, the virus was adapted to growth in MRC-5 cells and recloned by plaque purification.

HAV 4380 was prepared from Volunteer lot 87J19, passage level 41 of strain HM-175 HAV that was derived from previously characterized passage levels of the virus that have also been prepared as volunteer pools. Two such earlier passage pools were shown to be attenuated for chimpanzees and marmosets. However, neither was administered to volunteers because it was recognized that primary African green monkey kidney cells, the substrate for those volunteer pools, would not be available in sufficient quantities to produce an economically viable vaccine. Therefore, the virus was adapted to MRC-5-cells and further passaged to prepare volunteer lot 87J19 or HAV 4380.

The purpose of this experiment is to test the level of attenuation of this virus for marmosets and chimpanzees, prior to phase I trials in volunteers. Lot 87J19 was tested for safety and immunogenicity in four chimpanzees and four Saguinus mystax marmosets. Two additional marmosets served as uninoculated controls. The chimpanzees used in this study were bred and raised in captivity the marmosets were wild-caught animals. An inoculum of 10₄ TCID₅₀ of candidate vaccine lot 87J19 was administered intravenously to each animal. Residual inoculum was frozen and the titer reconfirmed subsequently in two different laboratories.

According to the experimental protocol, marmosets identified by the arbitrary ID numbers 570, 572, 566, and 575 and chimpanzees identified by the arbitrary ID numbers 1300, 1333, 1309 and 1313 received an inoculum of HAV 4380 from Clone 25-4-21, Lot 87 J 19575, 17/11/87 at a dose and route of administration of 10⁻³ dilution/1 ml/I.V. Marmosets No. 541 and 578 received a diluent at a dose and route of 1 ml/I.V.

A. Infection:

Three of four chimpanzees and one of four marmosets were infected, as determined by development of anti-HAV detectable by commercial radioimmunoassay (HAVAB, Abbott Laboratories, Chicago, Ill.). The chimpanzees seroconverted ten to eleven weeks following inoculation; the single marmoset seroconversion occurred eight weeks following inoculation. This marmoset subsequently died on week eleven of the study and another, noninfected, marmoset subsequently died on week fourteen, but neither death was attributable to the inoculum.

All three chimpanzees that seroconverted also developed IgM anti-HAV. Two of these, Chimp 1309 and Chimp 1313, developed IgM anti-HAV on weeks ten and thirteen, respectively, when tested by the standard HAVAB-M (Abbott Laboratories, Chicago, Ill.) at a final serum dilution of 1:4,000. When sera were tested at a dilution of 1:40, Chimp 1313 and Chimp 1333 seroconverted at weeks nine and five, respectively. The HAVAB-M test is a capture assay utilizing anti-human IgM and has not been standardized for use with sera from primates less closely related to man than to the chimpanzee. For this reason, the marmosets were not tested for IgM anti-HAV.

B. Biochemistry:

Biochemical evidence of hepatitis was monitored by weekly determinations of serum alanine amino transferase (ALT) and isocitric dehydrogenase (ICD). The former is the most reliable indirect means of diagnosing hepatitis in the chimpanzee and the latter is comparably sensitive for evaluating marmosets. None of the chimpanzees or marmosets had elevation of liver enzymes attributable to the inoculum. All values for chimpanzees were within normal limits. The only infected marmoset, number 582, had normal liver enzymes up to the time of its death. Marmosets 566, 570, and 578 each had one or more abnormal liver enzyme values, but the first two of these animals were not infected by the inoculum, as judged by failure to seroconvert, and the third was an uninoculated negative control.

Marmosets often have less stable liver enzyme values than chimpanzees, in part because they are, by nature, relatively fragile animals and because they are jungle-caught and therefore usually infected with a variety of endo- and ecto-parasites, including microfilaria.

C. Histology:

Histologic sections prepared from serial weekly liver biopsies obtained from the chimpanzees and marmosets were evaluated under code for histopathologic changes. Although some animals had a high base-line of histopathologic changes, none of the animals had evidence of histopathologic changes more severe than those seen in preinoculation biopsies. Equally important, there were no histologic changes that were temporally related to seroconversion in infected animals. The two marmosets that died were subjected to more extensive evaluation. Both animals had evidence of systemic disease that was probably etiologically related to their deaths, but histologic changes in the liver were diagnostic of chronic, not acute, disease and therefore not related to the inoculum.

A comparison of histopathologic changes observed in chimpanzees and marmosets with these various volunteer pools and wild-type virus was performed. See Tables II and III below.

TABLE II HISTOPATHOLOGY: CHIMPANZEES Liver Histopathology Range of Inoculum* # Inoc. # Infected # Severity** W.T. 4 4 4 ±-3+ P-21 6 6 1 0-3+ P-32 6 6 0 0 MRC-5 4 3 0 0 *Dose: 10³-10⁵ ID₅₀ IV **Scale of 0-3+

TABLE III HISTOPATHOLOGY: MARMOSETS Liver Histopathology Range of Inoculum* # Inoc. # Infected # Severity** W.T. 4 4 4 1+-2+ P-21 8 8 8 1+-3+ P-32 5 5 3  0-2+ MRC-5 4 1 0 0 *Dose: 10³-10⁵ ID₅₀ IV **Scale of 0-3+

Lot 87J19 appears to be more attenuated than the other volunteer pools or wild-type virus, based upon infectivity and severity of histopathologic changes.

D. Immunofluorescence:

Serial snap-frozen liver biopsies obtained from infected animals were evaluated for expression of viral antigen by immunofluorescence. Only one animal, Chimp 1313, was definitely but weakly positive for intrahepatic viral antigen. This animal was positive for only one week. These results were compared with those obtained in the previous study of other volunteer pools and wild-type virus. As seen in Tables IV and V, intrahepatic replication was further diminished in both chimpanzees and marmosets when compared with the AGMK-grown virus and wild-type virus.

TABLE IV VIRAL REPLICATION IN THE LIVER: MARMOSETS (IMMUNOFLUORESCENCE) Mean Mean Inoculum* # Inoc. # Infected Peak Duration (wks) W.T. 4 4 2.5+   12.2 P-21 8 8 1+ 3.5 P-32 5 5 <1+  2.4 MRC-5 4 1 0  0 *Dose: 10³-10⁵ ID₅₀ I.V.

TABLE V VIRAL REPLICATION IN THE LIVER: CHIMPANZEES (IMMUNOFLUORESCENCE) Mean Mean Inoculum* # Inoc. # Infected Peak Duration (wks) W.T. 4 4  1+ 1.8 P-21 6 6 <1+ 0.5 P-32 6 6 <1+ 0.6 MRC-5 4 3 <1+ 0.3 *Dose: 10³-10⁵ ID₅₀ I.V.

E. Protection:

Although the single infected marmoset on study died, all four chimpanzees were available for challenge with wild-type parent HAV to determine if the levels of anti-HAV present in infected animals were protective. Consequently, the three infected and one uninfected animal were challenged with approximately 10³ chimpanzee infectious doses of wild-type HM-175 strain HAV (human stool suspension), administered intravenously (FIGS. 1 through 4).

All three previously infected chimpanzees were protected against type A hepatitis, as measured by persistently normal serum enzyme values (FIGS. 1 through 3). All three protected animals had an anamnestic antibody response to the challenge virus, suggesting that there was limited replication. In contrast, the previously uninfected chimpanzee developed high enzyme values diagnostic of hepatitis following challenge with wild-type virus (FIG. 4). Thus, volunteer pool 87J19 produced an inapparent infection in chimpanzees that stimulated protection against subsequent challenge with virulent wild-type virus.

The results of these portions of the experiment demonstrate that volunteer pool 87J19 of HAV 4380, strain HM-175 (adapted to MRC-5 cells) was significantly more attenuated for chimpanzees and marmosets than its parent, HAV, strain HM-175 (AGMK, Pass-32). It is clear from these studies that HAV 4380, strain HM-175 volunteer pool 87J19, is highly attenuated for chimpanzees and marmosets which are accepted surrogates for man in the study of hepatitis A viruses.

EXAMPLE 2 CLINICAL STUDY OF VOLUNTEERS.

In this clinical trial, volunteers received increasing titers of the live attenuated hepatitis A vaccine 4380, volunteer pool 87J19, which was previously tested in chimpanzees and marmosets as described in Example 1. These pre-clinical studies demonstrated that the vaccine was safe, immunogenic, and efficacious in experimental animal models.

Volunteers were admitted to a closed clinical ward at the United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Md. Eight volunteers received the live attenuated hepatitis A vaccine (1 ml) by the oral route in the following manner: two received a 10⁴ TCID₅₀ dose, two a 10⁵ TCID₅₀ dose, two a 10⁶ TCID₅₀ dose, and two a 10⁷ TCID₅₀ dose. Six volunteers received the vaccine by the intramuscular route in the deltoid area in the following manner: 2 received a 10⁵ TCID₅₀ dose, 2 a 10⁶ d TCID₅₀ dose and 2 a 10⁷ TCID₅₀ dose.

Each volunteer remained on the ward for three days after immunization. Local or systemic side effects were monitored during the admission period and for 12 weeks following the immunization. Volunteers were asked to return at 6 and 12 months for serological follow-up.

Sera were obtained prior to immunization and once a week for the next 12 weeks. In volunteers who completed the appropriate follow-up time, sera were also obtained at 6 and 12 months after initial administration of vaccine. Serum specimens were tested for alanine aminotransferase (ALT) and antibody to hepatitis A. ALT was tested with a Kodak EKTA Chem 700XR analyzer (Rochester, N.Y.); normal values were 0 to 50 IU/ml. Antibody to hepatitis A was tested by four different methods, including a commercial radioimmunoassay (HAVAB, Abbott Laboratories, N. Chicago, Ill.). Second, an enzyme-linked immunoassay developed by SmithKline Beecham (SKB-ELISA), which was more sensitive than the standard HAVAB, in which a level of ≧20 milli-International Units (mIU) was considered positive. Selected sera were tested by the RIFIT (radioimmunofocus) assay for neutralizing antibody to hepatitis A. With this test, a serum titer of ≧1:10 was considered positive [S. M. Lemon et al, J. Infect. Dis., 148:1033-1039 (1983)]. Finally sera were tested for IgM anti-HAV by commercial radioimmunoassay (HAVAB-M, Abbott Laboratories, N. Chicago, Ill.).

Stools were collected from the volunteers two to three times per week for the first 12 weeks and were tested for the presence of hepatitis A virus by radioimmunoassay [R. H. Purcell et al, J. Immunol., 116:349-356 (1976)] and molecular biology techniques [J. Ticehurst et al, J. Clin. Microbiol., 25:1822-1829 (1987)].

All volunteers remained healthy during the follow-up period (14 weeks to one year). No systemic complaints were present immediately after immunization or during long-term follow-up. Serum alanine aminotransferase levels remained normal in all 14 individuals during the period of observation.

Antibody to hepatitis A was not observed in any of the eight volunteers who received the vaccine by the oral route or in the two volunteers who received the 10⁵ TCID₅₀ dose by the intramuscular route. The four volunteers who received higher doses of vaccine (10⁶ TCID₅₀ or 10⁷ TCID₅₀) all had detectable antibody by the SKB ELISA as early as 3 weeks after immunization. Detectable levels persisted for the 12 weeks of observation. Selected sera tested for neutralizing antibody had titers ranging from 1:10 to 1:40 in a volunteer who received a 10⁶ dose and 1:40 to 1:2560 in a volunteer who received a 10⁷ TCID₅₀ dose. The commercial HAVAB assay detected anti-HAV in only one of the volunteers, who received the 10⁷ dose. IgM anti-HAV was not detected in any of the volunteers who received the vaccine orally. Sera from volunteers who received 10⁷ TCID₅₀ I.M. had detectable IgM anti-HAV.

Stools from all volunteers who received the oral vaccine were negative for hepatitis A virus, while those from volunteers who had received the vaccine by intramuscular route are in the process of being tested.

Although only a small number of volunteers received the vaccine orally, it appeared that the vaccine is not immunogenic by this route. This is likely due to over-attenuation of the virus, although other causes, such as inactivation in the gastrointestinal tract or too small an inoculum, should be considered. The vaccine was safe and immunogenic by the intramuscular route at doses of 10⁶ and 10⁷ TCID₅₀. The antibody response was prompt: anti-HAV was observed within 3 weeks of immunization, persisted during the period of observation, and did not diminish in titer. Such a response to one single inoculation of a preparation which lacked an adjuvant, is remarkable. If indeed, anti-HAV persists for a long time after one dose, the logistics of administration of this product would be much simpler and more successful than with present hepatitis A vaccines. The presence of IgM anti-HAV in volunteers who received 10⁷ TCID₅₀ without evidence of hepatitis is suggestive of asymptomatic replication of the virus.

EXAMPLE 3 CONSTRUCTION OF CHIMERIC VIRUSES

Several exemplary chimeric viruses were generated to evaluate the effect of several of the mutations of Table I on host range and/or attenuation in primates. The sequence of the MRC-5-adapted virus 4380 was obtained using reverse-transcriptase:polymerase chain reaction (RT:PCR) to amplify regions of the virus as cDNA prior to sequencing (hence T instead of U in Table VI below). Numbers 2-10 in Table VI designate chimeric viruses made by inserting mutations found in the MRC-5-adapted virus 4380 into the cDNA clone of pHAV/7 encoding the attenuated HM-175 virus, Pass 35, of Cohen et al., J. Virol., 61:3035-3039 (1987) [SEQ ID NOs: 3 and 4]. Mutations introduced by “chimera” means a portion of the 4380 virus genome was amplified by RT:PCR, digested-with specific restriction enzymes and the fragment used to replace the homologous fragment in the cDNA clone pHAV/7. Mutations introduced by mutagenesis were inserted by oligonucleotide-directed mutagenesis of the cDNA clone pHAV/7 using the Amersham mutagenesis protocol.

The chimeric cDNAs were transcribed into RNA in vitro and the nucleic acids (both RNA and DNA) transfected into FRhK-4 cells to generate chimeric viruses. Quantification of chimeric virus growth for the exemplary chimeras was performed by slot-blot assay.

Table VI reports the results of the construction and testing of nine chimeric viruses. As used in Table VI, the following terms are defined: Cell culture refers to virus containing indicated mutations selected by growth in MRC-5 cells. Mutagenesis refers to oligonucleotide-directed mutagenesis of P-35 or H14-175 cDNA clones. A chimeric viral genome refers to the construction of a chimeric viral genome using portions of P-35 cDNA clone and PCR-generated fragments of the MRC-5 cell-adapted virus 4380. ND means that this study has not yet been performed. The + symbol refers to virus that has some growth in that cell type. The − symbol refers to virus that has little or no growth in that cell type. The two cell types employed to test the growth of the chimeric viruses are the human lung fibroblast-like cell line MRC-5 and fetal rhesus monkey kidney epithelial-like cell line, FRhK-4. Note that Virus #1 in the Table refers to MRC-5-adapted HAV 4380. Viruses #2 through 10 are chimeric viruses of this invention.

TABLE VI Differences in Nucleotide Sequence of MRC-5-Adapted Hepatitis A Virus: Comparison with P-35 HM-175 Virus Growth of Nucleotide Method Mutated Virus Differences Mutation in Cell Cultures from P-35 HM-175 Introduced FRhK-4 MRC-5 Virus #1 Cell Culture + + (MRC-5-adapted) 591 A to G 646 G to A 669 C to T 687 T to G 2750 C to T 3027 T to A 3196 G to A 3934 A to G 4418 A to T 4563 A to G 4643 A to T 5145 A to G 5745 A to T 6908 T to C 7032 C to T 7255 A to T Virus #2 Chimera + + 591 A to G 646 G to A 669 C to T 687 T to G Virus #3 Chimera + + 124 C to T 131 d to T 132 d to T 133 d to T 134 d to G 152 G to A 203-207 d to T 591 A to G 646 G to A 669 C to T 687 T to G Virus #4 Chimera + + 591 A to G 646 G to A 669 C to T 687 T to G 4418 A to T 4563 A to G 4643 A to T Virus #5 Chimera + + 124 C to T 131 d to T 132 d to T 133 d to T 134 d to T 152 G to A 203-207 d to T 591 A to G 646 G to A 669 C to T 687 T to G 4418 A to T 4563 A to G 4643 A to T Virus #6 Chimera + − 4418 A to T 4563 A to G 4643 A to T Virus #7 Chimera + ND Mutagenesis 591 A to G 4418 A to T 4563 A to G 4643 A to T Virus #8 Chimera + ND Mutagenesis 646 G to A 4418 A to T 4563 A to G 4643 A to T Virus #9 Chimera + ND Mutagenesis 669 C to T 4418 A to T 4563 A to G 4643 A to T  Virus #10 Chimera + ND Mutagenesis 687 T to G 4418 A to T 4563 A to G 4643 A to T d = Base at this position deleted in P-35 compared to wild-type

Introduction of four mutations found in the 5′ noncoding region, at nucleotide positions 591, 646, 669, and 687 of the P-35 genome, appear to be important for HAV host range in cell culture. They allow some growth of the transfected virus in MRC-5 cells, but do not account entirely for MRC-5 cell culture adaptation. Introduction of three mutations, at nucleotides 4418, 4563 and 4643 in the 2C region of the MRC-5-adapted virus, with the 5′ mutations allows full growth in MRC-5 cells. Thus the four mutations in the 5′ noncoding region and the three mutations in the 2C region of the genome of the MRC-5 cell-adapted virus appear to act synergistically in adaptation of this virus to efficient growth in MRC-5 cells. Introduction of only the three mutations in the 2C region into the P-35 AGMK genome does not permit discernible growth of the transfected virus in MRC-5 cells.

EXAMPLE 4 COMPARISON OF END POINT DILUTION OF CHIMERIC VIRUSES IN FRhK-4 VERSUS MRC-5 CELLS

Chimeric viruses with the composition described in Table VI were serially diluted in ten-fold increments, and an equal aliquot of each dilution was plated onto FRhK-4 and MRC-5 cells. After 21 days incubation at 34.5° C. to permit virus growth, the cells were lysed by the addition of a buffer solution containing sodium dodecyl sulfate. The viral RNA was extracted with phenol and quantified by slot blot hybridization using a [32p]-labeled riboprobe specific for Hepatitis A virus. A radioautograph of the slot blot obtained from the FRhK-4 cells and from the MRC-5 cells illustrates that the endpoint dilution of the MRC-5-adapted virus was the same in both cell lines, indicating that this virus can grow in either cell line. In contrast, the P35 EM-175 virus had an endpoint dilution of 10⁻⁵ on FRhK-4 cells and <10⁻¹ on MRC-5 cells, demonstrating that this virus is unable to grow successfully on MRC-5 cells. As FIG. 5 illustrates, virus #6 was most like the pass 35 virus while virus #4 was most like the MRC-5 adapted virus and viruses #2, 3, and 5 were intermediate. These results show that certain mutations from the MRC-5-adapted virus can be introduced into the pHAV/7 cDNA clone to generate new viruses which also have acquired the ability to grow in MRC-5 cells.

EXAMPLE 5 NUCLEOTIDE SEQUENCE OF MRC-5/9 VIRUS COMPARED WITH THE MR8 cDNA CLONE

The full length cDNA clone of an HAV chimeric virus, called MR8, was constructed by sequential replacement of AGMK/35m restriction fragments with those generated by RT-PCR amplification of the HAV 4380 (MRC-5/9) virus genome. The nucleotide sequence of the MR8 cDNA and of a subcloned PCR product from the 3′ end of the viral genome (base 7000 to polyA tail) were compared to that of a PCR consensus sequence previously determined for the MRC-5/9 virus. Based on these comparisons the original list of 12 mutations believed to be unique to MRC-5/9 virus has been changed by the addition of six more coding mutations (positions 2750, 3027, 3196, 4563, 7032 and 7255) and the deletion of two mutations (position 2864 and 6216) that originally were thought to have occurred during passage in MRC-5 cells but which were actually present in a subset of HM175 wild-type cDNA clones made from virus before passage in cell culture. The six new mutations were confirmed after reamplification of the MRC-5/9 RNA by RT-PCR.

The nucleotide sequence of the MR8 clone differed from the AGMK/35m clone at nucleotide numbers 591, 646, 669 and 687 in the 5′ non-coding region (identical to those in Table I). It also contained the same changes in Table I at nucleotides 2750, 3027, 3196, 3934, 4418, 4563, 4643, 5145, 5745, and 6908. It also contained at nucleotide 6383 a U, at nucleotide 7255 an A, and at nucleotide 7430 an A. Thus it contained only 7 mutations resulting in amino acid changes from AGMK/35m: (two in VP1/2A, one in 2B, two in 2C, one in 3A, and one in 3C). Only a few mutations, therefore, are responsible for a marked difference in the ability of the AGMK/35 virus and the MRC-5/9 virus to grow in MRC-5 cells.

All publications identified above are incorporated by reference. The parent applications are incorporated by reference. Numerous modifications and variations of the present invention are included in the above-identified specification and are expected to be obvious to one of skill in the art. Such modifications and alterations to the compositions and processes of the present invention are believed to be encompassed in the scope of the claims appended hereto.

                   #             SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 6 <210> SEQ ID NO 1 <211> LENGTH: 7493 <212> TYPE: DNA <213> ORGANISM: WILD-TYPE HUMAN HEPATITIS A VIRUS, # STRAIN HM-175 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (735)..(7415) <400> SEQUENCE: 1 ttcaagaggg gtctccggga atttccggag tccctcttgg aagtccatgg tg #aggggact     60 tgatacctca ccgccgtttg cctaggctat aggctaaatt ttccctttcc ct #tttccctt    120 tcctattccc tttgttttgc ttgtaaatat taattcctgc aggttcaggg tt #cttaaatc    180 tgtttctcta taagaacact catttttcac gctttctgtc ttctttcttc ca #gggctctc    240 cccttgccct aggctctggc cgttgcgccc ggcggggtca actccatgat ta #gcatggag    300 ctgtaggagt ctaaattggg gacacagatg tttggaacgt caccttgcag tg #ttaacttg    360 gctttcatga atctctttga tcttccacaa ggggtaggct acgggtgaaa cc #tcttaggc    420 taatacttct atgaagagat gccttggata gggtaacagc ggcggatatt gg #tgagttgt    480 taagacaaaa accattcaac gccggaggac tgactctcat ccagtggatg ca #ttgagtgg    540 attgactgtc agggctgtct ttaggcttaa ttccagacct ctctgtgctt ag #ggcaaaca    600 tcatttggcc ttaaatggga ttctgtgaga ggggatccct ccattgacag ct #ggactgtt    660 ctttggggcc ttatgtggtg tttgcctctg aggtactcag gggcatttag gt #ttttcctc    720 attcttaaat aata atg aac atg tct aga caa ggt a #tt ttc cag act gtt      770                 Met A #sn Met Ser Arg Gln Gly Ile Phe Gln Thr Va #l                    #1               5    #               10 ggg agt ggt ctt gac cac atc ctg tct ttg gc #a gac att gag gaa gag      818 Gly Ser Gly Leu Asp His Ile Leu Ser Leu Al #a Asp Ile Glu Glu Glu          15          #         20          #         25 caa atg att caa tca gtt gat agg act gca gt #g act ggt gct tct tat      866 Gln Met Ile Gln Ser Val Asp Arg Thr Ala Va #l Thr Gly Ala Ser Tyr      30              #     35              #     40 ttt act tct gtg gat caa tct tca gtt cat ac #a gct gag gtt gga tca      914 Phe Thr Ser Val Asp Gln Ser Ser Val His Th #r Ala Glu Val Gly Ser  45                  # 50                  # 55                  # 60 cac cag gtt gaa cct ttg aga acc tct gtt ga #t aaa ccc ggt tca aag      962 His Gln Val Glu Pro Leu Arg Thr Ser Val As #p Lys Pro Gly Ser Lys                  65  #                 70  #                 75 aag act cag gga gag aaa ttt ttc ttg att ca #t tct gca gat tgg ctt     1010 Lys Thr Gln Gly Glu Lys Phe Phe Leu Ile Hi #s Ser Ala Asp Trp Leu              80      #             85      #             90 act aca cat gct ctt ttc cat gaa gtt gca aa #a ttg gat gtg gtg aaa     1058 Thr Thr His Ala Leu Phe His Glu Val Ala Ly #s Leu Asp Val Val Lys          95          #        100          #        105 tta tta tac aat gag cag ttt gct gtt caa gg #g ttg ttg aga tac cat     1106 Leu Leu Tyr Asn Glu Gln Phe Ala Val Gln Gl #y Leu Leu Arg Tyr His     110               #   115               #   120 aca tat gca aga ttt ggc att gaa att caa gt #t cag ata aac cct aca     1154 Thr Tyr Ala Arg Phe Gly Ile Glu Ile Gln Va #l Gln Ile Asn Pro Thr 125                 1 #30                 1 #35                 1 #40 cct ttc caa cag ggg gga ttg atc tgt gct at #g gtt cct ggt gac cag     1202 Pro Phe Gln Gln Gly Gly Leu Ile Cys Ala Me #t Val Pro Gly Asp Gln                 145   #               150   #               155 agc tat ggt tct ata gca tca ttg act gtt ta #t cct cat ggt ttg tta     1250 Ser Tyr Gly Ser Ile Ala Ser Leu Thr Val Ty #r Pro His Gly Leu Leu             160       #           165       #           170 aat tgc aat att aac aat gtg gtt aga ata aa #g gtt cca ttt att tac     1298 Asn Cys Asn Ile Asn Asn Val Val Arg Ile Ly #s Val Pro Phe Ile Tyr         175           #       180           #       185 aca aga ggt gct tac cac ttt aaa gat cca ca #a tac cca gtt tgg gaa     1346 Thr Arg Gly Ala Tyr His Phe Lys Asp Pro Gl #n Tyr Pro Val Trp Glu     190               #   195               #   200 ttg aca att aga gtt tgg tca gaa tta aat at #t ggg aca gga act tca     1394 Leu Thr Ile Arg Val Trp Ser Glu Leu Asn Il #e Gly Thr Gly Thr Ser 205                 2 #10                 2 #15                 2 #20 gct tat act tca ctc aat gtt tta gct aga tt #t aca gat ttg gag ttg     1442 Ala Tyr Thr Ser Leu Asn Val Leu Ala Arg Ph #e Thr Asp Leu Glu Leu                 225   #               230   #               235 cat gga tta act cct ctt tct aca caa atg at #g aga aat gaa ttt agg     1490 His Gly Leu Thr Pro Leu Ser Thr Gln Met Me #t Arg Asn Glu Phe Arg             240       #           245       #           250 gtc agt act act gag aat gtg gtg aat ctg tc #a aat tat gaa gat gca     1538 Val Ser Thr Thr Glu Asn Val Val Asn Leu Se #r Asn Tyr Glu Asp Ala         255           #       260           #       265 aga gca aag atg tct ttt gct ttg gat cag ga #a gat tgg aaa tct gat     1586 Arg Ala Lys Met Ser Phe Ala Leu Asp Gln Gl #u Asp Trp Lys Ser Asp     270               #   275               #   280 ccg tcc cag ggt ggt ggg atc aaa att act ca #t ttt act act tgg aca     1634 Pro Ser Gln Gly Gly Gly Ile Lys Ile Thr Hi #s Phe Thr Thr Trp Thr 285                 2 #90                 2 #95                 3 #00 tct att cca act ttg gct gct cag ttt cca tt #t aat gct tca gac tca     1682 Ser Ile Pro Thr Leu Ala Ala Gln Phe Pro Ph #e Asn Ala Ser Asp Ser                 305   #               310   #               315 gtt ggt caa caa att aaa gtt att cca gtt ga #c cca tat ttt ttc caa     1730 Val Gly Gln Gln Ile Lys Val Ile Pro Val As #p Pro Tyr Phe Phe Gln             320       #           325       #           330 atg aca aat acg aat cct gac caa aaa tgt at #a act gct ttg gct tct     1778 Met Thr Asn Thr Asn Pro Asp Gln Lys Cys Il #e Thr Ala Leu Ala Ser         335           #       340           #       345 att tgt cag atg ttt tgt ttt tgg aga gga ga #t ctt gtc ttt gat ttt     1826 Ile Cys Gln Met Phe Cys Phe Trp Arg Gly As #p Leu Val Phe Asp Phe     350               #   355               #   360 caa gtt ttt ccc acc aaa tat cat tca ggt ag #a tta ctg ttt tgt ttt     1874 Gln Val Phe Pro Thr Lys Tyr His Ser Gly Ar #g Leu Leu Phe Cys Phe 365                 3 #70                 3 #75                 3 #80 gtt cct ggc aat gag cta ata gat gtt tct gg #a atc aca tta aag caa     1922 Val Pro Gly Asn Glu Leu Ile Asp Val Ser Gl #y Ile Thr Leu Lys Gln                 385   #               390   #               395 gca act act gct cct tgt gca gta atg gat at #t aca gga gtg cag tca     1970 Ala Thr Thr Ala Pro Cys Ala Val Met Asp Il #e Thr Gly Val Gln Ser             400       #           405       #           410 act ttg aga ttt cgt gtt ccc tgg att tct ga #c act cct tac aga gtg     2018 Thr Leu Arg Phe Arg Val Pro Trp Ile Ser As #p Thr Pro Tyr Arg Val         415           #       420           #       425 aac agg tat aca aag tca gca cat cag aaa gg #t gag tac act gcc att     2066 Asn Arg Tyr Thr Lys Ser Ala His Gln Lys Gl #y Glu Tyr Thr Ala Ile     430               #   435               #   440 ggg aag ctt att gtg tat tgt tat aac aga tt #g acc tct cct tct aac     2114 Gly Lys Leu Ile Val Tyr Cys Tyr Asn Arg Le #u Thr Ser Pro Ser Asn 445                 4 #50                 4 #55                 4 #60 gtt gct tcc cat gtc aga gtg aat gtt tat ct #t tca gca att aac ttg     2162 Val Ala Ser His Val Arg Val Asn Val Tyr Le #u Ser Ala Ile Asn Leu                 465   #               470   #               475 gaa tgt ttt gct cct ctt tat cat gct atg ga #t gtt act aca caa gtt     2210 Glu Cys Phe Ala Pro Leu Tyr His Ala Met As #p Val Thr Thr Gln Val             480       #           485       #           490 gga gat gat tct gga ggt ttt tca aca aca gt #t tct aca gaa cag aat     2258 Gly Asp Asp Ser Gly Gly Phe Ser Thr Thr Va #l Ser Thr Glu Gln Asn         495           #       500           #       505 gtt cca gat ccc caa gtt ggt ata aca acc at #g aaa gat ttg aaa gga     2306 Val Pro Asp Pro Gln Val Gly Ile Thr Thr Me #t Lys Asp Leu Lys Gly     510               #   515               #   520 aaa gct aac aga ggg aaa atg gat gtt tca gg #a gta caa gca cct gtg     2354 Lys Ala Asn Arg Gly Lys Met Asp Val Ser Gl #y Val Gln Ala Pro Val 525                 5 #30                 5 #35                 5 #40 gga gct atc aca aca att gag gat cca gtt tt #a gca aag aaa gta cct     2402 Gly Ala Ile Thr Thr Ile Glu Asp Pro Val Le #u Ala Lys Lys Val Pro                 545   #               550   #               555 gag aca ttt cct gaa ttg aaa cct gga gaa tc #c aga cat aca tca gat     2450 Glu Thr Phe Pro Glu Leu Lys Pro Gly Glu Se #r Arg His Thr Ser Asp             560       #           565       #           570 cat atg tcc atc tac aag ttt atg gga agg tc #t cat ttc ttg tgc act     2498 His Met Ser Ile Tyr Lys Phe Met Gly Arg Se #r His Phe Leu Cys Thr         575           #       580           #       585 ttt aca ttc aat tca aat aat aaa gag tac ac #a ttt cct ata acc ttg     2546 Phe Thr Phe Asn Ser Asn Asn Lys Glu Tyr Th #r Phe Pro Ile Thr Leu     590               #   595               #   600 tct tca acc tct aat cct cct cat ggt ttg cc #a tca aca ctg agg tgg     2594 Ser Ser Thr Ser Asn Pro Pro His Gly Leu Pr #o Ser Thr Leu Arg Trp 605                 6 #10                 6 #15                 6 #20 ttt ttc aac ttg ttt cag ttg tat aga ggg cc #t tta gat ctg aca att     2642 Phe Phe Asn Leu Phe Gln Leu Tyr Arg Gly Pr #o Leu Asp Leu Thr Ile                 625   #               630   #               635 att att aca gga gca act gat gta gat ggc at #g gcc tgg ttc act cca     2690 Ile Ile Thr Gly Ala Thr Asp Val Asp Gly Me #t Ala Trp Phe Thr Pro             640       #           645       #           650 gta ggt ctt gcc gtt gat act cct tgg gta ga #g aag gag tca gct ttg     2738 Val Gly Leu Ala Val Asp Thr Pro Trp Val Gl #u Lys Glu Ser Ala Leu         655           #       660           #       665 tct att gac tac aaa act gct ctt gga gct gt #c aga ttt aac aca agg     2786 Ser Ile Asp Tyr Lys Thr Ala Leu Gly Ala Va #l Arg Phe Asn Thr Arg     670               #   675               #   680 aga aca ggg aac att cag att aga tta cca tg #g tat tct tat tta tat     2834 Arg Thr Gly Asn Ile Gln Ile Arg Leu Pro Tr #p Tyr Ser Tyr Leu Tyr 685                 6 #90                 6 #95                 7 #00 gct gtg tct gga gca ctg gat ggt ttg ggt ga #c aag aca gat tct aca     2882 Ala Val Ser Gly Ala Leu Asp Gly Leu Gly As #p Lys Thr Asp Ser Thr                 705   #               710   #               715 ttt gga ttg gtt tct att cag att gca aat ta #c aat cat tct gat gaa     2930 Phe Gly Leu Val Ser Ile Gln Ile Ala Asn Ty #r Asn His Ser Asp Glu             720       #           725       #           730 tac ttg tct ttt agt tgt tat ttg tct gtc ac #a gaa caa tca gag ttt     2978 Tyr Leu Ser Phe Ser Cys Tyr Leu Ser Val Th #r Glu Gln Ser Glu Phe         735           #       740           #       745 tat ttt ccc aga gct cca ttg aac tca aat gc #c atg tta tcc act gaa     3026 Tyr Phe Pro Arg Ala Pro Leu Asn Ser Asn Al #a Met Leu Ser Thr Glu     750               #   755               #   760 tca atg atg agc aga att gca gct gga gac tt #g gag tca tca gtg gat     3074 Ser Met Met Ser Arg Ile Ala Ala Gly Asp Le #u Glu Ser Ser Val Asp 765                 7 #70                 7 #75                 7 #80 gat cct aga tca gag gaa gat aaa aga ttt ga #g agt cat ata gaa tgc     3122 Asp Pro Arg Ser Glu Glu Asp Lys Arg Phe Gl #u Ser His Ile Glu Cys                 785   #               790   #               795 agg aag cca tat aaa gaa ctg aga tta gaa gt #t ggg aaa caa aga ctc     3170 Arg Lys Pro Tyr Lys Glu Leu Arg Leu Glu Va #l Gly Lys Gln Arg Leu             800       #           805       #           810 aag tat gct cag gaa gaa ttg tca aat gaa gt #a ctt cca ccc cct agg     3218 Lys Tyr Ala Gln Glu Glu Leu Ser Asn Glu Va #l Leu Pro Pro Pro Arg         815           #       820           #       825 aaa atg aag gga ctg ttt tca caa gcc aaa at #t tct ctt ttt tat act     3266 Lys Met Lys Gly Leu Phe Ser Gln Ala Lys Il #e Ser Leu Phe Tyr Thr     830               #   835               #   840 gag gag cat gaa ata atg aag ttt tcc tgg ag #a ggt gtg act gct gat     3314 Glu Glu His Glu Ile Met Lys Phe Ser Trp Ar #g Gly Val Thr Ala Asp 845                 8 #50                 8 #55                 8 #60 act aga gct tta agg agg ttt gga ttc tct tt #g gcc gca ggc aga agt     3362 Thr Arg Ala Leu Arg Arg Phe Gly Phe Ser Le #u Ala Ala Gly Arg Ser                 865   #               870   #               875 gtg tgg act ctt gaa atg gat gct ggg gtt ct #t act ggg aga ctg att     3410 Val Trp Thr Leu Glu Met Asp Ala Gly Val Le #u Thr Gly Arg Leu Ile             880       #           885       #           890 aga ttg aat gat gag aaa tgg aca gaa atg aa #g gat gac aag att gtt     3458 Arg Leu Asn Asp Glu Lys Trp Thr Glu Met Ly #s Asp Asp Lys Ile Val         895           #       900           #       905 tca ttg att gaa aag ttt aca agt aac aaa ta #t tgg tcc aaa gtg aat     3506 Ser Leu Ile Glu Lys Phe Thr Ser Asn Lys Ty #r Trp Ser Lys Val Asn     910               #   915               #   920 ttc cca cat ggg atg ttg gat ctt gaa gaa at #t gct gcc aat tct aag     3554 Phe Pro His Gly Met Leu Asp Leu Glu Glu Il #e Ala Ala Asn Ser Lys 925                 9 #30                 9 #35                 9 #40 gat ttt cct aac atg tct gaa acg gat ttg tg #t ttc ttg ctg cat tgg     3602 Asp Phe Pro Asn Met Ser Glu Thr Asp Leu Cy #s Phe Leu Leu His Trp                 945   #               950   #               955 tta aat cca aag aaa att aat tta gca gat ag #a atg ctt gga ttg tct     3650 Leu Asn Pro Lys Lys Ile Asn Leu Ala Asp Ar #g Met Leu Gly Leu Ser             960       #           965       #           970 gga gtt cag gaa att aaa gaa caa ggt gtt gg #a tta ata gca gag tgt     3698 Gly Val Gln Glu Ile Lys Glu Gln Gly Val Gl #y Leu Ile Ala Glu Cys         975           #       980           #       985 aga act ttc tta gat tct att gct gga act tt #a aaa tct atg atg ttt     3746 Arg Thr Phe Leu Asp Ser Ile Ala Gly Thr Le #u Lys Ser Met Met Phe     990               #   995               #   1000 gga ttt cat cat tct gtg act gtt gaa att at #a aac act gtg ctc tgt     3794 Gly Phe His His Ser Val Thr Val Glu Ile Il #e Asn Thr Val Leu Cys 1005                1010 #                 101 #5                1020 ttt gtt aag agt gga att ttg ctt tat gta at #a caa caa ttg aat cag     3842 Phe Val Lys Ser Gly Ile Leu Leu Tyr Val Il #e Gln Gln Leu Asn Gln                 1025  #               1030   #              1035 gat gaa cat tct cac ata att ggt ttg ttg ag #a gtc atg aat tat gca     3890 Asp Glu His Ser His Ile Ile Gly Leu Leu Ar #g Val Met Asn Tyr Ala             1040      #           1045       #          1050 gat att ggt tgt tca gtt att tca tgt ggc aa #a gtt ttt tcc aaa atg     3938 Asp Ile Gly Cys Ser Val Ile Ser Cys Gly Ly #s Val Phe Ser Lys Met         1055          #       1060           #      1065 ctg gaa aca gtc ttt aat tgg caa atg gac tc #c aga atg atg gag tta     3986 Leu Glu Thr Val Phe Asn Trp Gln Met Asp Se #r Arg Met Met Glu Leu     1070              #   1075               #  1080 agg act cag agt ttt tcc aac tgg tta aga ga #t att tgt tct ggg atc     4034 Arg Thr Gln Ser Phe Ser Asn Trp Leu Arg As #p Ile Cys Ser Gly Ile 1085               1090  #               1095   #              1100 acc att ttt aaa aac ttc aag gat gca att ta #t tgg ctt tat aca aaa     4082 Thr Ile Phe Lys Asn Phe Lys Asp Ala Ile Ty #r Trp Leu Tyr Thr Lys                1105   #              1110    #             1115 tta aag gac ttt tat gaa gtg aat tat ggc aa #g aag aag gac att tta     4130 Leu Lys Asp Phe Tyr Glu Val Asn Tyr Gly Ly #s Lys Lys Asp Ile Leu             1120      #           1125       #          1130 aat att ctt aaa gat aac caa caa aaa ata ga #g aaa gcc att gag gaa     4178 Asn Ile Leu Lys Asp Asn Gln Gln Lys Ile Gl #u Lys Ala Ile Glu Glu         1135          #       1140           #      1145 gcc gat gaa ttt tgc att ttg caa atc caa ga #t gtg gaa aaa ttt gaa     4226 Ala Asp Glu Phe Cys Ile Leu Gln Ile Gln As #p Val Glu Lys Phe Glu     1150              #   1155               #  1160 cag tat cag aaa ggg gtt gac ttg ata caa aa #a ttg aga act gtt cat     4274 Gln Tyr Gln Lys Gly Val Asp Leu Ile Gln Ly #s Leu Arg Thr Val His 1165               1170  #               1175   #               1180 tca atg gct cag gtt gat cca aat tta atg gt #t cat ttg tca cct ttg     4322 Ser Met Ala Gln Val Asp Pro Asn Leu Met Va #l His Leu Ser Pro Leu                 1185  #               1190   #              1195 aga gat tgt ata gca aga gtt cat cag aaa ct #t aaa aac ctt gga tct     4370 Arg Asp Cys Ile Ala Arg Val His Gln Lys Le #u Lys Asn Leu Gly Ser             1200      #           1205       #          1210 ata aat cag gca atg gta acg aga tgt gag cc #a gtt gtt tgt tat tta     4418 Ile Asn Gln Ala Met Val Thr Arg Cys Glu Pr #o Val Val Cys Tyr Leu         1215          #       1220           #      1225 tat ggc aaa aga ggg gga gga aag agc tta ac #a tca att gca ttg gca     4466 Tyr Gly Lys Arg Gly Gly Gly Lys Ser Leu Th #r Ser Ile Ala Leu Ala     1230              #   1235               #  1240 acc aaa att tgt aaa cat tat ggt gtt gag cc #t gaa aag aat atc tat     4514 Thr Lys Ile Cys Lys His Tyr Gly Val Glu Pr #o Glu Lys Asn Ile Tyr 1245               1250  #               1255   #              1260 act aaa cct gtg gct tca gat tac tgg gat gg #a tat agt gga caa tta     4562 Thr Lys Pro Val Ala Ser Asp Tyr Trp Asp Gl #y Tyr Ser Gly Gln Leu                 1265  #               1270   #              1275 gtt tgc atc att gat gat att ggc caa aac ac #a aca gat gag gat tgg     4610 Val Cys Ile Ile Asp Asp Ile Gly Gln Asn Th #r Thr Asp Glu Asp Trp             1280      #           1285       #          1290 tca gat ttt tgt cag tta gtg tca gga tgt cc #a atg aga tta aac atg     4658 Ser Asp Phe Cys Gln Leu Val Ser Gly Cys Pr #o Met Arg Leu Asn Met         1295          #       1300           #      1305 gcc tct ctt gag gag aag ggt agg cat ttt tc #t tct cct ttt ata ata     4706 Ala Ser Leu Glu Glu Lys Gly Arg His Phe Se #r Ser Pro Phe Ile Ile     1310              #   1315               #  1320 gca act tca aat tgg tca aat cca agt cca aa #a aca gtt tat gtt aag     4754 Ala Thr Ser Asn Trp Ser Asn Pro Ser Pro Ly #s Thr Val Tyr Val Lys 1325               1330  #               1335   #              1340 gaa gca att gac cgc aga ctc cat ttc aag gt #t gaa gtt aaa cct gct     4802 Glu Ala Ile Asp Arg Arg Leu His Phe Lys Va #l Glu Val Lys Pro Ala                 1345  #               1350   #              1355 tca ttt ttc aaa aat cct cac aat gat atg tt #g aat gtt aat tta gct     4850 Ser Phe Phe Lys Asn Pro His Asn Asp Met Le #u Asn Val Asn Leu Ala             1360      #           1365       #          1370 aaa aca aat gat gca atc aaa gat atg tct tg #t gtt gat ttg ata atg     4898 Lys Thr Asn Asp Ala Ile Lys Asp Met Ser Cy #s Val Asp Leu Ile Met         1375          #       1380           #      1385 gat gga cat aat gtt tca ttg atg gat ttg ct #c agt tct tta gtc atg     4946 Asp Gly His Asn Val Ser Leu Met Asp Leu Le #u Ser Ser Leu Val Met     1390              #   1395               #  1400 aca gtt gaa att aga aaa caa aac atg act ga #a ttc atg gag ttg tgg     4994 Thr Val Glu Ile Arg Lys Gln Asn Met Thr Gl #u Phe Met Glu Leu Trp 1405               1410  #               1415   #               1420 tct cag gga att tca gat gat gat aat gat ag #t gca gta gct gag ttt     5042 Ser Gln Gly Ile Ser Asp Asp Asp Asn Asp Se #r Ala Val Ala Glu Phe                 1425  #               1430   #              1435 ttc cag tct ttt cca tct ggt gaa cca tcg aa #c tct aaa tta tct ggc     5090 Phe Gln Ser Phe Pro Ser Gly Glu Pro Ser As #n Ser Lys Leu Ser Gly             1440      #           1445       #          1450 ttt ttc caa tct gtt act aat cac aag tgg gt #t gct gtg gga gct gca     5138 Phe Phe Gln Ser Val Thr Asn His Lys Trp Va #l Ala Val Gly Ala Ala         1455          #       1460           #      1465 gtt ggc att ctt gga gtg ctc gtt gga gga tg #g ttt gtg tat aag cat     5186 Val Gly Ile Leu Gly Val Leu Val Gly Gly Tr #p Phe Val Tyr Lys His     1470              #   1475               #  1480 ttc tcc cgc aaa gag gag gaa cca atc cca gc #t gaa ggg gta tat cat     5234 Phe Ser Arg Lys Glu Glu Glu Pro Ile Pro Al #a Glu Gly Val Tyr His 1485               1490  #               1495   #              1500 ggt gta act aag ccc aag caa gtg att aaa tt #a gat gca gat cca gta     5282 Gly Val Thr Lys Pro Lys Gln Val Ile Lys Le #u Asp Ala Asp Pro Val                 1505  #               1510   #              1515 gaa tct cag tca act ttg gaa ata gca gga ct #g gtt agg aag aac ttg     5330 Glu Ser Gln Ser Thr Leu Glu Ile Ala Gly Le #u Val Arg Lys Asn Leu             1520      #           1525       #          1530 gtt cag ttt gga gtt gga gag aag aat gga tg #t gtg aga tgg gtt atg     5378 Val Gln Phe Gly Val Gly Glu Lys Asn Gly Cy #s Val Arg Trp Val Met         1535          #       1540           #      1545 aat gcc ttg gga gtg aaa gat gat tgg ctg ct #t gtg cct tcc cat gct     5426 Asn Ala Leu Gly Val Lys Asp Asp Trp Leu Le #u Val Pro Ser His Ala     1550              #   1555               #  1560 tat aaa ttt gag aaa gat tat gaa atg atg ga #g ttt tat ttt aat aga     5474 Tyr Lys Phe Glu Lys Asp Tyr Glu Met Met Gl #u Phe Tyr Phe Asn Arg 1565               1570  #               1575   #              1580 ggt gga act tac tat tca att tca gct ggt aa #t gtt gtt att caa tct     5522 Gly Gly Thr Tyr Tyr Ser Ile Ser Ala Gly As #n Val Val Ile Gln Ser                 1585  #               1590   #              1595 ttg gat gtg gga ttc cag gat gtt gtt ctg at #g aag gtt cct aca att     5570 Leu Asp Val Gly Phe Gln Asp Val Val Leu Me #t Lys Val Pro Thr Ile             1600      #           1605       #          1610 cct aag ttt aga gat att act cag cat ttt at #t aag aaa ggg gat gtg     5618 Pro Lys Phe Arg Asp Ile Thr Gln His Phe Il #e Lys Lys Gly Asp Val         1615          #       1620           #      1625 cct aga gct ttg aat cgc ctg gca aca tta gt #g aca act gta aat gga     5666 Pro Arg Ala Leu Asn Arg Leu Ala Thr Leu Va #l Thr Thr Val Asn Gly     1630              #   1635               #  1640 acc cct atg tta att tct gag ggc cca cta aa #g atg gaa gag aaa gct     5714 Thr Pro Met Leu Ile Ser Glu Gly Pro Leu Ly #s Met Glu Glu Lys Ala 1645               1650  #               1655   #              1660 act tat gtt cat aag aaa aat gat ggt aca ac #a gtt gat tta act gtg     5762 Thr Tyr Val His Lys Lys Asn Asp Gly Thr Th #r Val Asp Leu Thr Val                 1665  #               1670   #              1675 gat cag gca tgg aga gga aaa ggc gaa ggt ct #t cct gga atg tgt ggt     5810 Asp Gln Ala Trp Arg Gly Lys Gly Glu Gly Le #u Pro Gly Met Cys Gly             1680      #           1685       #          1690 ggg gcc ttg gtt tca tcg aat caa tct ata ca #g aat gca atc ttg ggc     5858 Gly Ala Leu Val Ser Ser Asn Gln Ser Ile Gl #n Asn Ala Ile Leu Gly         1695          #       1700           #      1705 atc cat gtt gct gga gga aat tca att ctt gt #t gca aaa ttg gtt act     5906 Ile His Val Ala Gly Gly Asn Ser Ile Leu Va #l Ala Lys Leu Val Thr     1710              #   1715               #  1720 caa gaa atg ttc caa aat att gat aag aaa at #t gaa agt cag aga att     5954 Gln Glu Met Phe Gln Asn Ile Asp Lys Lys Il #e Glu Ser Gln Arg Ile 1725               1730  #               1735   #              1740 atg aaa gtg gag ttt act cag tgt tca atg aa #t gtg gtc tcc aaa acg     6002 Met Lys Val Glu Phe Thr Gln Cys Ser Met As #n Val Val Ser Lys Thr                 1745  #               1750   #              1755 ctt ttt aga aag agt ccc att tat cat cac at #t gat aaa acc atg att     6050 Leu Phe Arg Lys Ser Pro Ile Tyr His His Il #e Asp Lys Thr Met Ile             1760      #           1765       #          1770 aat ttt cct gca gct atg ccc ttt tct aaa gc #t gaa att gat cca atg     6098 Asn Phe Pro Ala Ala Met Pro Phe Ser Lys Al #a Glu Ile Asp Pro Met         1775          #       1780           #      1785 gct gtg atg tta tct aag tat tca tta cct at #t gta gaa gaa cca gag     6146 Ala Val Met Leu Ser Lys Tyr Ser Leu Pro Il #e Val Glu Glu Pro Glu     1790              #   1795               #  1800 gat tat aaa gag gct tca att ttt tat caa aa #t aaa ata gtg ggt aag     6194 Asp Tyr Lys Glu Ala Ser Ile Phe Tyr Gln As #n Lys Ile Val Gly Lys 1805               1810  #               1815   #              1820 act cag tta gtt gat gat ttt tta gat ctt ga #t atg gcc att aca ggg     6242 Thr Gln Leu Val Asp Asp Phe Leu Asp Leu As #p Met Ala Ile Thr Gly                 1825  #               1830   #              1835 gcc cca gga att gat gct atc aac atg gat tc #a tct cct gga ttt cct     6290 Ala Pro Gly Ile Asp Ala Ile Asn Met Asp Se #r Ser Pro Gly Phe Pro             1840      #           1845       #          1850 tat gtc cag gag aag ttg acc aaa aga gat tt #a att tgg ttg gat gaa     6338 Tyr Val Gln Glu Lys Leu Thr Lys Arg Asp Le #u Ile Trp Leu Asp Glu         1855          #       1860           #      1865 aat ggt tta ttg ctg gga gtt cat cca aga tt #g gct cag aga atc tta     6386 Asn Gly Leu Leu Leu Gly Val His Pro Arg Le #u Ala Gln Arg Ile Leu     1870              #   1875               #  1880 ttc aat act gtc atg atg gaa aat tgt tct ga #t ttg gat gtt gtt ttt     6434 Phe Asn Thr Val Met Met Glu Asn Cys Ser As #p Leu Asp Val Val Phe 1885               1890  #               1895   #              1900 aca acc tgt cca aaa gat gaa ttg aga cca tt #a gag aaa gtg ttg gaa     6482 Thr Thr Cys Pro Lys Asp Glu Leu Arg Pro Le #u Glu Lys Val Leu Glu                 1905  #               1910   #              1915 tca aaa aca aga gct att gat gct tgt cct ct #g gat tac tca att ttg     6530 Ser Lys Thr Arg Ala Ile Asp Ala Cys Pro Le #u Asp Tyr Ser Ile Leu             1920      #           1925       #          1930 tgc cga atg tat tgg ggt cca gct att agt ta #t ttt cat ttg aat cca     6578 Cys Arg Met Tyr Trp Gly Pro Ala Ile Ser Ty #r Phe His Leu Asn Pro         1935          #       1940           #      1945 ggt ttc cat aca ggt gtt gct att ggc ata ga #t cct gat aga cag tgg     6626 Gly Phe His Thr Gly Val Ala Ile Gly Ile As #p Pro Asp Arg Gln Trp     1950              #   1955               #  1960 gat gaa tta ttt aaa aca atg ata aga ttc gg #a gat gtt ggt ctt gat     6674 Asp Glu Leu Phe Lys Thr Met Ile Arg Phe Gl #y Asp Val Gly Leu Asp 1965                1970 #                1975  #               1980 tta gat ttc tct gct ttt gat gct agt ctt ag #t cca ttt atg att aga     6722 Leu Asp Phe Ser Ala Phe Asp Ala Ser Leu Se #r Pro Phe Met Ile Arg                 1985  #               1990   #              1995 gaa gca ggt aga atc atg agt gaa cta tct gg #a act cca tcc cat ttt     6770 Glu Ala Gly Arg Ile Met Ser Glu Leu Ser Gl #y Thr Pro Ser His Phe             2000      #           2005       #          2010 ggc aca gct ctt atc aat act atc att tat tc #c aag cat ttg ctg tat     6818 Gly Thr Ala Leu Ile Asn Thr Ile Ile Tyr Se #r Lys His Leu Leu Tyr         2015          #       2020           #      2025 aac tgt tgt tac cat gtc tgt ggt tca atg cc #c tct ggg tct cct tgt     6866 Asn Cys Cys Tyr His Val Cys Gly Ser Met Pr #o Ser Gly Ser Pro Cys     2030              #   2035               #  2040 aca gct ttg cta aat tca att att aat aat gt #c aat ttg tat tat gtg     6914 Thr Ala Leu Leu Asn Ser Ile Ile Asn Asn Va #l Asn Leu Tyr Tyr Val 2045                2050 #                2055  #               2060 ttt tcc aag ata ttt gga aag tct cca gtt tt #c ttt tgt cag gct ttg     6962 Phe Ser Lys Ile Phe Gly Lys Ser Pro Val Ph #e Phe Cys Gln Ala Leu                 2065  #               2070   #              2075 aag att ctc tgt tat gga gat gat gtt tta at #a gtt ttc tct cga gat     7010 Lys Ile Leu Cys Tyr Gly Asp Asp Val Leu Il #e Val Phe Ser Arg Asp             2080      #           2085       #          2090 gtt cag att gat aat ctt gat ttg att gga ca #a aaa att gta gat gag     7058 Val Gln Ile Asp Asn Leu Asp Leu Ile Gly Gl #n Lys Ile Val Asp Glu         2095          #       2100           #      2105 ttt aag aaa ctt ggc atg aca gct act tct gc #t gac aag aat gta cct     7106 Phe Lys Lys Leu Gly Met Thr Ala Thr Ser Al #a Asp Lys Asn Val Pro     2110              #   2115               #  2120 cag ctg aaa cca gtt tcg gaa ttg act ttt ct #c aaa aga tct ttc aat     7154 Gln Leu Lys Pro Val Ser Glu Leu Thr Phe Le #u Lys Arg Ser Phe Asn 2125               2130  #               2135   #              2140 ttg gta gag gat aga att aga cct gca att tc #g gaa aaa aca att tgg     7202 Leu Val Glu Asp Arg Ile Arg Pro Ala Ile Se #r Glu Lys Thr Ile Trp                 2145  #               2150   #              2155 tct tta ata gca tgg cag aga agt aac gct ga #g ttt gag cag aat tta     7250 Ser Leu Ile Ala Trp Gln Arg Ser Asn Ala Gl #u Phe Glu Gln Asn Leu             2160      #           2165       #          2170 gaa aat gct cag tgg ttt gct ttt atg cat gg #c tat gag ttt tat cag     7298 Glu Asn Ala Gln Trp Phe Ala Phe Met His Gl #y Tyr Glu Phe Tyr Gln         2175          #       2180           #      2185 aaa ttt tat tat ttt gtt cag tcc tgt ttg ga #g aaa gag atg ata gaa     7346 Lys Phe Tyr Tyr Phe Val Gln Ser Cys Leu Gl #u Lys Glu Met Ile Glu     2190              #   2195               #  2200 tac aga ctt aaa tct tat gat tgg tgg aga at #g aga ttt tat gac cag     7394 Tyr Arg Leu Lys Ser Tyr Asp Trp Trp Arg Me #t Arg Phe Tyr Asp Gln 2205                2210 #                2215  #               2220 tgt ttc att tgt gac ctt tca tgatttgttt aaacaaatt #t tcttaaaatt        7445 Cys Phe Ile Cys Asp Leu Ser                 2225 tctgaggttt gtttatttct tttatcagta aataaaaaaa aaaaaaaa   #              7493 <210> SEQ ID NO 2 <211> LENGTH: 2227 <212> TYPE: PRT <213> ORGANISM: WILD-TYPE HUMAN HEPATITIS A VIRUS, # STRAIN HM-175 <400> SEQUENCE: 2 Met Asn Met Ser Arg Gln Gly Ile Phe Gln Th #r Val Gly Ser Gly Leu   1               5  #                 10  #                 15 Asp His Ile Leu Ser Leu Ala Asp Ile Glu Gl #u Glu Gln Met Ile Gln              20      #             25      #             30 Ser Val Asp Arg Thr Ala Val Thr Gly Ala Se #r Tyr Phe Thr Ser Val          35          #         40          #         45 Asp Gln Ser Ser Val His Thr Ala Glu Val Gl #y Ser His Gln Val Glu      50              #     55              #     60 Pro Leu Arg Thr Ser Val Asp Lys Pro Gly Se #r Lys Lys Thr Gln Gly  65                  # 70                  # 75                  # 80 Glu Lys Phe Phe Leu Ile His Ser Ala Asp Tr #p Leu Thr Thr His Ala                  85  #                 90  #                 95 Leu Phe His Glu Val Ala Lys Leu Asp Val Va #l Lys Leu Leu Tyr Asn             100       #           105       #           110 Glu Gln Phe Ala Val Gln Gly Leu Leu Arg Ty #r His Thr Tyr Ala Arg         115           #       120           #       125 Phe Gly Ile Glu Ile Gln Val Gln Ile Asn Pr #o Thr Pro Phe Gln Gln     130               #   135               #   140 Gly Gly Leu Ile Cys Ala Met Val Pro Gly As #p Gln Ser Tyr Gly Ser 145                 1 #50                 1 #55                 1 #60 Ile Ala Ser Leu Thr Val Tyr Pro His Gly Le #u Leu Asn Cys Asn Ile                 165   #               170   #               175 Asn Asn Val Val Arg Ile Lys Val Pro Phe Il #e Tyr Thr Arg Gly Ala             180       #           185       #           190 Tyr His Phe Lys Asp Pro Gln Tyr Pro Val Tr #p Glu Leu Thr Ile Arg         195           #       200           #       205 Val Trp Ser Glu Leu Asn Ile Gly Thr Gly Th #r Ser Ala Tyr Thr Ser     210               #   215               #   220 Leu Asn Val Leu Ala Arg Phe Thr Asp Leu Gl #u Leu His Gly Leu Thr 225                 2 #30                 2 #35                 2 #40 Pro Leu Ser Thr Gln Met Met Arg Asn Glu Ph #e Arg Val Ser Thr Thr                 245   #               250   #               255 Glu Asn Val Val Asn Leu Ser Asn Tyr Glu As #p Ala Arg Ala Lys Met             260       #           265       #           270 Ser Phe Ala Leu Asp Gln Glu Asp Trp Lys Se #r Asp Pro Ser Gln Gly         275           #       280           #       285 Gly Gly Ile Lys Ile Thr His Phe Thr Thr Tr #p Thr Ser Ile Pro Thr     290               #   295               #   300 Leu Ala Ala Gln Phe Pro Phe Asn Ala Ser As #p Ser Val Gly Gln Gln 305                 3 #10                 3 #15                 3 #20 Ile Lys Val Ile Pro Val Asp Pro Tyr Phe Ph #e Gln Met Thr Asn Thr                 325   #               330   #               335 Asn Pro Asp Gln Lys Cys Ile Thr Ala Leu Al #a Ser Ile Cys Gln Met             340       #           345       #           350 Phe Cys Phe Trp Arg Gly Asp Leu Val Phe As #p Phe Gln Val Phe Pro         355           #       360           #       365 Thr Lys Tyr His Ser Gly Arg Leu Leu Phe Cy #s Phe Val Pro Gly Asn     370               #   375               #   380 Glu Leu Ile Asp Val Ser Gly Ile Thr Leu Ly #s Gln Ala Thr Thr Ala 385                 3 #90                 3 #95                 4 #00 Pro Cys Ala Val Met Asp Ile Thr Gly Val Gl #n Ser Thr Leu Arg Phe                 405   #               410   #               415 Arg Val Pro Trp Ile Ser Asp Thr Pro Tyr Ar #g Val Asn Arg Tyr Thr             420       #           425       #           430 Lys Ser Ala His Gln Lys Gly Glu Tyr Thr Al #a Ile Gly Lys Leu Ile         435           #       440           #       445 Val Tyr Cys Tyr Asn Arg Leu Thr Ser Pro Se #r Asn Val Ala Ser His     450               #   455               #   460 Val Arg Val Asn Val Tyr Leu Ser Ala Ile As #n Leu Glu Cys Phe Ala 465                 4 #70                 4 #75                 4 #80 Pro Leu Tyr His Ala Met Asp Val Thr Thr Gl #n Val Gly Asp Asp Ser                 485   #               490   #               495 Gly Gly Phe Ser Thr Thr Val Ser Thr Glu Gl #n Asn Val Pro Asp Pro             500       #           505       #           510 Gln Val Gly Ile Thr Thr Met Lys Asp Leu Ly #s Gly Lys Ala Asn Arg         515           #       520           #       525 Gly Lys Met Asp Val Ser Gly Val Gln Ala Pr #o Val Gly Ala Ile Thr     530               #   535               #   540 Thr Ile Glu Asp Pro Val Leu Ala Lys Lys Va #l Pro Glu Thr Phe Pro 545                 5 #50                 5 #55                 5 #60 Glu Leu Lys Pro Gly Glu Ser Arg His Thr Se #r Asp His Met Ser Ile                 565   #               570   #               575 Tyr Lys Phe Met Gly Arg Ser His Phe Leu Cy #s Thr Phe Thr Phe Asn             580       #           585       #           590 Ser Asn Asn Lys Glu Tyr Thr Phe Pro Ile Th #r Leu Ser Ser Thr Ser         595           #       600           #       605 Asn Pro Pro His Gly Leu Pro Ser Thr Leu Ar #g Trp Phe Phe Asn Leu     610               #   615               #   620 Phe Gln Leu Tyr Arg Gly Pro Leu Asp Leu Th #r Ile Ile Ile Thr Gly 625                 6 #30                 6 #35                 6 #40 Ala Thr Asp Val Asp Gly Met Ala Trp Phe Th #r Pro Val Gly Leu Ala                 645   #               650   #               655 Val Asp Thr Pro Trp Val Glu Lys Glu Ser Al #a Leu Ser Ile Asp Tyr             660       #           665       #           670 Lys Thr Ala Leu Gly Ala Val Arg Phe Asn Th #r Arg Arg Thr Gly Asn         675           #       680           #       685 Ile Gln Ile Arg Leu Pro Trp Tyr Ser Tyr Le #u Tyr Ala Val Ser Gly     690               #   695               #   700 Ala Leu Asp Gly Leu Gly Asp Lys Thr Asp Se #r Thr Phe Gly Leu Val 705                 7 #10                 7 #15                 7 #20 Ser Ile Gln Ile Ala Asn Tyr Asn His Ser As #p Glu Tyr Leu Ser Phe                 725   #               730   #               735 Ser Cys Tyr Leu Ser Val Thr Glu Gln Ser Gl #u Phe Tyr Phe Pro Arg             740       #           745       #           750 Ala Pro Leu Asn Ser Asn Ala Met Leu Ser Th #r Glu Ser Met Met Ser         755           #       760           #       765 Arg Ile Ala Ala Gly Asp Leu Glu Ser Ser Va #l Asp Asp Pro Arg Ser     770               #   775               #   780 Glu Glu Asp Lys Arg Phe Glu Ser His Ile Gl #u Cys Arg Lys Pro Tyr 785                 7 #90                 7 #95                 8 #00 Lys Glu Leu Arg Leu Glu Val Gly Lys Gln Ar #g Leu Lys Tyr Ala Gln                 805   #               810   #               815 Glu Glu Leu Ser Asn Glu Val Leu Pro Pro Pr #o Arg Lys Met Lys Gly             820       #           825       #           830 Leu Phe Ser Gln Ala Lys Ile Ser Leu Phe Ty #r Thr Glu Glu His Glu         835           #       840           #       845 Ile Met Lys Phe Ser Trp Arg Gly Val Thr Al #a Asp Thr Arg Ala Leu     850               #   855               #   860 Arg Arg Phe Gly Phe Ser Leu Ala Ala Gly Ar #g Ser Val Trp Thr Leu 865                 8 #70                 8 #75                 8 #80 Glu Met Asp Ala Gly Val Leu Thr Gly Arg Le #u Ile Arg Leu Asn Asp                 885   #               890   #               895 Glu Lys Trp Thr Glu Met Lys Asp Asp Lys Il #e Val Ser Leu Ile Glu             900       #           905       #           910 Lys Phe Thr Ser Asn Lys Tyr Trp Ser Lys Va #l Asn Phe Pro His Gly         915           #       920           #       925 Met Leu Asp Leu Glu Glu Ile Ala Ala Asn Se #r Lys Asp Phe Pro Asn     930               #   935               #   940 Met Ser Glu Thr Asp Leu Cys Phe Leu Leu Hi #s Trp Leu Asn Pro Lys 945                 9 #50                 9 #55                 9 #60 Lys Ile Asn Leu Ala Asp Arg Met Leu Gly Le #u Ser Gly Val Gln Glu                 965   #               970   #               975 Ile Lys Glu Gln Gly Val Gly Leu Ile Ala Gl #u Cys Arg Thr Phe Leu             980       #           985       #           990 Asp Ser Ile Ala Gly Thr Leu Lys Ser Met Me #t Phe Gly Phe His His         995           #       1000           #      1005 Ser Val Thr Val Glu Ile Ile Asn Thr Val Le #u Cys Phe Val Lys Ser     1010              #   1015               #  1020 Gly Ile Leu Leu Tyr Val Ile Gln Gln Leu As #n Gln Asp Glu His Ser 1025                1030 #                1035  #               1040 His Ile Ile Gly Leu Leu Arg Val Met Asn Ty #r Ala Asp Ile Gly Cys                 1045  #               1050   #              1055 Ser Val Ile Ser Cys Gly Lys Val Phe Ser Ly #s Met Leu Glu Thr Val             1060      #           1065       #          1070 Phe Asn Trp Gln Met Asp Ser Arg Met Met Gl #u Leu Arg Thr Gln Ser         1075          #       1080           #      1085 Phe Ser Asn Trp Leu Arg Asp Ile Cys Ser Gl #y Ile Thr Ile Phe Lys     1090              #   1095               #  1100 Asn Phe Lys Asp Ala Ile Tyr Trp Leu Tyr Th #r Lys Leu Lys Asp Phe 1105                1110 #                1115  #               1120 Tyr Glu Val Asn Tyr Gly Lys Lys Lys Asp Il #e Leu Asn Ile Leu Lys                 1125  #               1130   #              1135 Asp Asn Gln Gln Lys Ile Glu Lys Ala Ile Gl #u Glu Ala Asp Glu Phe             1140      #           1145       #          1150 Cys Ile Leu Gln Ile Gln Asp Val Glu Lys Ph #e Glu Gln Tyr Gln Lys         1155          #       1160           #      1165 Gly Val Asp Leu Ile Gln Lys Leu Arg Thr Va #l His Ser Met Ala Gln     1170              #   1175               #  1180 Val Asp Pro Asn Leu Met Val His Leu Ser Pr #o Leu Arg Asp Cys Ile 1185                1190 #                1195  #               1200 Ala Arg Val His Gln Lys Leu Lys Asn Leu Gl #y Ser Ile Asn Gln Ala                 1205  #               1210   #              1215 Met Val Thr Arg Cys Glu Pro Val Val Cys Ty #r Leu Tyr Gly Lys Arg             1220      #           1225       #          1230 Gly Gly Gly Lys Ser Leu Thr Ser Ile Ala Le #u Ala Thr Lys Ile Cys         1235          #       1240           #      1245 Lys His Tyr Gly Val Glu Pro Glu Lys Asn Il #e Tyr Thr Lys Pro Val     1250              #   1255               #  1260 Ala Ser Asp Tyr Trp Asp Gly Tyr Ser Gly Gl #n Leu Val Cys Ile Ile 1265                1270 #                1275  #               1280 Asp Asp Ile Gly Gln Asn Thr Thr Asp Glu As #p Trp Ser Asp Phe Cys                 1285  #               1290   #              1295 Gln Leu Val Ser Gly Cys Pro Met Arg Leu As #n Met Ala Ser Leu Glu             1300      #           1305       #          1310 Glu Lys Gly Arg His Phe Ser Ser Pro Phe Il #e Ile Ala Thr Ser Asn         1315          #       1320           #      1325 Trp Ser Asn Pro Ser Pro Lys Thr Val Tyr Va #l Lys Glu Ala Ile Asp     1330              #   1335               #  1340 Arg Arg Leu His Phe Lys Val Glu Val Lys Pr #o Ala Ser Phe Phe Lys 1345                1350 #                1355  #               1360 Asn Pro His Asn Asp Met Leu Asn Val Asn Le #u Ala Lys Thr Asn Asp                 1365  #               1370   #              1375 Ala Ile Lys Asp Met Ser Cys Val Asp Leu Il #e Met Asp Gly His Asn             1380      #           1385       #          1390 Val Ser Leu Met Asp Leu Leu Ser Ser Leu Va #l Met Thr Val Glu Ile         1395          #       1400           #      1405 Arg Lys Gln Asn Met Thr Glu Phe Met Glu Le #u Trp Ser Gln Gly Ile     1410              #   1415               #  1420 Ser Asp Asp Asp Asn Asp Ser Ala Val Ala Gl #u Phe Phe Gln Ser Phe 1425                1430 #                1435  #               1440 Pro Ser Gly Glu Pro Ser Asn Ser Lys Leu Se #r Gly Phe Phe Gln Ser                 1445  #               1450   #              1455 Val Thr Asn His Lys Trp Val Ala Val Gly Al #a Ala Val Gly Ile Leu             1460      #           1465       #          1470 Gly Val Leu Val Gly Gly Trp Phe Val Tyr Ly #s His Phe Ser Arg Lys         1475          #       1480           #      1485 Glu Glu Glu Pro Ile Pro Ala Glu Gly Val Ty #r His Gly Val Thr Lys     1490              #   1495               #  1500 Pro Lys Gln Val Ile Lys Leu Asp Ala Asp Pr #o Val Glu Ser Gln Ser 1505                1510 #                1515  #               1520 Thr Leu Glu Ile Ala Gly Leu Val Arg Lys As #n Leu Val Gln Phe Gly                 1525  #               1530   #              1535 Val Gly Glu Lys Asn Gly Cys Val Arg Trp Va #l Met Asn Ala Leu Gly             1540      #           1545       #          1550 Val Lys Asp Asp Trp Leu Leu Val Pro Ser Hi #s Ala Tyr Lys Phe Glu         1555          #       1560           #      1565 Lys Asp Tyr Glu Met Met Glu Phe Tyr Phe As #n Arg Gly Gly Thr Tyr     1570              #   1575               #  1580 Tyr Ser Ile Ser Ala Gly Asn Val Val Ile Gl #n Ser Leu Asp Val Gly 1585                1590 #                1595  #               1600 Phe Gln Asp Val Val Leu Met Lys Val Pro Th #r Ile Pro Lys Phe Arg                 1605  #               1610   #              1615 Asp Ile Thr Gln His Phe Ile Lys Lys Gly As #p Val Pro Arg Ala Leu             1620      #           1625       #          1630 Asn Arg Leu Ala Thr Leu Val Thr Thr Val As #n Gly Thr Pro Met Leu         1635          #       1640           #      1645 Ile Ser Glu Gly Pro Leu Lys Met Glu Glu Ly #s Ala Thr Tyr Val His     1650              #   1655               #  1660 Lys Lys Asn Asp Gly Thr Thr Val Asp Leu Th #r Val Asp Gln Ala Trp 1665                1670 #                1675  #               1680 Arg Gly Lys Gly Glu Gly Leu Pro Gly Met Cy #s Gly Gly Ala Leu Val                 1685  #               1690   #              1695 Ser Ser Asn Gln Ser Ile Gln Asn Ala Ile Le #u Gly Ile His Val Ala             1700      #           1705       #          1710 Gly Gly Asn Ser Ile Leu Val Ala Lys Leu Va #l Thr Gln Glu Met Phe         1715          #       1720           #      1725 Gln Asn Ile Asp Lys Lys Ile Glu Ser Gln Ar #g Ile Met Lys Val Glu     1730              #   1735               #  1740 Phe Thr Gln Cys Ser Met Asn Val Val Ser Ly #s Thr Leu Phe Arg Lys 1745                1750 #                1755  #               1760 Ser Pro Ile Tyr His His Ile Asp Lys Thr Me #t Ile Asn Phe Pro Ala                 1765  #               1770   #              1775 Ala Met Pro Phe Ser Lys Ala Glu Ile Asp Pr #o Met Ala Val Met Leu             1780      #           1785       #          1790 Ser Lys Tyr Ser Leu Pro Ile Val Glu Glu Pr #o Glu Asp Tyr Lys Glu         1795          #       1800           #      1805 Ala Ser Ile Phe Tyr Gln Asn Lys Ile Val Gl #y Lys Thr Gln Leu Val     1810              #   1815               #  1820 Asp Asp Phe Leu Asp Leu Asp Met Ala Ile Th #r Gly Ala Pro Gly Ile 1825                1830 #                1835  #               1840 Asp Ala Ile Asn Met Asp Ser Ser Pro Gly Ph #e Pro Tyr Val Gln Glu                 1845  #               1850   #              1855 Lys Leu Thr Lys Arg Asp Leu Ile Trp Leu As #p Glu Asn Gly Leu Leu             1860      #           1865       #          1870 Leu Gly Val His Pro Arg Leu Ala Gln Arg Il #e Leu Phe Asn Thr Val         1875          #       1880           #      1885 Met Met Glu Asn Cys Ser Asp Leu Asp Val Va #l Phe Thr Thr Cys Pro     1890              #   1895               #  1900 Lys Asp Glu Leu Arg Pro Leu Glu Lys Val Le #u Glu Ser Lys Thr Arg 1905                1910 #                1915  #               1920 Ala Ile Asp Ala Cys Pro Leu Asp Tyr Ser Il #e Leu Cys Arg Met Tyr                 1925  #               1930   #              1935 Trp Gly Pro Ala Ile Ser Tyr Phe His Leu As #n Pro Gly Phe His Thr             1940      #           1945       #          1950 Gly Val Ala Ile Gly Ile Asp Pro Asp Arg Gl #n Trp Asp Glu Leu Phe         1955          #       1960           #      1965 Lys Thr Met Ile Arg Phe Gly Asp Val Gly Le #u Asp Leu Asp Phe Ser     1970              #   1975               #  1980 Ala Phe Asp Ala Ser Leu Ser Pro Phe Met Il #e Arg Glu Ala Gly Arg 1985                1990 #                1995  #               2000 Ile Met Ser Glu Leu Ser Gly Thr Pro Ser Hi #s Phe Gly Thr Ala Leu                 2005  #               2010   #              2015 Ile Asn Thr Ile Ile Tyr Ser Lys His Leu Le #u Tyr Asn Cys Cys Tyr             2020      #           2025       #          2030 His Val Cys Gly Ser Met Pro Ser Gly Ser Pr #o Cys Thr Ala Leu Leu         2035          #       2040           #      2045 Asn Ser Ile Ile Asn Asn Val Asn Leu Tyr Ty #r Val Phe Ser Lys Ile     2050              #   2055               #  2060 Phe Gly Lys Ser Pro Val Phe Phe Cys Gln Al #a Leu Lys Ile Leu Cys 2065                2070 #                2075  #               2080 Tyr Gly Asp Asp Val Leu Ile Val Phe Ser Ar #g Asp Val Gln Ile Asp                 2085  #               2090   #              2095 Asn Leu Asp Leu Ile Gly Gln Lys Ile Val As #p Glu Phe Lys Lys Leu             2100      #           2105       #          2110 Gly Met Thr Ala Thr Ser Ala Asp Lys Asn Va #l Pro Gln Leu Lys Pro         2115          #       2120           #      2125 Val Ser Glu Leu Thr Phe Leu Lys Arg Ser Ph #e Asn Leu Val Glu Asp     2130              #   2135               #  2140 Arg Ile Arg Pro Ala Ile Ser Glu Lys Thr Il #e Trp Ser Leu Ile Ala 2145                2150 #                2155  #               2160 Trp Gln Arg Ser Asn Ala Glu Phe Glu Gln As #n Leu Glu Asn Ala Gln                 2165  #               2170   #              2175 Trp Phe Ala Phe Met His Gly Tyr Glu Phe Ty #r Gln Lys Phe Tyr Tyr             2180      #           2185       #          2190 Phe Val Gln Ser Cys Leu Glu Lys Glu Met Il #e Glu Tyr Arg Leu Lys         2195          #       2200           #      2205 Ser Tyr Asp Trp Trp Arg Met Arg Phe Tyr As #p Gln Cys Phe Ile Cys     2210              #   2215               #  2220 Asp Leu Ser 2225 <210> SEQ ID NO 3 <211> LENGTH: 7488 <212> TYPE: DNA <213> ORGANISM: Attenuated (Pass 35) HAV, strain  #HM-175 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (730)..(7410) <400> SEQUENCE: 3 ttcaagaggg gtctccggga atttccggag tccctcttgg aagtccatgg tg #aggggact     60 tgatacctca ccgccgtttg cctaggctat aggctaaatt ttccctttcc ct #tttccctt    120 tcccattccc ttttgcttgt aaatattgat tcctgcaggt tcagggttct ta #aatctgtt    180 tctctataag aacactcatt ttcacgcttt ctgtcttctt tcttccaggg ct #ctcccctt    240 gccctaggct ctggccgttg cgcccggcgg ggtcaactcc atgattagca tg #gagctgta    300 ggagtctaaa ttggggacac agatgtttgg aacgtcacct tgcagtgtta ac #ttggcttt    360 catgaatctc tttgatcttc cacaaggggt aggctacggg tgaaacctct ta #ggctaata    420 cttctatgaa gagatgcctt ggatagggta acagcggcgg atattggtga gt #tgttaaga    480 caaaaaccat tcaacgccgg aggactgact ctcatccagt ggatgcattg ag #tggattga    540 ctgtcagggc tgtctttagg cttaattcca gacctctctg tgcttagggc aa #acatcatt    600 tggccttaaa tgggattctg tgagagggga tccctccatt gacagctgga ct #gttctttg    660 gggccttatg tggtgtttgc ctctgaggta ctcaggggca tttaggtttt tc #ctcattct    720 taaataata atg aac atg tct aga caa ggt att ttc # cag act gtt ggg agt    771           Met Asn Met Ser Arg  #Gln Gly Ile Phe Gln Thr Val Gly Ser             1       #         5          #         10 ggt ctt gac cac atc ctg tct ttg gca gac at #t gag gaa gag caa atg      819 Gly Leu Asp His Ile Leu Ser Leu Ala Asp Il #e Glu Glu Glu Gln Met  15                  # 20                  # 25                  # 30 att caa tca gtt gat agg act gca gtg act gg #t gct tct tat ttt act      867 Ile Gln Ser Val Asp Arg Thr Ala Val Thr Gl #y Ala Ser Tyr Phe Thr                  35  #                 40  #                 45 tct gtg gat caa tct tca gtt cat aca gct ga #g gtt gga tca cac cag      915 Ser Val Asp Gln Ser Ser Val His Thr Ala Gl #u Val Gly Ser His Gln              50      #             55      #             60 gtt gaa cct ttg aga acc tct gtt gat aaa cc #c ggt tca aag agg act      963 Val Glu Pro Leu Arg Thr Ser Val Asp Lys Pr #o Gly Ser Lys Arg Thr          65          #         70          #         75 cag gga gag aaa ttt ttc ttg att cat tct gc #a gat tgg ctt act aca     1011 Gln Gly Glu Lys Phe Phe Leu Ile His Ser Al #a Asp Trp Leu Thr Thr      80              #     85              #     90 cat gct ctt ttc cat gaa gtt gca aaa ttg ga #t gtg gtg aaa tta tta     1059 His Ala Leu Phe His Glu Val Ala Lys Leu As #p Val Val Lys Leu Leu  95                  #100                  #105                  #110 tac aat gag cag ttt gct gtt caa ggg ttg tt #g aga tac cat aca tat     1107 Tyr Asn Glu Gln Phe Ala Val Gln Gly Leu Le #u Arg Tyr His Thr Tyr                 115   #               120   #               125 gca aga ttt ggc att gaa att caa gtt cag at #a aac cct aca cct ttc     1155 Ala Arg Phe Gly Ile Glu Ile Gln Val Gln Il #e Asn Pro Thr Pro Phe             130       #           135       #           140 caa cag ggg gga ttg atc tgt gct atg gtt cc #t ggt gac cag agc tat     1203 Gln Gln Gly Gly Leu Ile Cys Ala Met Val Pr #o Gly Asp Gln Ser Tyr         145           #       150           #       155 ggt tct ata gca tca ttg act gtt tat cct ca #t ggt ttg tta aat tgc     1251 Gly Ser Ile Ala Ser Leu Thr Val Tyr Pro Hi #s Gly Leu Leu Asn Cys     160               #   165               #   170 aat att aac aat gtg gtt aga ata aag gtt cc #a ttt att tac aca aga     1299 Asn Ile Asn Asn Val Val Arg Ile Lys Val Pr #o Phe Ile Tyr Thr Arg 175                 1 #80                 1 #85                 1 #90 ggt gct tac cac ttt aaa gat cca caa tac cc #a gtt tgg gaa ttg aca     1347 Gly Ala Tyr His Phe Lys Asp Pro Gln Tyr Pr #o Val Trp Glu Leu Thr                 195   #               200   #               205 att aga gtt tgg tca gaa tta aat att ggg ac #a gga act tca gct tat     1395 Ile Arg Val Trp Ser Glu Leu Asn Ile Gly Th #r Gly Thr Ser Ala Tyr             210       #           215       #           220 act tca ctc aat gtt tta gct aga ttt aca ga #t ttg gag ttg cat gga     1443 Thr Ser Leu Asn Val Leu Ala Arg Phe Thr As #p Leu Glu Leu His Gly         225           #       230           #       235 tta act cct ctt tct aca caa atg atg aga aa #t gaa ttt agg gtc agt     1491 Leu Thr Pro Leu Ser Thr Gln Met Met Arg As #n Glu Phe Arg Val Ser     240               #   245               #   250 act act gag aat gtg gtg aat ctg tca aat ta #t gaa gat gca aga gca     1539 Thr Thr Glu Asn Val Val Asn Leu Ser Asn Ty #r Glu Asp Ala Arg Ala 255                 2 #60                 2 #65                 2 #70 aag atg tct ttt gct ttg gat cag gaa gat tg #g aaa tct gat ccg tcc     1587 Lys Met Ser Phe Ala Leu Asp Gln Glu Asp Tr #p Lys Ser Asp Pro Ser                 275   #               280   #               285 cag ggt ggt ggg atc aaa att act cat ttt ac #t act tgg aca tct att     1635 Gln Gly Gly Gly Ile Lys Ile Thr His Phe Th #r Thr Trp Thr Ser Ile             290       #           295       #           300 cca act ttg gct gct cag ttt cca ttt aat gc #t tca gac tca gtt ggt     1683 Pro Thr Leu Ala Ala Gln Phe Pro Phe Asn Al #a Ser Asp Ser Val Gly         305           #       310           #       315 caa caa att aaa gtt att cca gtt gac cca ta #t ttt ttc caa atg aca     1731 Gln Gln Ile Lys Val Ile Pro Val Asp Pro Ty #r Phe Phe Gln Met Thr     320               #   325               #   330 aat aca aat cct gac caa aaa tgt ata act gc #t ttg gct tct att tgt     1779 Asn Thr Asn Pro Asp Gln Lys Cys Ile Thr Al #a Leu Ala Ser Ile Cys 335                 3 #40                 3 #45                 3 #50 cag atg ttt tgt ttt tgg aga gga gat ctt gt #c ttt gat ttt caa gtt     1827 Gln Met Phe Cys Phe Trp Arg Gly Asp Leu Va #l Phe Asp Phe Gln Val                 355   #               360   #               365 ttt ccc acc aaa tat cat tca ggt aga tta ct #g ttt tgt ttt gtt cct     1875 Phe Pro Thr Lys Tyr His Ser Gly Arg Leu Le #u Phe Cys Phe Val Pro             370       #           375       #           380 ggc aat gag cta ata gat gtt tct gga atc ac #a tta aag caa gca act     1923 Gly Asn Glu Leu Ile Asp Val Ser Gly Ile Th #r Leu Lys Gln Ala Thr         385           #       390           #       395 act gct cct tgt gca gta atg gat att aca gg #a gtg cag tca act ttg     1971 Thr Ala Pro Cys Ala Val Met Asp Ile Thr Gl #y Val Gln Ser Thr Leu     400               #   405               #   410 aga ttt cgt gtt ccc tgg att tct gac act cc #t tac aga gtg aac agg     2019 Arg Phe Arg Val Pro Trp Ile Ser Asp Thr Pr #o Tyr Arg Val Asn Arg 415                 4 #20                 4 #25                 4 #30 tat aca aag tca gca cat cag aaa ggt gag ta #c act gcc att ggg aag     2067 Tyr Thr Lys Ser Ala His Gln Lys Gly Glu Ty #r Thr Ala Ile Gly Lys                 435   #               440   #               445 ctt att gtg tat tgt tat aac aga ttg acc tc #t cct tct aac gtt gct     2115 Leu Ile Val Tyr Cys Tyr Asn Arg Leu Thr Se #r Pro Ser Asn Val Ala             450       #           455       #           460 tcc cat gtc aga gtg aat gtt tat ctt tca gc #a att aac ttg gaa tgt     2163 Ser His Val Arg Val Asn Val Tyr Leu Ser Al #a Ile Asn Leu Glu Cys         465           #       470           #       475 ttt gct cct ctt tat cat gct atg gat gtt ac #t aca caa gtt gga gat     2211 Phe Ala Pro Leu Tyr His Ala Met Asp Val Th #r Thr Gln Val Gly Asp     480               #   485               #   490 gat tct gga ggt ttt tca aca aca gtt tct ac #a gaa cag aat gtt cca     2259 Asp Ser Gly Gly Phe Ser Thr Thr Val Ser Th #r Glu Gln Asn Val Pro 495                 5 #00                 5 #05                 5 #10 gat ccc caa gtt ggt ata aca acc atg aaa ga #t ttg aaa gga aaa gct     2307 Asp Pro Gln Val Gly Ile Thr Thr Met Lys As #p Leu Lys Gly Lys Ala                 515   #               520   #               525 aac aga ggg aaa atg gat gtt tca gga gta ca #a gca cct gtg gga gct     2355 Asn Arg Gly Lys Met Asp Val Ser Gly Val Gl #n Ala Pro Val Gly Ala             530       #           535       #           540 atc aca aca att gag gat cca gtt tta gca aa #g aaa gta cct gag aca     2403 Ile Thr Thr Ile Glu Asp Pro Val Leu Ala Ly #s Lys Val Pro Glu Thr         545           #       550           #       555 ttt cct gaa ttg aaa cct gga gaa tcc aga ca #t aca tca gat cat atg     2451 Phe Pro Glu Leu Lys Pro Gly Glu Ser Arg Hi #s Thr Ser Asp His Met     560               #   565               #   570 tcc atc tac aag ttt atg gga agg tct cat tt #c ttg tgc act ttt aca     2499 Ser Ile Tyr Lys Phe Met Gly Arg Ser His Ph #e Leu Cys Thr Phe Thr 575                 5 #80                 5 #85                 5 #90 ttc aat tca aat aat aaa gag tac aca ttt cc #t ata acc ttg tct tca     2547 Phe Asn Ser Asn Asn Lys Glu Tyr Thr Phe Pr #o Ile Thr Leu Ser Ser                 595   #               600   #               605 acc tct aat cct cct cat ggt ttg cca tca ac #a ctg agg tgg ttt ttc     2595 Thr Ser Asn Pro Pro His Gly Leu Pro Ser Th #r Leu Arg Trp Phe Phe             610       #           615       #           620 aac ttg ttt cag ttg tat aga ggg cct tta ga #t ctg aca att att att     2643 Asn Leu Phe Gln Leu Tyr Arg Gly Pro Leu As #p Leu Thr Ile Ile Ile         625           #       630           #       635 aca gga gca act gat gta gat ggc atg gcc tg #g ttc act cca gta ggt     2691 Thr Gly Ala Thr Asp Val Asp Gly Met Ala Tr #p Phe Thr Pro Val Gly     640               #   645               #   650 ctt gcc gtt gat act cct tgg gta gag aag ga #g tca gct ttg tct att     2739 Leu Ala Val Asp Thr Pro Trp Val Glu Lys Gl #u Ser Ala Leu Ser Ile 655                 6 #60                 6 #65                 6 #70 gac tac aaa act gct ctt gga gct gtc aga tt #t aac aca agg aga aca     2787 Asp Tyr Lys Thr Ala Leu Gly Ala Val Arg Ph #e Asn Thr Arg Arg Thr                 675   #               680   #               685 ggg aac att cag att aga tta cca tgg tat tc #t tat tta tat gct gtg     2835 Gly Asn Ile Gln Ile Arg Leu Pro Trp Tyr Se #r Tyr Leu Tyr Ala Val             690       #           695       #           700 tct gga gca ctg gat ggt ttg gga gac aag ac #a gat tct aca ttt gga     2883 Ser Gly Ala Leu Asp Gly Leu Gly Asp Lys Th #r Asp Ser Thr Phe Gly         705           #       710           #       715 ttg gtt tct att cag att gca aat tac aat ca #t tct gat gaa tac ttg     2931 Leu Val Ser Ile Gln Ile Ala Asn Tyr Asn Hi #s Ser Asp Glu Tyr Leu     720               #   725               #   730 tct ttt agt tgt tat ttg tct gtc aca gaa ca #a tca gag ttt tat ttt     2979 Ser Phe Ser Cys Tyr Leu Ser Val Thr Glu Gl #n Ser Glu Phe Tyr Phe 735                 7 #40                 7 #45                 7 #50 ccc aga gct cca ttg aac tca aat gcc atg tt #a tcc act gta tca atg     3027 Pro Arg Ala Pro Leu Asn Ser Asn Ala Met Le #u Ser Thr Val Ser Met                 755   #               760   #               765 atg agc aga att gca gct gga gac ttg gag tc #a tca gtg gat gat cct     3075 Met Ser Arg Ile Ala Ala Gly Asp Leu Glu Se #r Ser Val Asp Asp Pro             770       #           775       #           780 aga tca gag gaa gat aaa aga ttt gag agt ca #t ata gaa tgc agg aag     3123 Arg Ser Glu Glu Asp Lys Arg Phe Glu Ser Hi #s Ile Glu Cys Arg Lys         785           #       790           #       795 cca tat aaa gaa ctg aga tta gaa gtt ggg aa #a caa aga ctc aag tat     3171 Pro Tyr Lys Glu Leu Arg Leu Glu Val Gly Ly #s Gln Arg Leu Lys Tyr     800               #   805               #   810 gct cag gaa gaa ttg tca agt gaa gta ctt cc #a ccc cct agg aaa atg     3219 Ala Gln Glu Glu Leu Ser Ser Glu Val Leu Pr #o Pro Pro Arg Lys Met 815                 8 #20                 8 #25                 8 #30 aag gga ctg ttt tca caa gcc aaa att tct ct #t ttt tat act gag gag     3267 Lys Gly Leu Phe Ser Gln Ala Lys Ile Ser Le #u Phe Tyr Thr Glu Glu                 835   #               840   #               845 cat gaa ata atg aag ttt tcc tgg aga ggt gt #g act gct gat act aga     3315 His Glu Ile Met Lys Phe Ser Trp Arg Gly Va #l Thr Ala Asp Thr Arg             850       #           855       #           860 gct tta agg agg ttt gga ttc tct ttg gcc gc #a ggc aga agt gtg tgg     3363 Ala Leu Arg Arg Phe Gly Phe Ser Leu Ala Al #a Gly Arg Ser Val Trp         865           #       870           #       875 act ctt gaa atg gat gct ggg gtt ctt act gg #g aga ctg att aga ttg     3411 Thr Leu Glu Met Asp Ala Gly Val Leu Thr Gl #y Arg Leu Ile Arg Leu     880               #   885               #   890 aat gat gag aaa tgg aca gaa atg aag gat ga #c aag att gtt tca ttg     3459 Asn Asp Glu Lys Trp Thr Glu Met Lys Asp As #p Lys Ile Val Ser Leu 895                 9 #00                 9 #05                 9 #10 att gaa aag ttt aca agt aac aaa tat tgg tc #c aaa gtg aat ttc cca     3507 Ile Glu Lys Phe Thr Ser Asn Lys Tyr Trp Se #r Lys Val Asn Phe Pro                 915   #               920   #               925 cat ggg atg ttg gat ctt gaa gaa att gct gc #c aat tct aag gat ttt     3555 His Gly Met Leu Asp Leu Glu Glu Ile Ala Al #a Asn Ser Lys Asp Phe             930       #           935       #           940 cct aac atg tct gaa acg gat ttg tgt ttc tt #g ctg cat tgg tta aat     3603 Pro Asn Met Ser Glu Thr Asp Leu Cys Phe Le #u Leu His Trp Leu Asn         945           #       950           #       955 cca aag aaa att aat tta gca gat aga atg ct #t gga ttg tct gga gtt     3651 Pro Lys Lys Ile Asn Leu Ala Asp Arg Met Le #u Gly Leu Ser Gly Val     960               #   965               #   970 cag gaa att aaa gaa caa ggt gtt gga tta at #a gca gag tgt aga act     3699 Gln Glu Ile Lys Glu Gln Gly Val Gly Leu Il #e Ala Glu Cys Arg Thr 975                 9 #80                 9 #85                 9 #90 ttc tta gat tct att gct gga act tta aaa tc #t atg atg ttt gga ttt     3747 Phe Leu Asp Ser Ile Ala Gly Thr Leu Lys Se #r Met Met Phe Gly Phe                 995   #               1000   #              1005 cat cat tct gtg act gtt gaa att ata aac ac #t gtg ctc tgt ttt gtt     3795 His His Ser Val Thr Val Glu Ile Ile Asn Th #r Val Leu Cys Phe Val             1010      #           1015       #          1020 aag agt gga att ttg ctt tat gta ata caa ca #a ttg aat cag gat gaa     3843 Lys Ser Gly Ile Leu Leu Tyr Val Ile Gln Gl #n Leu Asn Gln Asp Glu         1025          #       1030           #      1035 cat tct cac ata att ggt ttg ttg aga gtc at #g aat tat gta gat att     3891 His Ser His Ile Ile Gly Leu Leu Arg Val Me #t Asn Tyr Val Asp Ile     1040              #   1045               #  1050 ggt tgt tca gtt att tca tgt gcc aaa gtt tt #t tcc aaa atg ctg gaa     3939 Gly Cys Ser Val Ile Ser Cys Ala Lys Val Ph #e Ser Lys Met Leu Glu 1055                1060 #                1065  #               1070 aca gtc ttt aat tgg caa atg gac tcc aga at #g atg gag tta agg act     3987 Thr Val Phe Asn Trp Gln Met Asp Ser Arg Me #t Met Glu Leu Arg Thr                 1075  #               1080   #              1085 cag agt ttt tcc aac tgg tta aga gat att tg #t tct ggg atc acc att     4035 Gln Ser Phe Ser Asn Trp Leu Arg Asp Ile Cy #s Ser Gly Ile Thr Ile             1090      #           1095       #          1100 ttc aaa aac ttc aag gat gca att tat tgg ct #t tat aca aaa tta atg     4083 Phe Lys Asn Phe Lys Asp Ala Ile Tyr Trp Le #u Tyr Thr Lys Leu Met         1105          #       1110           #      1115 gac ttt tat gaa gtg aat tat ggc aag aag aa #g gac att tta aat att     4131 Asp Phe Tyr Glu Val Asn Tyr Gly Lys Lys Ly #s Asp Ile Leu Asn Ile     1120              #   1125               #  1130 ctt aaa gat aac caa caa aaa ata gag aaa gc #c att gag gaa gcc gat     4179 Leu Lys Asp Asn Gln Gln Lys Ile Glu Lys Al #a Ile Glu Glu Ala Asp 1135               1140  #               1145   #              1150 aaa ttt tgc att ttg caa atc caa gat gtg ga #a aaa tct gaa cag tat     4227 Lys Phe Cys Ile Leu Gln Ile Gln Asp Val Gl #u Lys Ser Glu Gln Tyr                 1155  #               1160   #              1165 cag aaa ggg gtt gac ttg ata caa aaa ttg ag #a act gtt cat tca atg     4275 Gln Lys Gly Val Asp Leu Ile Gln Lys Leu Ar #g Thr Val His Ser Met             1170      #           1175       #          1180 gct cag gtt gat cca aat tta atg gtt cat tt #g tca cct ttg aga gat     4323 Ala Gln Val Asp Pro Asn Leu Met Val His Le #u Ser Pro Leu Arg Asp         1185          #       1190           #      1195 tgt ata gca aga gtt cat cag aaa ctt aaa aa #c ctt gga tct ata aat     4371 Cys Ile Ala Arg Val His Gln Lys Leu Lys As #n Leu Gly Ser Ile Asn     1200              #   1205               #  1210 cag gca atg gta acg aga tgt gag cca gtt gt #t tgt tat tta tat ggc     4419 Gln Ala Met Val Thr Arg Cys Glu Pro Val Va #l Cys Tyr Leu Tyr Gly 1215                1220 #                1225  #               1230 aaa aga ggg gga gga aag agc tta aca tca at #t gca ttg gca acc aaa     4467 Lys Arg Gly Gly Gly Lys Ser Leu Thr Ser Il #e Ala Leu Ala Thr Lys                 1235  #               1240   #              1245 att tgt aaa cat tat ggt gtt gag cct gaa aa #g aat atc tat act aaa     4515 Ile Cys Lys His Tyr Gly Val Glu Pro Glu Ly #s Asn Ile Tyr Thr Lys             1250      #           1255       #          1260 cct gtg gct tca gat tac tgg gat gga tat ag #t gga caa tta att tgc     4563 Pro Val Ala Ser Asp Tyr Trp Asp Gly Tyr Se #r Gly Gln Leu Ile Cys         1265          #       1270           #      1275 atc att gat gat att ggc caa aac aca aca ga #t gag gat tgg tca gat     4611 Ile Ile Asp Asp Ile Gly Gln Asn Thr Thr As #p Glu Asp Trp Ser Asp     1280              #   1285               #  1290 ttt tgt cag tta gtg tca gga tgt cca atg ag #a tta aac atg gcc tct     4659 Phe Cys Gln Leu Val Ser Gly Cys Pro Met Ar #g Leu Asn Met Ala Ser 1295                1300 #                1305  #               1310 ctt gag gag aag ggt agg cat ttt tct tct cc #t ttt ata ata gca act     4707 Leu Glu Glu Lys Gly Arg His Phe Ser Ser Pr #o Phe Ile Ile Ala Thr                 1315  #               1320   #              1325 tca aat tgg tca aat cca agt cca aaa aca gt #t tat gtt aag gaa gca     4755 Ser Asn Trp Ser Asn Pro Ser Pro Lys Thr Va #l Tyr Val Lys Glu Ala             1330      #           1335       #          1340 att gac cgc aga ctc cat ttc aag gtt gaa gt #t aaa cct gct tca ttt     4803 Ile Asp Arg Arg Leu His Phe Lys Val Glu Va #l Lys Pro Ala Ser Phe         1345          #       1350           #      1355 ttc aaa aat cct cac aat gat atg ttg aat gt #t aat tta gct aaa aca     4851 Phe Lys Asn Pro His Asn Asp Met Leu Asn Va #l Asn Leu Ala Lys Thr     1360              #   1365               #  1370 aat gat gca atc aaa gat atg tct tgt gtt ga #t ttg ata atg gat gga     4899 Asn Asp Ala Ile Lys Asp Met Ser Cys Val As #p Leu Ile Met Asp Gly 1375                1380 #                1385  #               1390 cat aat gtt tca ttg atg gat ttg ctc agt tc #t tta gtc atg aca gtt     4947 His Asn Val Ser Leu Met Asp Leu Leu Ser Se #r Leu Val Met Thr Val                 1395  #               1400   #              1405 gaa att aga aaa caa aac atg act gaa ttc at #g gag ttg tgg tct cag     4995 Glu Ile Arg Lys Gln Asn Met Thr Glu Phe Me #t Glu Leu Trp Ser Gln             1410      #           1415       #          1420 gga att tca gat gat gat aat gat agt gca gt #a gct gag ttt ttc cag     5043 Gly Ile Ser Asp Asp Asp Asn Asp Ser Ala Va #l Ala Glu Phe Phe Gln         1425          #       1430           #      1435 tct ttt cca tct ggt gaa cca tcg aac tct aa #a tta tct ggc ttt ttc     5091 Ser Phe Pro Ser Gly Glu Pro Ser Asn Ser Ly #s Leu Ser Gly Phe Phe     1440              #   1445               #  1450 caa tct gtt act aat cac aag tgg gtt gct gt #g gga gct gca gtt ggc     5139 Gln Ser Val Thr Asn His Lys Trp Val Ala Va #l Gly Ala Ala Val Gly 1455                1460 #                1465  #               1470 att ctt gga gtg ctc gtt gga gga tgg ttt gt #g tat aag cat ttc tcc     5187 Ile Leu Gly Val Leu Val Gly Gly Trp Phe Va #l Tyr Lys His Phe Ser                 1475  #               1480   #              1485 cgc aaa gag gaa gaa cca atc cca gct gaa gg #g gta tat tat ggt gta     5235 Arg Lys Glu Glu Glu Pro Ile Pro Ala Glu Gl #y Val Tyr Tyr Gly Val             1490      #           1495       #          1500 act aag ccc aag caa gtg att aaa tta gat gc #a gat cca gta gaa tct     5283 Thr Lys Pro Lys Gln Val Ile Lys Leu Asp Al #a Asp Pro Val Glu Ser         1505          #       1510           #      1515 cag tca act ttg gaa ata gca gga ctg gtt ag #g aag aac ttg gtt cag     5331 Gln Ser Thr Leu Glu Ile Ala Gly Leu Val Ar #g Lys Asn Leu Val Gln     1520              #   1525               #  1530 ttt gga gtt gga gag aag aat gga tgt gtg ag #a tgg gtt atg aat gcc     5379 Phe Gly Val Gly Glu Lys Asn Gly Cys Val Ar #g Trp Val Met Asn Ala 1535               1540  #               1545   #              1550 ttg gga gtg aaa gat gat tgg ctg ctt gtg cc #t tcc cat gct tat aaa     5427 Leu Gly Val Lys Asp Asp Trp Leu Leu Val Pr #o Ser His Ala Tyr Lys                 1555  #               1560   #              1565 ttt gag aaa gat tat gaa atg atg gag ttt ta #t ttt aat aga ggt gga     5475 Phe Glu Lys Asp Tyr Glu Met Met Glu Phe Ty #r Phe Asn Arg Gly Gly             1570      #           1575       #          1580 act tac tat tca att tca gct ggt aat gtt gt #t att caa tct ttg gat     5523 Thr Tyr Tyr Ser Ile Ser Ala Gly Asn Val Va #l Ile Gln Ser Leu Asp         1585          #       1590           #      1595 gtg gga ttc cag gat gtt gtt ctg atg aag gt #t cct aca att cct aag     5571 Val Gly Phe Gln Asp Val Val Leu Met Lys Va #l Pro Thr Ile Pro Lys     1600              #   1605               #  1610 ttt aga gat att act cag cat ttt att aag aa #a ggg gat gtg cct aga     5619 Phe Arg Asp Ile Thr Gln His Phe Ile Lys Ly #s Gly Asp Val Pro Arg 1615                1620 #                1625  #               1630 gct ttg aat cgc ctg gca aca tta gtg aca ac #t gta aat gga acc cct     5667 Ala Leu Asn Arg Leu Ala Thr Leu Val Thr Th #r Val Asn Gly Thr Pro                 1635  #               1640   #              1645 atg tta att tct gag ggc cca cta aag atg ga #a gag aaa gct act tat     5715 Met Leu Ile Ser Glu Gly Pro Leu Lys Met Gl #u Glu Lys Ala Thr Tyr             1650      #           1655       #          1660 gtt cat aag aaa aat gat ggt aca aca gtt ga #t tta act gtg gat cag     5763 Val His Lys Lys Asn Asp Gly Thr Thr Val As #p Leu Thr Val Asp Gln         1665          #       1670           #      1675 gca tgg aga gga aaa ggc gaa ggt ctt cct gg #a atg tgt ggt ggg gcc     5811 Ala Trp Arg Gly Lys Gly Glu Gly Leu Pro Gl #y Met Cys Gly Gly Ala     1680              #   1685               #  1690 ttg gtt tca tcg aat caa tct ata cag aat gc #a atc ttg ggc atc cat     5859 Leu Val Ser Ser Asn Gln Ser Ile Gln Asn Al #a Ile Leu Gly Ile His 1695                1700 #                1705  #               1710 gtt gct gga gga aat tca att ctt gtt gca aa #a ttg gtt act caa gaa     5907 Val Ala Gly Gly Asn Ser Ile Leu Val Ala Ly #s Leu Val Thr Gln Glu                 1715  #               1720   #              1725 atg ttc caa aat att gat aag aaa att gaa ag #t cag aga att atg aaa     5955 Met Phe Gln Asn Ile Asp Lys Lys Ile Glu Se #r Gln Arg Ile Met Lys             1730      #           1735       #          1740 gtg gag ttt act cag tgt tca atg aat gtg gt #c tcc aaa acg ctt ttt     6003 Val Glu Phe Thr Gln Cys Ser Met Asn Val Va #l Ser Lys Thr Leu Phe         1745          #       1750           #      1755 aga aag agt ccc att tat cat cac att gat aa #a acc atg att aat ttt     6051 Arg Lys Ser Pro Ile Tyr His His Ile Asp Ly #s Thr Met Ile Asn Phe     1760              #   1765               #  1770 cct gca gct atg ccc ttt tct aaa gct gaa at #t gat cca atg gct gtg     6099 Pro Ala Ala Met Pro Phe Ser Lys Ala Glu Il #e Asp Pro Met Ala Val 1775                1780 #                1785  #               1790 atg tta tct aag tat tca tta cct att gta ga #a gaa cca gag aat tat     6147 Met Leu Ser Lys Tyr Ser Leu Pro Ile Val Gl #u Glu Pro Glu Asn Tyr                 1795  #               1800   #              1805 aaa gag gct tca att ttt tat caa aat aaa at #a gtg ggt aag act cag     6195 Lys Glu Ala Ser Ile Phe Tyr Gln Asn Lys Il #e Val Gly Lys Thr Gln             1810      #           1815       #          1820 tta gtt gat gat ttt tta gat ctt gat atg gc #c att aca ggg gcc cca     6243 Leu Val Asp Asp Phe Leu Asp Leu Asp Met Al #a Ile Thr Gly Ala Pro         1825          #       1830           #      1835 gga att gat gct atc aac atg gat tca tct cc #t gga ttt cct tat gtc     6291 Gly Ile Asp Ala Ile Asn Met Asp Ser Ser Pr #o Gly Phe Pro Tyr Val     1840              #   1845               #  1850 cag gag aag ttg acc aaa aga gat tta att tg #g ttg gat gaa aat ggt     6339 Gln Glu Lys Leu Thr Lys Arg Asp Leu Ile Tr #p Leu Asp Glu Asn Gly 1855                1860 #                1865  #               1870 tta ttg ctg gga gtt cat cca aga ttg gct ca #g aga atc tta ttc aat     6387 Leu Leu Leu Gly Val His Pro Arg Leu Ala Gl #n Arg Ile Leu Phe Asn                 1875  #               1880   #              1885 act gtc atg atg gaa aat tgt tct gat ttg ga #t gtt gtt ttt aca acc     6435 Thr Val Met Met Glu Asn Cys Ser Asp Leu As #p Val Val Phe Thr Thr             1890      #           1895       #          1900 tgt cca aaa gat gaa ttg aga cca tta gag aa #a gtg ttg gaa tca aaa     6483 Cys Pro Lys Asp Glu Leu Arg Pro Leu Glu Ly #s Val Leu Glu Ser Lys         1905          #       1910           #      1915 aca aga gct att gat gct tgt cct ctg gat ta #c aca att ttg tgc cga     6531 Thr Arg Ala Ile Asp Ala Cys Pro Leu Asp Ty #r Thr Ile Leu Cys Arg     1920              #   1925               #  1930 atg tat tgg ggt cca gct att agt tat ttt ca #t ttg aat cca ggt ttc     6579 Met Tyr Trp Gly Pro Ala Ile Ser Tyr Phe Hi #s Leu Asn Pro Gly Phe 1935                1940 #                1945  #               1950 cat aca ggt gtt gct att ggc ata gat cct ga #t aga cag tgg gat gaa     6627 His Thr Gly Val Ala Ile Gly Ile Asp Pro As #p Arg Gln Trp Asp Glu                 1955  #               1960   #              1965 tta ttt aaa aca atg ata aga ttc gga gat gt #t ggt ctt gat tta gat     6675 Leu Phe Lys Thr Met Ile Arg Phe Gly Asp Va #l Gly Leu Asp Leu Asp             1970      #           1975       #          1980 ttc tct gct ttt gat gct agt ctt agt cca tt #t atg att aga gaa gca     6723 Phe Ser Ala Phe Asp Ala Ser Leu Ser Pro Ph #e Met Ile Arg Glu Ala         1985          #       1990           #      1995 ggt aga atc atg agt gaa cta tct gga act cc #a tcc cat ttt ggc aca     6771 Gly Arg Ile Met Ser Glu Leu Ser Gly Thr Pr #o Ser His Phe Gly Thr     2000              #   2005               #  2010 gct ctt atc aat act atc att tat tcc aag ca #t ttg ctg tat aac tgt     6819 Ala Leu Ile Asn Thr Ile Ile Tyr Ser Lys Hi #s Leu Leu Tyr Asn Cys 2015                2020 #                2025  #               2030 tgt tac cat gtc tgt ggt tca atg ccc tct gg #g tct cct tgt aca gct     6867 Cys Tyr His Val Cys Gly Ser Met Pro Ser Gl #y Ser Pro Cys Thr Ala                 2035  #               2040   #              2045 ttg cta aat tca att att aat aat gtc aat tt #g tat tat gtg ttt tcc     6915 Leu Leu Asn Ser Ile Ile Asn Asn Val Asn Le #u Tyr Tyr Val Phe Ser             2050      #           2055       #          2060 aag ata ttt gga aag tct cca gtt ttc ttt tg #t cag gct ttg aag att     6963 Lys Ile Phe Gly Lys Ser Pro Val Phe Phe Cy #s Gln Ala Leu Lys Ile         2065          #       2070           #      2075 ctc tgt tat gga gat gat gtt tta ata gtt tt #c tct cga gat gtt cag     7011 Leu Cys Tyr Gly Asp Asp Val Leu Ile Val Ph #e Ser Arg Asp Val Gln     2080              #   2085               #  2090 att gat aat ctt gat ctg att gga caa aaa at #t gta gat gag ttt aag     7059 Ile Asp Asn Leu Asp Leu Ile Gly Gln Lys Il #e Val Asp Glu Phe Lys 2095                2100 #                2105  #               2110 aaa ctt ggc atg aca gct act tct gct gac aa #g aat gta cct cag ctg     7107 Lys Leu Gly Met Thr Ala Thr Ser Ala Asp Ly #s Asn Val Pro Gln Leu                 2115  #               2120   #              2125 aaa cca gtt tcg gaa ttg act ttt ctc aaa ag #a tct ttc aat ttg gta     7155 Lys Pro Val Ser Glu Leu Thr Phe Leu Lys Ar #g Ser Phe Asn Leu Val             2130      #           2135       #          2140 gag gat aga att aga cct gca att tcg gaa aa #a aca att tgg tct tta     7203 Glu Asp Arg Ile Arg Pro Ala Ile Ser Glu Ly #s Thr Ile Trp Ser Leu         2145          #       2150           #      2155 ata gca tgg cag aga agt aac gct gag ttt ga #g cag aat tta gaa aat     7251 Ile Ala Trp Gln Arg Ser Asn Ala Glu Phe Gl #u Gln Asn Leu Glu Asn     2160              #   2165               #  2170 gct cag tgg ttt gct ttt atg cat ggc tat ga #g ttt tat cag aaa ttt     7299 Ala Gln Trp Phe Ala Phe Met His Gly Tyr Gl #u Phe Tyr Gln Lys Phe 2175                2180 #                2185  #               2190 tat tat ttt gtt cag tcc tgt ttg gag aaa ga #g atg ata gaa tac aga     7347 Tyr Tyr Phe Val Gln Ser Cys Leu Glu Lys Gl #u Met Ile Glu Tyr Arg                 2195  #               2200   #              2205 ctt aaa tct tat gat tgg tgg aga atg aga tt #t tat gac cag tgt ttc     7395 Leu Lys Ser Tyr Asp Trp Trp Arg Met Arg Ph #e Tyr Asp Gln Cys Phe             2210      #           2215       #          2220 att tgt gac ctt tca tgatttgttt aaacgaattt tcttaaaat #t tctgaggttt     7450 Ile Cys Asp Leu Ser         2225 gtttatttct tttatcagta aataaaaaaa aaaaaaaa       #                   #   7488 <210> SEQ ID NO 4 <211> LENGTH: 2227 <212> TYPE: PRT <213> ORGANISM: Attenuated HAV (Pass 35), strain  #HM-175 <400> SEQUENCE: 4 Met Asn Met Ser Arg Gln Gly Ile Phe Gln Th #r Val Gly Ser Gly Leu   1               5  #                 10  #                 15 Asp His Ile Leu Ser Leu Ala Asp Ile Glu Gl #u Glu Gln Met Ile Gln              20      #             25      #             30 Ser Val Asp Arg Thr Ala Val Thr Gly Ala Se #r Tyr Phe Thr Ser Val          35          #         40          #         45 Asp Gln Ser Ser Val His Thr Ala Glu Val Gl #y Ser His Gln Val Glu      50              #     55              #     60 Pro Leu Arg Thr Ser Val Asp Lys Pro Gly Se #r Lys Arg Thr Gln Gly  65                  # 70                  # 75                  # 80 Glu Lys Phe Phe Leu Ile His Ser Ala Asp Tr #p Leu Thr Thr His Ala                  85  #                 90  #                 95 Leu Phe His Glu Val Ala Lys Leu Asp Val Va #l Lys Leu Leu Tyr Asn             100       #           105       #           110 Glu Gln Phe Ala Val Gln Gly Leu Leu Arg Ty #r His Thr Tyr Ala Arg         115           #       120           #       125 Phe Gly Ile Glu Ile Gln Val Gln Ile Asn Pr #o Thr Pro Phe Gln Gln     130               #   135               #   140 Gly Gly Leu Ile Cys Ala Met Val Pro Gly As #p Gln Ser Tyr Gly Ser 145                 1 #50                 1 #55                 1 #60 Ile Ala Ser Leu Thr Val Tyr Pro His Gly Le #u Leu Asn Cys Asn Ile                 165   #               170   #               175 Asn Asn Val Val Arg Ile Lys Val Pro Phe Il #e Tyr Thr Arg Gly Ala             180       #           185       #           190 Tyr His Phe Lys Asp Pro Gln Tyr Pro Val Tr #p Glu Leu Thr Ile Arg         195           #       200           #       205 Val Trp Ser Glu Leu Asn Ile Gly Thr Gly Th #r Ser Ala Tyr Thr Ser     210               #   215               #   220 Leu Asn Val Leu Ala Arg Phe Thr Asp Leu Gl #u Leu His Gly Leu Thr 225                 2 #30                 2 #35                 2 #40 Pro Leu Ser Thr Gln Met Met Arg Asn Glu Ph #e Arg Val Ser Thr Thr                 245   #               250   #               255 Glu Asn Val Val Asn Leu Ser Asn Tyr Glu As #p Ala Arg Ala Lys Met             260       #           265       #           270 Ser Phe Ala Leu Asp Gln Glu Asp Trp Lys Se #r Asp Pro Ser Gln Gly         275           #       280           #       285 Gly Gly Ile Lys Ile Thr His Phe Thr Thr Tr #p Thr Ser Ile Pro Thr     290               #   295               #   300 Leu Ala Ala Gln Phe Pro Phe Asn Ala Ser As #p Ser Val Gly Gln Gln 305                 3 #10                 3 #15                 3 #20 Ile Lys Val Ile Pro Val Asp Pro Tyr Phe Ph #e Gln Met Thr Asn Thr                 325   #               330   #               335 Asn Pro Asp Gln Lys Cys Ile Thr Ala Leu Al #a Ser Ile Cys Gln Met             340       #           345       #           350 Phe Cys Phe Trp Arg Gly Asp Leu Val Phe As #p Phe Gln Val Phe Pro         355           #       360           #       365 Thr Lys Tyr His Ser Gly Arg Leu Leu Phe Cy #s Phe Val Pro Gly Asn     370               #   375               #   380 Glu Leu Ile Asp Val Ser Gly Ile Thr Leu Ly #s Gln Ala Thr Thr Ala 385                 3 #90                 3 #95                 4 #00 Pro Cys Ala Val Met Asp Ile Thr Gly Val Gl #n Ser Thr Leu Arg Phe                 405   #               410   #               415 Arg Val Pro Trp Ile Ser Asp Thr Pro Tyr Ar #g Val Asn Arg Tyr Thr             420       #           425       #           430 Lys Ser Ala His Gln Lys Gly Glu Tyr Thr Al #a Ile Gly Lys Leu Ile         435           #       440           #       445 Val Tyr Cys Tyr Asn Arg Leu Thr Ser Pro Se #r Asn Val Ala Ser His     450               #   455               #   460 Val Arg Val Asn Val Tyr Leu Ser Ala Ile As #n Leu Glu Cys Phe Ala 465                 4 #70                 4 #75                 4 #80 Pro Leu Tyr His Ala Met Asp Val Thr Thr Gl #n Val Gly Asp Asp Ser                 485   #               490   #               495 Gly Gly Phe Ser Thr Thr Val Ser Thr Glu Gl #n Asn Val Pro Asp Pro             500       #           505       #           510 Gln Val Gly Ile Thr Thr Met Lys Asp Leu Ly #s Gly Lys Ala Asn Arg         515           #       520           #       525 Gly Lys Met Asp Val Ser Gly Val Gln Ala Pr #o Val Gly Ala Ile Thr     530               #   535               #   540 Thr Ile Glu Asp Pro Val Leu Ala Lys Lys Va #l Pro Glu Thr Phe Pro 545                 5 #50                 5 #55                 5 #60 Glu Leu Lys Pro Gly Glu Ser Arg His Thr Se #r Asp His Met Ser Ile                 565   #               570   #               575 Tyr Lys Phe Met Gly Arg Ser His Phe Leu Cy #s Thr Phe Thr Phe Asn             580       #           585       #           590 Ser Asn Asn Lys Glu Tyr Thr Phe Pro Ile Th #r Leu Ser Ser Thr Ser         595           #       600           #       605 Asn Pro Pro His Gly Leu Pro Ser Thr Leu Ar #g Trp Phe Phe Asn Leu     610               #   615               #   620 Phe Gln Leu Tyr Arg Gly Pro Leu Asp Leu Th #r Ile Ile Ile Thr Gly 625                 6 #30                 6 #35                 6 #40 Ala Thr Asp Val Asp Gly Met Ala Trp Phe Th #r Pro Val Gly Leu Ala                 645   #               650   #               655 Val Asp Thr Pro Trp Val Glu Lys Glu Ser Al #a Leu Ser Ile Asp Tyr             660       #           665       #           670 Lys Thr Ala Leu Gly Ala Val Arg Phe Asn Th #r Arg Arg Thr Gly Asn         675           #       680           #       685 Ile Gln Ile Arg Leu Pro Trp Tyr Ser Tyr Le #u Tyr Ala Val Ser Gly     690               #   695               #   700 Ala Leu Asp Gly Leu Gly Asp Lys Thr Asp Se #r Thr Phe Gly Leu Val 705                 7 #10                 7 #15                 7 #20 Ser Ile Gln Ile Ala Asn Tyr Asn His Ser As #p Glu Tyr Leu Ser Phe                 725   #               730   #               735 Ser Cys Tyr Leu Ser Val Thr Glu Gln Ser Gl #u Phe Tyr Phe Pro Arg             740       #           745       #           750 Ala Pro Leu Asn Ser Asn Ala Met Leu Ser Th #r Val Ser Met Met Ser         755           #       760           #       765 Arg Ile Ala Ala Gly Asp Leu Glu Ser Ser Va #l Asp Asp Pro Arg Ser     770               #   775               #   780 Glu Glu Asp Lys Arg Phe Glu Ser His Ile Gl #u Cys Arg Lys Pro Tyr 785                 7 #90                 7 #95                 8 #00 Lys Glu Leu Arg Leu Glu Val Gly Lys Gln Ar #g Leu Lys Tyr Ala Gln                 805   #               810   #               815 Glu Glu Leu Ser Ser Glu Val Leu Pro Pro Pr #o Arg Lys Met Lys Gly             820       #           825       #           830 Leu Phe Ser Gln Ala Lys Ile Ser Leu Phe Ty #r Thr Glu Glu His Glu         835           #       840           #       845 Ile Met Lys Phe Ser Trp Arg Gly Val Thr Al #a Asp Thr Arg Ala Leu     850               #   855               #   860 Arg Arg Phe Gly Phe Ser Leu Ala Ala Gly Ar #g Ser Val Trp Thr Leu 865                 8 #70                 8 #75                 8 #80 Glu Met Asp Ala Gly Val Leu Thr Gly Arg Le #u Ile Arg Leu Asn Asp                 885   #               890   #               895 Glu Lys Trp Thr Glu Met Lys Asp Asp Lys Il #e Val Ser Leu Ile Glu             900       #           905       #           910 Lys Phe Thr Ser Asn Lys Tyr Trp Ser Lys Va #l Asn Phe Pro His Gly         915           #       920           #       925 Met Leu Asp Leu Glu Glu Ile Ala Ala Asn Se #r Lys Asp Phe Pro Asn     930               #   935               #   940 Met Ser Glu Thr Asp Leu Cys Phe Leu Leu Hi #s Trp Leu Asn Pro Lys 945                 9 #50                 9 #55                 9 #60 Lys Ile Asn Leu Ala Asp Arg Met Leu Gly Le #u Ser Gly Val Gln Glu                 965   #               970   #               975 Ile Lys Glu Gln Gly Val Gly Leu Ile Ala Gl #u Cys Arg Thr Phe Leu             980       #           985       #           990 Asp Ser Ile Ala Gly Thr Leu Lys Ser Met Me #t Phe Gly Phe His His         995           #       1000           #      1005 Ser Val Thr Val Glu Ile Ile Asn Thr Val Le #u Cys Phe Val Lys Ser     1010              #   1015               #  1020 Gly Ile Leu Leu Tyr Val Ile Gln Gln Leu As #n Gln Asp Glu His Ser 1025                1030 #                1035  #               1040 His Ile Ile Gly Leu Leu Arg Val Met Asn Ty #r Val Asp Ile Gly Cys                 1045  #               1050   #              1055 Ser Val Ile Ser Cys Ala Lys Val Phe Ser Ly #s Met Leu Glu Thr Val             1060      #           1065       #          1070 Phe Asn Trp Gln Met Asp Ser Arg Met Met Gl #u Leu Arg Thr Gln Ser         1075          #       1080           #      1085 Phe Ser Asn Trp Leu Arg Asp Ile Cys Ser Gl #y Ile Thr Ile Phe Lys     1090              #   1095               #  1100 Asn Phe Lys Asp Ala Ile Tyr Trp Leu Tyr Th #r Lys Leu Met Asp Phe 1105                1110 #                1115  #               1120 Tyr Glu Val Asn Tyr Gly Lys Lys Lys Asp Il #e Leu Asn Ile Leu Lys                 1125  #               1130   #              1135 Asp Asn Gln Gln Lys Ile Glu Lys Ala Ile Gl #u Glu Ala Asp Lys Phe             1140      #           1145       #          1150 Cys Ile Leu Gln Ile Gln Asp Val Glu Lys Se #r Glu Gln Tyr Gln Lys         1155          #       1160           #      1165 Gly Val Asp Leu Ile Gln Lys Leu Arg Thr Va #l His Ser Met Ala Gln     1170              #   1175               #  1180 Val Asp Pro Asn Leu Met Val His Leu Ser Pr #o Leu Arg Asp Cys Ile 1185                1190 #                1195  #               1200 Ala Arg Val His Gln Lys Leu Lys Asn Leu Gl #y Ser Ile Asn Gln Ala                 1205  #               1210   #              1215 Met Val Thr Arg Cys Glu Pro Val Val Cys Ty #r Leu Tyr Gly Lys Arg             1220      #           1225       #          1230 Gly Gly Gly Lys Ser Leu Thr Ser Ile Ala Le #u Ala Thr Lys Ile Cys         1235          #       1240           #      1245 Lys His Tyr Gly Val Glu Pro Glu Lys Asn Il #e Tyr Thr Lys Pro Val     1250              #   1255               #  1260 Ala Ser Asp Tyr Trp Asp Gly Tyr Ser Gly Gl #n Leu Ile Cys Ile Ile 1265                1270 #                1275  #               1280 Asp Asp Ile Gly Gln Asn Thr Thr Asp Glu As #p Trp Ser Asp Phe Cys                 1285  #               1290   #              1295 Gln Leu Val Ser Gly Cys Pro Met Arg Leu As #n Met Ala Ser Leu Glu             1300      #           1305       #          1310 Glu Lys Gly Arg His Phe Ser Ser Pro Phe Il #e Ile Ala Thr Ser Asn         1315          #       1320           #      1325 Trp Ser Asn Pro Ser Pro Lys Thr Val Tyr Va #l Lys Glu Ala Ile Asp     1330              #   1335               #  1340 Arg Arg Leu His Phe Lys Val Glu Val Lys Pr #o Ala Ser Phe Phe Lys 1345                1350 #                1355  #               1360 Asn Pro His Asn Asp Met Leu Asn Val Asn Le #u Ala Lys Thr Asn Asp                 1365  #               1370   #              1375 Ala Ile Lys Asp Met Ser Cys Val Asp Leu Il #e Met Asp Gly His Asn             1380      #           1385       #          1390 Val Ser Leu Met Asp Leu Leu Ser Ser Leu Va #l Met Thr Val Glu Ile         1395          #       1400           #      1405 Arg Lys Gln Asn Met Thr Glu Phe Met Glu Le #u Trp Ser Gln Gly Ile     1410              #   1415               #  1420 Ser Asp Asp Asp Asn Asp Ser Ala Val Ala Gl #u Phe Phe Gln Ser Phe 1425                1430 #                1435  #               1440 Pro Ser Gly Glu Pro Ser Asn Ser Lys Leu Se #r Gly Phe Phe Gln Ser                 1445  #               1450   #              1455 Val Thr Asn His Lys Trp Val Ala Val Gly Al #a Ala Val Gly Ile Leu             1460      #           1465       #          1470 Gly Val Leu Val Gly Gly Trp Phe Val Tyr Ly #s His Phe Ser Arg Lys         1475          #       1480           #      1485 Glu Glu Glu Pro Ile Pro Ala Glu Gly Val Ty #r Tyr Gly Val Thr Lys     1490              #   1495               #  1500 Pro Lys Gln Val Ile Lys Leu Asp Ala Asp Pr #o Val Glu Ser Gln Ser 1505                1510 #                1515  #               1520 Thr Leu Glu Ile Ala Gly Leu Val Arg Lys As #n Leu Val Gln Phe Gly                 1525  #               1530   #              1535 Val Gly Glu Lys Asn Gly Cys Val Arg Trp Va #l Met Asn Ala Leu Gly             1540      #           1545       #          1550 Val Lys Asp Asp Trp Leu Leu Val Pro Ser Hi #s Ala Tyr Lys Phe Glu         1555          #       1560           #      1565 Lys Asp Tyr Glu Met Met Glu Phe Tyr Phe As #n Arg Gly Gly Thr Tyr     1570              #   1575               #  1580 Tyr Ser Ile Ser Ala Gly Asn Val Val Ile Gl #n Ser Leu Asp Val Gly 1585                1590 #                1595  #               1600 Phe Gln Asp Val Val Leu Met Lys Val Pro Th #r Ile Pro Lys Phe Arg                 1605  #               1610   #              1615 Asp Ile Thr Gln His Phe Ile Lys Lys Gly As #p Val Pro Arg Ala Leu             1620      #           1625       #          1630 Asn Arg Leu Ala Thr Leu Val Thr Thr Val As #n Gly Thr Pro Met Leu         1635          #       1640           #      1645 Ile Ser Glu Gly Pro Leu Lys Met Glu Glu Ly #s Ala Thr Tyr Val His     1650              #   1655               #  1660 Lys Lys Asn Asp Gly Thr Thr Val Asp Leu Th #r Val Asp Gln Ala Trp 1665                1670 #                1675  #               1680 Arg Gly Lys Gly Glu Gly Leu Pro Gly Met Cy #s Gly Gly Ala Leu Val                 1685  #               1690   #              1695 Ser Ser Asn Gln Ser Ile Gln Asn Ala Ile Le #u Gly Ile His Val Ala             1700      #           1705       #          1710 Gly Gly Asn Ser Ile Leu Val Ala Lys Leu Va #l Thr Gln Glu Met Phe         1715          #       1720           #      1725 Gln Asn Ile Asp Lys Lys Ile Glu Ser Gln Ar #g Ile Met Lys Val Glu     1730              #   1735               #  1740 Phe Thr Gln Cys Ser Met Asn Val Val Ser Ly #s Thr Leu Phe Arg Lys 1745                1750 #                1755  #               1760 Ser Pro Ile Tyr His His Ile Asp Lys Thr Me #t Ile Asn Phe Pro Ala                 1765  #               1770   #              1775 Ala Met Pro Phe Ser Lys Ala Glu Ile Asp Pr #o Met Ala Val Met Leu             1780      #           1785       #          1790 Ser Lys Tyr Ser Leu Pro Ile Val Glu Glu Pr #o Glu Asn Tyr Lys Glu         1795          #       1800           #      1805 Ala Ser Ile Phe Tyr Gln Asn Lys Ile Val Gl #y Lys Thr Gln Leu Val     1810              #   1815               #  1820 Asp Asp Phe Leu Asp Leu Asp Met Ala Ile Th #r Gly Ala Pro Gly Ile 1825                1830 #                1835  #               1840 Asp Ala Ile Asn Met Asp Ser Ser Pro Gly Ph #e Pro Tyr Val Gln Glu                 1845  #               1850   #              1855 Lys Leu Thr Lys Arg Asp Leu Ile Trp Leu As #p Glu Asn Gly Leu Leu             1860      #           1865       #          1870 Leu Gly Val His Pro Arg Leu Ala Gln Arg Il #e Leu Phe Asn Thr Val         1875          #       1880           #      1885 Met Met Glu Asn Cys Ser Asp Leu Asp Val Va #l Phe Thr Thr Cys Pro     1890              #   1895               #  1900 Lys Asp Glu Leu Arg Pro Leu Glu Lys Val Le #u Glu Ser Lys Thr Arg 1905                1910 #                1915  #               1920 Ala Ile Asp Ala Cys Pro Leu Asp Tyr Thr Il #e Leu Cys Arg Met Tyr                 1925  #               1930   #              1935 Trp Gly Pro Ala Ile Ser Tyr Phe His Leu As #n Pro Gly Phe His Thr             1940      #           1945       #          1950 Gly Val Ala Ile Gly Ile Asp Pro Asp Arg Gl #n Trp Asp Glu Leu Phe         1955          #       1960           #      1965 Lys Thr Met Ile Arg Phe Gly Asp Val Gly Le #u Asp Leu Asp Phe Ser     1970              #   1975               #  1980 Ala Phe Asp Ala Ser Leu Ser Pro Phe Met Il #e Arg Glu Ala Gly Arg 1985                1990 #                1995  #               2000 Ile Met Ser Glu Leu Ser Gly Thr Pro Ser Hi #s Phe Gly Thr Ala Leu                 2005  #               2010   #              2015 Ile Asn Thr Ile Ile Tyr Ser Lys His Leu Le #u Tyr Asn Cys Cys Tyr             2020      #           2025       #          2030 His Val Cys Gly Ser Met Pro Ser Gly Ser Pr #o Cys Thr Ala Leu Leu         2035          #       2040           #      2045 Asn Ser Ile Ile Asn Asn Val Asn Leu Tyr Ty #r Val Phe Ser Lys Ile     2050              #   2055               #  2060 Phe Gly Lys Ser Pro Val Phe Phe Cys Gln Al #a Leu Lys Ile Leu Cys 2065                2070 #                2075  #               2080 Tyr Gly Asp Asp Val Leu Ile Val Phe Ser Ar #g Asp Val Gln Ile Asp                 2085  #               2090   #              2095 Asn Leu Asp Leu Ile Gly Gln Lys Ile Val As #p Glu Phe Lys Lys Leu             2100      #           2105       #          2110 Gly Met Thr Ala Thr Ser Ala Asp Lys Asn Va #l Pro Gln Leu Lys Pro         2115          #       2120           #      2125 Val Ser Glu Leu Thr Phe Leu Lys Arg Ser Ph #e Asn Leu Val Glu Asp     2130              #   2135               #  2140 Arg Ile Arg Pro Ala Ile Ser Glu Lys Thr Il #e Trp Ser Leu Ile Ala 2145                2150 #                2155  #               2160 Trp Gln Arg Ser Asn Ala Glu Phe Glu Gln As #n Leu Glu Asn Ala Gln                 2165  #               2170   #              2175 Trp Phe Ala Phe Met His Gly Tyr Glu Phe Ty #r Gln Lys Phe Tyr Tyr             2180      #           2185       #          2190 Phe Val Gln Ser Cys Leu Glu Lys Glu Met Il #e Glu Tyr Arg Leu Lys         2195          #       2200           #      2205 Ser Tyr Asp Trp Trp Arg Met Arg Phe Tyr As #p Gln Cys Phe Ile Cys     2210              #   2215               #  2220 Asp Leu Ser 2225 <210> SEQ ID NO 5 <211> LENGTH: 7486 <212> TYPE: DNA <213> ORGANISM: Attenuated HAV (4380), strain HM-1 #75 <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (730)..(7410) <400> SEQUENCE: 5 ttcaagaggg gtctccggga atttccggag tccctcttgg aagtccatgg tg #aggggact     60 tgatacctca ccgccgtttg cctaggctat aggctaaatt ttccctttcc ct #tttccctt    120 tcccattccc ttttgcttgt aaatattgat tcctgcaggt tcagggttct ta #aatctgtt    180 tctctataag aacactcatt ttcacgcttt ctgtcttctt tcttccaggg ct #ctcccctt    240 gccctaggct ctggccgttg cgcccggcgg ggtcaactcc atgattagca tg #gagctgta    300 ggagtctaaa ttggggacac agatgtttgg aacgtcacct tgcagtgtta ac #ttggcttt    360 catgaatctc tttgatcttc cacaaggggt aggctacggg tgaaacctct ta #ggctaata    420 cttctatgaa gagatgcctt ggatagggta acagcggcgg atattggtga gt #tgttaaga    480 caaaaaccat tcaacgccgg aggactgact ctcatccagt ggatgcattg ag #tggattga    540 ctgtcagggc tgtctttagg cttaattcca gacctctctg tgcttggggc aa #acatcatt    600 tggccttaaa tgggattctg tgagagggga tccctccatt aacagctgga ct #gttctttg    660 gggtcttatg tggtgtttgc cgctgaggta ctcaggggca tttaggtttt tc #ctcattct    720 taaataata atg aac atg tct aga caa ggt att ttc # cag act gtt ggg agt    771           Met Asn Met Ser Arg  #Gln Gly Ile Phe Gln Thr Val Gly Ser             1       #         5          #         10 ggt ctt gac cac atc ctg tct ttg gca gac at #t gag gaa gag caa atg      819 Gly Leu Asp His Ile Leu Ser Leu Ala Asp Il #e Glu Glu Glu Gln Met  15                  # 20                  # 25                  # 30 att caa tca gtt gat agg act gca gtg act gg #t gct tct tat ttt act      867 Ile Gln Ser Val Asp Arg Thr Ala Val Thr Gl #y Ala Ser Tyr Phe Thr                  35  #                 40  #                 45 tct gtg gat caa tct tca gtt cat aca gct ga #g gtt gga tca cac cag      915 Ser Val Asp Gln Ser Ser Val His Thr Ala Gl #u Val Gly Ser His Gln              50      #             55      #             60 gtt gaa cct ttg aga acc tct gtt gat aaa cc #c ggt tca aag agg act      963 Val Glu Pro Leu Arg Thr Ser Val Asp Lys Pr #o Gly Ser Lys Arg Thr          65          #         70          #         75 cag gga gag aaa ttt ttc ttg att cat tct gc #a gat tgg ctt act aca     1011 Gln Gly Glu Lys Phe Phe Leu Ile His Ser Al #a Asp Trp Leu Thr Thr      80              #     85              #     90 cat gct ctt ttc cat gaa gtt gca aaa ttg ga #t gtg gtg aaa tta tta     1059 His Ala Leu Phe His Glu Val Ala Lys Leu As #p Val Val Lys Leu Leu  95                  #100                  #105                  #110 tac aat gag cag ttt gct gtt caa ggg ttg tt #g aga tac cat aca tat     1107 Tyr Asn Glu Gln Phe Ala Val Gln Gly Leu Le #u Arg Tyr His Thr Tyr                 115   #               120   #               125 gca aga ttt ggc att gaa att caa gtt cag at #a aac cct aca cct ttc     1155 Ala Arg Phe Gly Ile Glu Ile Gln Val Gln Il #e Asn Pro Thr Pro Phe             130       #           135       #           140 caa cag ggg gga ttg atc tgt gct atg gtt cc #t ggt gac cag agc tat     1203 Gln Gln Gly Gly Leu Ile Cys Ala Met Val Pr #o Gly Asp Gln Ser Tyr         145           #       150           #       155 ggt tct ata gca tca ttg act gtt tat cct ca #t ggt ttg tta aat tgc     1251 Gly Ser Ile Ala Ser Leu Thr Val Tyr Pro Hi #s Gly Leu Leu Asn Cys     160               #   165               #   170 aat att aac aat gtg gtt aga ata aag gtt cc #a ttt att tac aca aga     1299 Asn Ile Asn Asn Val Val Arg Ile Lys Val Pr #o Phe Ile Tyr Thr Arg 175                 1 #80                 1 #85                 1 #90 ggt gct tac cac ttt aaa gat cca caa tac cc #a gtt tgg gaa ttg aca     1347 Gly Ala Tyr His Phe Lys Asp Pro Gln Tyr Pr #o Val Trp Glu Leu Thr                 195   #               200   #               205 att aga gtt tgg tca gaa tta aat att ggg ac #a gga act tca gct tat     1395 Ile Arg Val Trp Ser Glu Leu Asn Ile Gly Th #r Gly Thr Ser Ala Tyr             210       #           215       #           220 act tca ctc aat gtt tta gct aga ttt aca ga #t ttg gag ttg cat gga     1443 Thr Ser Leu Asn Val Leu Ala Arg Phe Thr As #p Leu Glu Leu His Gly         225           #       230           #       235 tta act cct ctt tct aca caa atg atg aga aa #t gaa ttt agg gtc agt     1491 Leu Thr Pro Leu Ser Thr Gln Met Met Arg As #n Glu Phe Arg Val Ser     240               #   245               #   250 act act gag aat gtg gtg aat ctg tca aat ta #t gaa gat gca aga gca     1539 Thr Thr Glu Asn Val Val Asn Leu Ser Asn Ty #r Glu Asp Ala Arg Ala 255                 2 #60                 2 #65                 2 #70 aag atg tct ttt gct ttg gat cag gaa gat tg #g aaa tct gat ccg tcc     1587 Lys Met Ser Phe Ala Leu Asp Gln Glu Asp Tr #p Lys Ser Asp Pro Ser                 275   #               280   #               285 cag ggt ggt ggg atc aaa att act cat ttt ac #t act tgg aca tct att     1635 Gln Gly Gly Gly Ile Lys Ile Thr His Phe Th #r Thr Trp Thr Ser Ile             290       #           295       #           300 cca act ttg gct gct cag ttt cca ttt aat gc #t tca gac tca gtt ggt     1683 Pro Thr Leu Ala Ala Gln Phe Pro Phe Asn Al #a Ser Asp Ser Val Gly         305           #       310           #       315 caa caa att aaa gtt att cca gtt gac cca ta #t ttt ttc caa atg aca     1731 Gln Gln Ile Lys Val Ile Pro Val Asp Pro Ty #r Phe Phe Gln Met Thr     320               #   325               #   330 aat aca aat cct gac caa aaa tgt ata act gc #t ttg gct tct att tgt     1779 Asn Thr Asn Pro Asp Gln Lys Cys Ile Thr Al #a Leu Ala Ser Ile Cys 335                 3 #40                 3 #45                 3 #50 cag atg ttt tgt ttt tgg aga gga gat ctt gt #c ttt gat ttt caa gtt     1827 Gln Met Phe Cys Phe Trp Arg Gly Asp Leu Va #l Phe Asp Phe Gln Val                 355   #               360   #               365 ttt ccc acc aaa tat cat tca ggt aga tta ct #g ttt tgt ttt gtt cct     1875 Phe Pro Thr Lys Tyr His Ser Gly Arg Leu Le #u Phe Cys Phe Val Pro             370       #           375       #           380 ggc aat gag cta ata gat gtt tct gga atc ac #a tta aag caa gca act     1923 Gly Asn Glu Leu Ile Asp Val Ser Gly Ile Th #r Leu Lys Gln Ala Thr         385           #       390           #       395 act gct cct tgt gca gta atg gat att aca gg #a gtg cag tca act ttg     1971 Thr Ala Pro Cys Ala Val Met Asp Ile Thr Gl #y Val Gln Ser Thr Leu     400               #   405               #   410 aga ttt cgt gtt ccc tgg att tct gac act cc #t tac aga gtg aac agg     2019 Arg Phe Arg Val Pro Trp Ile Ser Asp Thr Pr #o Tyr Arg Val Asn Arg 415                 4 #20                 4 #25                 4 #30 tat aca aag tca gca cat cag aaa ggt gag ta #c act gcc att ggg aag     2067 Tyr Thr Lys Ser Ala His Gln Lys Gly Glu Ty #r Thr Ala Ile Gly Lys                 435   #               440   #               445 ctt att gtg tat tgt tat aac aga ttg acc tc #t cct tct aac gtt gct     2115 Leu Ile Val Tyr Cys Tyr Asn Arg Leu Thr Se #r Pro Ser Asn Val Ala             450       #           455       #           460 tcc cat gtc aga gtg aat gtt tat ctt tca gc #a att aac ttg gaa tgt     2163 Ser His Val Arg Val Asn Val Tyr Leu Ser Al #a Ile Asn Leu Glu Cys         465           #       470           #       475 ttt gct cct ctt tat cat gct atg gat gtt ac #t aca caa gtt gga gat     2211 Phe Ala Pro Leu Tyr His Ala Met Asp Val Th #r Thr Gln Val Gly Asp     480               #   485               #   490 gat tct gga ggt ttt tca aca aca gtt tct ac #a gaa cag aat gtt cca     2259 Asp Ser Gly Gly Phe Ser Thr Thr Val Ser Th #r Glu Gln Asn Val Pro 495                 5 #00                 5 #05                 5 #10 gat ccc caa gtt ggt ata aca acc atg aaa ga #t ttg aaa gga aaa gct     2307 Asp Pro Gln Val Gly Ile Thr Thr Met Lys As #p Leu Lys Gly Lys Ala                 515   #               520   #               525 aac aga ggg aaa atg gat gtt tca gga gta ca #a gca cct gtg gga gct     2355 Asn Arg Gly Lys Met Asp Val Ser Gly Val Gl #n Ala Pro Val Gly Ala             530       #           535       #           540 atc aca aca att gag gat cca gtt tta gca aa #g aaa gta cct gag aca     2403 Ile Thr Thr Ile Glu Asp Pro Val Leu Ala Ly #s Lys Val Pro Glu Thr         545           #       550           #       555 ttt cct gaa ttg aaa cct gga gaa tcc aga ca #t aca tca gat cat atg     2451 Phe Pro Glu Leu Lys Pro Gly Glu Ser Arg Hi #s Thr Ser Asp His Met     560               #   565               #   570 tcc atc tac aag ttt atg gga agg tct cat tt #c ttg tgc act ttt aca     2499 Ser Ile Tyr Lys Phe Met Gly Arg Ser His Ph #e Leu Cys Thr Phe Thr 575                 5 #80                 5 #85                 5 #90 ttc aat tca aat aat aaa gag tac aca ttt cc #t ata acc ttg tct tca     2547 Phe Asn Ser Asn Asn Lys Glu Tyr Thr Phe Pr #o Ile Thr Leu Ser Ser                 595   #               600   #               605 acc tct aat cct cct cat ggt ttg cca tca ac #a ctg agg tgg ttt ttc     2595 Thr Ser Asn Pro Pro His Gly Leu Pro Ser Th #r Leu Arg Trp Phe Phe             610       #           615       #           620 aac ttg ttt cag ttg tat aga ggg cct tta ga #t ctg aca att att att     2643 Asn Leu Phe Gln Leu Tyr Arg Gly Pro Leu As #p Leu Thr Ile Ile Ile         625           #       630           #       635 aca gga gca act gat gta gat ggc atg gcc tg #g ttc act cca gta ggt     2691 Thr Gly Ala Thr Asp Val Asp Gly Met Ala Tr #p Phe Thr Pro Val Gly     640               #   645               #   650 ctt gcc gtt gat act cct tgg gta gag aag ga #g tca gct ttg tct att     2739 Leu Ala Val Asp Thr Pro Trp Val Glu Lys Gl #u Ser Ala Leu Ser Ile 655                 6 #60                 6 #65                 6 #70 gac tat aaa act gct ctt gga gct gtc aga tt #t aac aca agg aga aca     2787 Asp Tyr Lys Thr Ala Leu Gly Ala Val Arg Ph #e Asn Thr Arg Arg Thr                 675   #               680   #               685 ggg aac att cag att aga tta cca tgg tat tc #t tat tta tat gct gtg     2835 Gly Asn Ile Gln Ile Arg Leu Pro Trp Tyr Se #r Tyr Leu Tyr Ala Val             690       #           695       #           700 tct gga gca ctg gat ggt ttg gga gac aag ac #a gat tct aca ttt gga     2883 Ser Gly Ala Leu Asp Gly Leu Gly Asp Lys Th #r Asp Ser Thr Phe Gly         705           #       710           #       715 ttg gtt tct att cag att gca aat tac aat ca #t tct gat gaa tac ttg     2931 Leu Val Ser Ile Gln Ile Ala Asn Tyr Asn Hi #s Ser Asp Glu Tyr Leu     720               #   725               #   730 tct ttt agt tgt tat ttg tct gtc aca gaa ca #a tca gag ttt tat ttt     2979 Ser Phe Ser Cys Tyr Leu Ser Val Thr Glu Gl #n Ser Glu Phe Tyr Phe 735                 7 #40                 7 #45                 7 #50 ccc aga gct cca ttg aac tca aat gcc atg tt #a tcc act gta aca atg     3027 Pro Arg Ala Pro Leu Asn Ser Asn Ala Met Le #u Ser Thr Val Thr Met                 755   #               760   #               765 atg agc aga att gca gct gga gac ttg gag tc #a tca gtg gat gat cct     3075 Met Ser Arg Ile Ala Ala Gly Asp Leu Glu Se #r Ser Val Asp Asp Pro             770       #           775       #           780 aga tca gag gaa gat aaa aga ttt gag agt ca #t ata gaa tgc agg aag     3123 Arg Ser Glu Glu Asp Lys Arg Phe Glu Ser Hi #s Ile Glu Cys Arg Lys         785           #       790           #       795 cca tat aaa gaa ctg aga tta gaa gtt ggg aa #a caa aga ctc aag tat     3171 Pro Tyr Lys Glu Leu Arg Leu Glu Val Gly Ly #s Gln Arg Leu Lys Tyr     800               #   805               #   810 gct cag gaa gaa ttg tca aat gaa gta ctt cc #a ccc cct agg aaa atg     3219 Ala Gln Glu Glu Leu Ser Asn Glu Val Leu Pr #o Pro Pro Arg Lys Met 815                 8 #20                 8 #25                 8 #30 aag gga ctg ttt tca caa gcc aaa att tct ct #t ttt tat act gag gag     3267 Lys Gly Leu Phe Ser Gln Ala Lys Ile Ser Le #u Phe Tyr Thr Glu Glu                 835   #               840   #               845 cat gaa ata atg aag ttt tcc tgg aga ggt gt #g act gct gat act aga     3315 His Glu Ile Met Lys Phe Ser Trp Arg Gly Va #l Thr Ala Asp Thr Arg             850       #           855       #           860 gct tta agg agg ttt gga ttc tct ttg gcc gc #a ggc aga agt gtg tgg     3363 Ala Leu Arg Arg Phe Gly Phe Ser Leu Ala Al #a Gly Arg Ser Val Trp         865           #       870           #       875 act ctt gaa atg gat gct ggg gtt ctt act gg #g aga ctg att aga ttg     3411 Thr Leu Glu Met Asp Ala Gly Val Leu Thr Gl #y Arg Leu Ile Arg Leu     880               #   885               #   890 aat gat gag aaa tgg aca gaa atg aag gat ga #c aag att gtt tca ttg     3459 Asn Asp Glu Lys Trp Thr Glu Met Lys Asp As #p Lys Ile Val Ser Leu 895                 9 #00                 9 #05                 9 #10 att gaa aag ttt aca agt aac aaa tat tgg tc #c aaa gtg aat ttc cca     3507 Ile Glu Lys Phe Thr Ser Asn Lys Tyr Trp Se #r Lys Val Asn Phe Pro                 915   #               920   #               925 cat ggg atg ttg gat ctt gaa gaa att gct gc #c aat tct aag gat ttt     3555 His Gly Met Leu Asp Leu Glu Glu Ile Ala Al #a Asn Ser Lys Asp Phe             930       #           935       #           940 cct aac atg tct gaa acg gat ttg tgt ttc tt #g ctg cat tgg tta aat     3603 Pro Asn Met Ser Glu Thr Asp Leu Cys Phe Le #u Leu His Trp Leu Asn         945           #       950           #       955 cca aag aaa att aat tta gca gat aga atg ct #t gga ttg tct gga gtt     3651 Pro Lys Lys Ile Asn Leu Ala Asp Arg Met Le #u Gly Leu Ser Gly Val     960               #   965               #   970 cag gaa att aaa gaa caa ggt gtt gga tta at #a gca gag tgt aga act     3699 Gln Glu Ile Lys Glu Gln Gly Val Gly Leu Il #e Ala Glu Cys Arg Thr 975                 9 #80                 9 #85                 9 #90 ttc tta gat tct att gct gga act tta aaa tc #t atg atg ttt gga ttt     3747 Phe Leu Asp Ser Ile Ala Gly Thr Leu Lys Se #r Met Met Phe Gly Phe                 995   #               1000   #              1005 cat cat tct gtg act gtt gaa att ata aac ac #t gtg ctc tgt ttt gtt     3795 His His Ser Val Thr Val Glu Ile Ile Asn Th #r Val Leu Cys Phe Val             1010      #           1015       #          1020 aag agt gga att ttg ctt tat gta ata caa ca #a ttg aat cag gat gaa     3843 Lys Ser Gly Ile Leu Leu Tyr Val Ile Gln Gl #n Leu Asn Gln Asp Glu         1025          #       1030           #      1035 cat tct cac ata att ggt ttg ttg aga gtc at #g aat tat gta gat att     3891 His Ser His Ile Ile Gly Leu Leu Arg Val Me #t Asn Tyr Val Asp Ile     1040              #   1045               #  1050 ggt tgt tca gtt att tca tgt gcc aaa gtt tt #t tcc aga atg ctg gaa     3939 Gly Cys Ser Val Ile Ser Cys Ala Lys Val Ph #e Ser Arg Met Leu Glu 1055                1060 #                1065  #               1070 aca gtc ttt aat tgg caa atg gac tcc aga at #g atg gag tta agg act     3987 Thr Val Phe Asn Trp Gln Met Asp Ser Arg Me #t Met Glu Leu Arg Thr                 1075  #               1080   #              1085 cag agt ttt tcc aac tgg tta aga gat att tg #t tct ggg atc acc att     4035 Gln Ser Phe Ser Asn Trp Leu Arg Asp Ile Cy #s Ser Gly Ile Thr Ile             1090      #           1095       #          1100 ttc aaa aac ttc aag gat gca att tat tgg ct #t tat aca aaa tta atg     4083 Phe Lys Asn Phe Lys Asp Ala Ile Tyr Trp Le #u Tyr Thr Lys Leu Met         1105          #       1110           #      1115 gac ttt tat gaa gtg aat tat ggc aag aag aa #g gac att tta aat att     4131 Asp Phe Tyr Glu Val Asn Tyr Gly Lys Lys Ly #s Asp Ile Leu Asn Ile     1120              #   1125               #  1130 ctt aaa gat aac caa caa aaa ata gag aaa gc #c att gag gaa gcc gat     4179 Leu Lys Asp Asn Gln Gln Lys Ile Glu Lys Al #a Ile Glu Glu Ala Asp 1135                1140 #                1145  #               1150 aaa ttt tgc att ttg caa atc caa gat gtg ga #a aaa tct gaa cag tat     4227 Lys Phe Cys Ile Leu Gln Ile Gln Asp Val Gl #u Lys Ser Glu Gln Tyr                 1155  #               1160   #              1165 cag aaa ggg gtt gac ttg ata caa aaa ttg ag #a act gtt cat tca atg     4275 Gln Lys Gly Val Asp Leu Ile Gln Lys Leu Ar #g Thr Val His Ser Met             1170      #           1175       #          1180 gct cag gtt gat cca aat tta atg gtt cat tt #g tca cct ttg aga gat     4323 Ala Gln Val Asp Pro Asn Leu Met Val His Le #u Ser Pro Leu Arg Asp         1185          #       1190           #      1195 tgt ata gca aga gtt cat cag aaa ctt aaa aa #c ctt gga tct ata aat     4371 Cys Ile Ala Arg Val His Gln Lys Leu Lys As #n Leu Gly Ser Ile Asn     1200              #   1205               #  1210 cag gca atg gta acg aga tgt gag cca gtt gt #t tgt tat ttt tat ggc     4419 Gln Ala Met Val Thr Arg Cys Glu Pro Val Va #l Cys Tyr Phe Tyr Gly 1215                1220 #                1225  #               1230 aaa aga ggg gga gga aag agc tta aca tca at #t gca ttg gca acc aaa     4467 Lys Arg Gly Gly Gly Lys Ser Leu Thr Ser Il #e Ala Leu Ala Thr Lys                 1235  #               1240   #              1245 att tgt aaa cat tat ggt gtt gag cct gaa aa #g aat atc tat act aaa     4515 Ile Cys Lys His Tyr Gly Val Glu Pro Glu Ly #s Asn Ile Tyr Thr Lys             1250      #           1255       #          1260 cct gtg gct tca gat tac tgg gat gga tat ag #t gga caa tta gtt tgc     4563 Pro Val Ala Ser Asp Tyr Trp Asp Gly Tyr Se #r Gly Gln Leu Val Cys         1265          #       1270           #      1275 atc att gat gat att ggc caa aac aca aca ga #t gag gat tgg tca gat     4611 Ile Ile Asp Asp Ile Gly Gln Asn Thr Thr As #p Glu Asp Trp Ser Asp     1280              #   1285               #  1290 ttt tgt cag tta gtg tca gga tgt cct atg ag #a tta aac atg gcc tct     4659 Phe Cys Gln Leu Val Ser Gly Cys Pro Met Ar #g Leu Asn Met Ala Ser 1295                1300 #                1305  #               1310 ctt gag gag aag ggt agg cat ttt tct tct cc #t ttt ata ata gca act     4707 Leu Glu Glu Lys Gly Arg His Phe Ser Ser Pr #o Phe Ile Ile Ala Thr                 1315  #               1320   #              1325 tca aat tgg tca aat cca agt cca aaa aca gt #t tat gtt aag gaa gca     4755 Ser Asn Trp Ser Asn Pro Ser Pro Lys Thr Va #l Tyr Val Lys Glu Ala             1330      #           1335       #          1340 att gac cgc aga ctc cat ttc aag gtt gaa gt #t aaa cct gct tca ttt     4803 Ile Asp Arg Arg Leu His Phe Lys Val Glu Va #l Lys Pro Ala Ser Phe         1345          #       1350           #      1355 ttc aaa aat cct cac aat gat atg ttg aat gt #t aat tta gct aaa aca     4851 Phe Lys Asn Pro His Asn Asp Met Leu Asn Va #l Asn Leu Ala Lys Thr     1360              #   1365               #  1370 aat gat gca atc aaa gat atg tct tgt gtt ga #t ttg ata atg gat gga     4899 Asn Asp Ala Ile Lys Asp Met Ser Cys Val As #p Leu Ile Met Asp Gly 1375                1380 #                1385  #               1390 cat aat gtt tca ttg atg gat ttg ctc agt tc #t tta gtc atg aca gtt     4947 His Asn Val Ser Leu Met Asp Leu Leu Ser Se #r Leu Val Met Thr Val                 1395  #               1400   #              1405 gaa att aga aaa caa aac atg act gaa ttc at #g gag ttg tgg tct cag     4995 Glu Ile Arg Lys Gln Asn Met Thr Glu Phe Me #t Glu Leu Trp Ser Gln             1410      #           1415       #          1420 gga att tca gat gat gat aat gat agt gca gt #a gct gag ttt ttc cag     5043 Gly Ile Ser Asp Asp Asp Asn Asp Ser Ala Va #l Ala Glu Phe Phe Gln         1425          #       1430           #      1435 tct ttt cca tct ggt gaa cca tcg aac tct aa #a tta tct ggc ttt ttc     5091 Ser Phe Pro Ser Gly Glu Pro Ser Asn Ser Ly #s Leu Ser Gly Phe Phe     1440              #   1445               #  1450 caa tct gtt act aat cac aag tgg gtt gct gt #g gga gct gca gtt ggc     5139 Gln Ser Val Thr Asn His Lys Trp Val Ala Va #l Gly Ala Ala Val Gly 1455                1460 #                1465  #               1470 gtt ctt gga gtg ctc gtt gga gga tgg ttt gt #g tat aag cat ttc tcc     5187 Val Leu Gly Val Leu Val Gly Gly Trp Phe Va #l Tyr Lys His Phe Ser                 1475  #               1480   #              1485 cgc aaa gag gaa gaa cca atc cca gct gaa gg #g gta tat tat ggt gta     5235 Arg Lys Glu Glu Glu Pro Ile Pro Ala Glu Gl #y Val Tyr Tyr Gly Val             1490      #           1495       #          1500 act aag ccc aag caa gtg att aaa tta gat gc #a gat cca gta gaa tct     5283 Thr Lys Pro Lys Gln Val Ile Lys Leu Asp Al #a Asp Pro Val Glu Ser         1505          #       1510           #      1515 cag tca act ttg gaa ata gca gga ctg gtt ag #g aag aac ttg gtt cag     5331 Gln Ser Thr Leu Glu Ile Ala Gly Leu Val Ar #g Lys Asn Leu Val Gln     1520              #   1525               #  1530 ttt gga gtt gga gag aag aat gga tgt gtg ag #a tgg gtt atg aat gcc     5379 Phe Gly Val Gly Glu Lys Asn Gly Cys Val Ar #g Trp Val Met Asn Ala 1535                1540 #                1545  #               1550 ttg gga gtg aaa gat gat tgg ctg ctt gtg cc #t tcc cat gct tat aaa     5427 Leu Gly Val Lys Asp Asp Trp Leu Leu Val Pr #o Ser His Ala Tyr Lys                 1555  #               1560   #              1565 ttt gag aaa gat tat gaa atg atg gag ttt ta #t ttt aat aga ggt gga     5475 Phe Glu Lys Asp Tyr Glu Met Met Glu Phe Ty #r Phe Asn Arg Gly Gly             1570      #           1575       #          1580 act tac tat tca att tca gct ggt aat gtt gt #t att caa tct ttg gat     5523 Thr Tyr Tyr Ser Ile Ser Ala Gly Asn Val Va #l Ile Gln Ser Leu Asp         1585          #       1590           #      1595 gtg gga ttc cag gat gtt gtt ctg atg aag gt #t cct aca att cct aag     5571 Val Gly Phe Gln Asp Val Val Leu Met Lys Va #l Pro Thr Ile Pro Lys     1600              #   1605               #  1610 ttt aga gat att act cag cat ttt att aag aa #a ggg gat gtg cct aga     5619 Phe Arg Asp Ile Thr Gln His Phe Ile Lys Ly #s Gly Asp Val Pro Arg 1615                1620 #                1625  #               1630 gct ttg aat cgc ctg gca aca tta gtg aca ac #t gta aat gga acc cct     5667 Ala Leu Asn Arg Leu Ala Thr Leu Val Thr Th #r Val Asn Gly Thr Pro                 1635  #               1640   #              1645 atg tta att tct gag ggc cca cta aag atg ga #a gag aaa gct act tat     5715 Met Leu Ile Ser Glu Gly Pro Leu Lys Met Gl #u Glu Lys Ala Thr Tyr             1650      #           1655       #          1660 gtt cat aag aaa aat gat ggt aca tca gtt ga #t tta act gtg gat cag     5763 Val His Lys Lys Asn Asp Gly Thr Ser Val As #p Leu Thr Val Asp Gln         1665          #       1670           #      1675 gca tgg aga gga aaa ggc gaa ggt ctt cct gg #a atg tgt ggt ggg gcc     5811 Ala Trp Arg Gly Lys Gly Glu Gly Leu Pro Gl #y Met Cys Gly Gly Ala     1680              #   1685               #  1690 ttg gtt tca tcg aat caa tct ata cag aat gc #a atc ttg ggc atc cat     5859 Leu Val Ser Ser Asn Gln Ser Ile Gln Asn Al #a Ile Leu Gly Ile His 1695                1700 #                1705  #               1710 gtt gct gga gga aat tca att ctt gtt gca aa #a ttg gtt act caa gaa     5907 Val Ala Gly Gly Asn Ser Ile Leu Val Ala Ly #s Leu Val Thr Gln Glu                 1715  #               1720   #              1725 atg ttc caa aat att gat aag aaa att gaa ag #t cag aga att atg aaa     5955 Met Phe Gln Asn Ile Asp Lys Lys Ile Glu Se #r Gln Arg Ile Met Lys             1730      #           1735       #          1740 gtg gag ttt act cag tgt tca atg aat gtg gt #c tcc aaa acg ctt ttt     6003 Val Glu Phe Thr Gln Cys Ser Met Asn Val Va #l Ser Lys Thr Leu Phe         1745          #       1750           #      1755 aga aag agt ccc att tat cat cac att gat aa #a acc atg att aat ttt     6051 Arg Lys Ser Pro Ile Tyr His His Ile Asp Ly #s Thr Met Ile Asn Phe     1760              #   1765               #  1770 cct gca gct atg ccc ttt tct aaa gct gaa at #t gat cca atg gct gtg     6099 Pro Ala Ala Met Pro Phe Ser Lys Ala Glu Il #e Asp Pro Met Ala Val 1775                1780 #                1785  #               1790 atg tta tct aag tat tca tta cct att gta ga #a gaa cca gag aat tat     6147 Met Leu Ser Lys Tyr Ser Leu Pro Ile Val Gl #u Glu Pro Glu Asn Tyr                 1795  #               1800   #              1805 aaa gag gct tca att ttt tat caa aat aaa at #a gtg ggt aag act cag     6195 Lys Glu Ala Ser Ile Phe Tyr Gln Asn Lys Il #e Val Gly Lys Thr Gln             1810      #           1815       #          1820 tta gtt gat gat ttt cta gat ctt gat atg gc #c att aca ggg gcc cca     6243 Leu Val Asp Asp Phe Leu Asp Leu Asp Met Al #a Ile Thr Gly Ala Pro         1825          #       1830           #      1835 gga att gat gct atc aac atg gat tca tct cc #t gga ttt cct tat gtc     6291 Gly Ile Asp Ala Ile Asn Met Asp Ser Ser Pr #o Gly Phe Pro Tyr Val     1840              #   1845               #  1850 cag gag aag ttg acc aaa aga gat tta att tg #g ttg gat gaa aat ggt     6339 Gln Glu Lys Leu Thr Lys Arg Asp Leu Ile Tr #p Leu Asp Glu Asn Gly 1855                1860 #                1865  #               1870 tta ttg ctg gga gtt cat cca aga ttg gct ca #g aga atc tta ttc aat     6387 Leu Leu Leu Gly Val His Pro Arg Leu Ala Gl #n Arg Ile Leu Phe Asn                 1875  #               1880   #              1885 act gtc atg atg gaa aat tgt tct gat ttg ga #t gtt gtt ttt aca acc     6435 Thr Val Met Met Glu Asn Cys Ser Asp Leu As #p Val Val Phe Thr Thr             1890      #           1895       #          1900 tgt cca aaa gat gaa ttg aga cca tta gag aa #a gtg ttg gaa tca aaa     6483 Cys Pro Lys Asp Glu Leu Arg Pro Leu Glu Ly #s Val Leu Glu Ser Lys         1905          #       1910           #      1915 aca aga gct att gat gct tgt cct ctg gat ta #c aca att ttg tgc cga     6531 Thr Arg Ala Ile Asp Ala Cys Pro Leu Asp Ty #r Thr Ile Leu Cys Arg     1920              #   1925               #  1930 atg tat tgg ggt cca gct att agt tat ttt ca #t ttg aat cca ggt ttc     6579 Met Tyr Trp Gly Pro Ala Ile Ser Tyr Phe Hi #s Leu Asn Pro Gly Phe 1935                1940 #                1945  #               1950 cat aca ggt gtt gct att ggc ata gat cct ga #t aga cag tgg gat gaa     6627 His Thr Gly Val Ala Ile Gly Ile Asp Pro As #p Arg Gln Trp Asp Glu                 1955  #               1960   #              1965 tta ttt aaa aca atg ata aga ttc gga gat gt #t ggt ctt gat tta gat     6675 Leu Phe Lys Thr Met Ile Arg Phe Gly Asp Va #l Gly Leu Asp Leu Asp             1970      #           1975       #          1980 ttc tct gct ttt gat gct agt ctt agt cca tt #t atg att aga gaa gca     6723 Phe Ser Ala Phe Asp Ala Ser Leu Ser Pro Ph #e Met Ile Arg Glu Ala         1985          #       1990           #      1995 ggt aga atc atg agt gaa cta tct gga act cc #a tcc cat ttt ggc aca     6771 Gly Arg Ile Met Ser Glu Leu Ser Gly Thr Pr #o Ser His Phe Gly Thr     2000              #   2005               #  2010 gct ctt atc aat act atc att tat tcc aag ca #t ttg ctg tat aac tgt     6819 Ala Leu Ile Asn Thr Ile Ile Tyr Ser Lys Hi #s Leu Leu Tyr Asn Cys 2015                2020 #                2025  #               2030 tgt tac cat gtc tgt ggt tca atg ccc tct gg #g tct cct tgt aca gct     6867 Cys Tyr His Val Cys Gly Ser Met Pro Ser Gl #y Ser Pro Cys Thr Ala                 2035  #               2040   #              2045 ttg cta aat tca att att aat aat gtc aat tt #g tac tat gtg ttt tcc     6915 Leu Leu Asn Ser Ile Ile Asn Asn Val Asn Le #u Tyr Tyr Val Phe Ser             2050      #           2055       #          2060 aag ata ttt gga aag tct cca gtt ttc ttt tg #t cag gct ttg aag att     6963 Lys Ile Phe Gly Lys Ser Pro Val Phe Phe Cy #s Gln Ala Leu Lys Ile         2065          #       2070           #      2075 ctc tgt tat gga gat gat gtt tta ata gtt tt #c tct cga gat gtt cag     7011 Leu Cys Tyr Gly Asp Asp Val Leu Ile Val Ph #e Ser Arg Asp Val Gln     2080              #   2085               #  2090 att gat aat ctt gat ttg att gga caa aaa at #t gta gat gag ttt aag     7059 Ile Asp Asn Leu Asp Leu Ile Gly Gln Lys Il #e Val Asp Glu Phe Lys 2095                2100 #                2105  #               2110 aaa ctt ggc atg aca gct act tct gct gac aa #g aat gta cct cag ctg     7107 Lys Leu Gly Met Thr Ala Thr Ser Ala Asp Ly #s Asn Val Pro Gln Leu                 2115  #               2120   #              2125 aaa cca gtt tcg gaa ttg act ttt ctc aaa ag #a tct ttc aat ttg gta     7155 Lys Pro Val Ser Glu Leu Thr Phe Leu Lys Ar #g Ser Phe Asn Leu Val             2130      #           2135       #          2140 gag gat aga att aga cct gca att tcg gaa aa #a aca att tgg tct tta     7203 Glu Asp Arg Ile Arg Pro Ala Ile Ser Glu Ly #s Thr Ile Trp Ser Leu         2145          #       2150           #      2155 ata gca tgg cag aga agt aac gct gag ttt ga #g cag aat tta gaa att     7251 Ile Ala Trp Gln Arg Ser Asn Ala Glu Phe Gl #u Gln Asn Leu Glu Ile     2160              #   2165               #  2170 gct cag tgg ttt gct ttt atg cat ggc tat ga #g ttt tat cag aaa ttt     7299 Ala Gln Trp Phe Ala Phe Met His Gly Tyr Gl #u Phe Tyr Gln Lys Phe 2175                2180 #                2185  #               2190 tat tat ttt gtt cag tcc tgt ttg gag aaa ga #g atg ata gaa tac aga     7347 Tyr Tyr Phe Val Gln Ser Cys Leu Glu Lys Gl #u Met Ile Glu Tyr Arg                 2195  #               2200   #              2205 ctt aaa tct tat gat tgg tgg aga atg aga tt #t tat gac cag tgt ttc     7395 Leu Lys Ser Tyr Asp Trp Trp Arg Met Arg Ph #e Tyr Asp Gln Cys Phe             2210      #           2215       #          2220 att tgt gac ctt tca tgatttgttt aaacgaattt tcttaaaat #t tctgaggttt     7450 Ile Cys Asp Leu Ser         2225 gtttatttct tttatcagta aataaaaaaa aaaaaa       #                   #     7486 <210> SEQ ID NO 6 <211> LENGTH: 2227 <212> TYPE: PRT <213> ORGANISM: Attenuated (4380) HAV, strain HM-1 #75 <400> SEQUENCE: 6 Met Asn Met Ser Arg Gln Gly Ile Phe Gln Th #r Val Gly Ser Gly Leu   1               5  #                 10  #                 15 Asp His Ile Leu Ser Leu Ala Asp Ile Glu Gl #u Glu Gln Met Ile Gln              20      #             25      #             30 Ser Val Asp Arg Thr Ala Val Thr Gly Ala Se #r Tyr Phe Thr Ser Val          35          #         40          #         45 Asp Gln Ser Ser Val His Thr Ala Glu Val Gl #y Ser His Gln Val Glu      50              #     55              #     60 Pro Leu Arg Thr Ser Val Asp Lys Pro Gly Se #r Lys Arg Thr Gln Gly  65                  # 70                  # 75                  # 80 Glu Lys Phe Phe Leu Ile His Ser Ala Asp Tr #p Leu Thr Thr His Ala                  85  #                 90  #                 95 Leu Phe His Glu Val Ala Lys Leu Asp Val Va #l Lys Leu Leu Tyr Asn             100       #           105       #           110 Glu Gln Phe Ala Val Gln Gly Leu Leu Arg Ty #r His Thr Tyr Ala Arg         115           #       120           #       125 Phe Gly Ile Glu Ile Gln Val Gln Ile Asn Pr #o Thr Pro Phe Gln Gln     130               #   135               #   140 Gly Gly Leu Ile Cys Ala Met Val Pro Gly As #p Gln Ser Tyr Gly Ser 145                 1 #50                 1 #55                 1 #60 Ile Ala Ser Leu Thr Val Tyr Pro His Gly Le #u Leu Asn Cys Asn Ile                 165   #               170   #               175 Asn Asn Val Val Arg Ile Lys Val Pro Phe Il #e Tyr Thr Arg Gly Ala             180       #           185       #           190 Tyr His Phe Lys Asp Pro Gln Tyr Pro Val Tr #p Glu Leu Thr Ile Arg         195           #       200           #       205 Val Trp Ser Glu Leu Asn Ile Gly Thr Gly Th #r Ser Ala Tyr Thr Ser     210               #   215               #   220 Leu Asn Val Leu Ala Arg Phe Thr Asp Leu Gl #u Leu His Gly Leu Thr 225                 2 #30                 2 #35                 2 #40 Pro Leu Ser Thr Gln Met Met Arg Asn Glu Ph #e Arg Val Ser Thr Thr                 245   #               250   #               255 Glu Asn Val Val Asn Leu Ser Asn Tyr Glu As #p Ala Arg Ala Lys Met             260       #           265       #           270 Ser Phe Ala Leu Asp Gln Glu Asp Trp Lys Se #r Asp Pro Ser Gln Gly         275           #       280           #       285 Gly Gly Ile Lys Ile Thr His Phe Thr Thr Tr #p Thr Ser Ile Pro Thr     290               #   295               #   300 Leu Ala Ala Gln Phe Pro Phe Asn Ala Ser As #p Ser Val Gly Gln Gln 305                 3 #10                 3 #15                 3 #20 Ile Lys Val Ile Pro Val Asp Pro Tyr Phe Ph #e Gln Met Thr Asn Thr                 325   #               330   #               335 Asn Pro Asp Gln Lys Cys Ile Thr Ala Leu Al #a Ser Ile Cys Gln Met             340       #           345       #           350 Phe Cys Phe Trp Arg Gly Asp Leu Val Phe As #p Phe Gln Val Phe Pro         355           #       360           #       365 Thr Lys Tyr His Ser Gly Arg Leu Leu Phe Cy #s Phe Val Pro Gly Asn     370               #   375               #   380 Glu Leu Ile Asp Val Ser Gly Ile Thr Leu Ly #s Gln Ala Thr Thr Ala 385                 3 #90                 3 #95                 4 #00 Pro Cys Ala Val Met Asp Ile Thr Gly Val Gl #n Ser Thr Leu Arg Phe                 405   #               410   #               415 Arg Val Pro Trp Ile Ser Asp Thr Pro Tyr Ar #g Val Asn Arg Tyr Thr             420       #           425       #           430 Lys Ser Ala His Gln Lys Gly Glu Tyr Thr Al #a Ile Gly Lys Leu Ile         435           #       440           #       445 Val Tyr Cys Tyr Asn Arg Leu Thr Ser Pro Se #r Asn Val Ala Ser His     450               #   455               #   460 Val Arg Val Asn Val Tyr Leu Ser Ala Ile As #n Leu Glu Cys Phe Ala 465                 4 #70                 4 #75                 4 #80 Pro Leu Tyr His Ala Met Asp Val Thr Thr Gl #n Val Gly Asp Asp Ser                 485   #               490   #               495 Gly Gly Phe Ser Thr Thr Val Ser Thr Glu Gl #n Asn Val Pro Asp Pro             500       #           505       #           510 Gln Val Gly Ile Thr Thr Met Lys Asp Leu Ly #s Gly Lys Ala Asn Arg         515           #       520           #       525 Gly Lys Met Asp Val Ser Gly Val Gln Ala Pr #o Val Gly Ala Ile Thr     530               #   535               #   540 Thr Ile Glu Asp Pro Val Leu Ala Lys Lys Va #l Pro Glu Thr Phe Pro 545                 5 #50                 5 #55                 5 #60 Glu Leu Lys Pro Gly Glu Ser Arg His Thr Se #r Asp His Met Ser Ile                 565   #               570   #               575 Tyr Lys Phe Met Gly Arg Ser His Phe Leu Cy #s Thr Phe Thr Phe Asn             580       #           585       #           590 Ser Asn Asn Lys Glu Tyr Thr Phe Pro Ile Th #r Leu Ser Ser Thr Ser         595           #       600           #       605 Asn Pro Pro His Gly Leu Pro Ser Thr Leu Ar #g Trp Phe Phe Asn Leu     610               #   615               #   620 Phe Gln Leu Tyr Arg Gly Pro Leu Asp Leu Th #r Ile Ile Ile Thr Gly 625                 6 #30                 6 #35                 6 #40 Ala Thr Asp Val Asp Gly Met Ala Trp Phe Th #r Pro Val Gly Leu Ala                 645   #               650   #               655 Val Asp Thr Pro Trp Val Glu Lys Glu Ser Al #a Leu Ser Ile Asp Tyr             660       #           665       #           670 Lys Thr Ala Leu Gly Ala Val Arg Phe Asn Th #r Arg Arg Thr Gly Asn         675           #       680           #       685 Ile Gln Ile Arg Leu Pro Trp Tyr Ser Tyr Le #u Tyr Ala Val Ser Gly     690               #   695               #   700 Ala Leu Asp Gly Leu Gly Asp Lys Thr Asp Se #r Thr Phe Gly Leu Val 705                 7 #10                 7 #15                 7 #20 Ser Ile Gln Ile Ala Asn Tyr Asn His Ser As #p Glu Tyr Leu Ser Phe                 725   #               730   #               735 Ser Cys Tyr Leu Ser Val Thr Glu Gln Ser Gl #u Phe Tyr Phe Pro Arg             740       #           745       #           750 Ala Pro Leu Asn Ser Asn Ala Met Leu Ser Th #r Val Thr Met Met Ser         755           #       760           #       765 Arg Ile Ala Ala Gly Asp Leu Glu Ser Ser Va #l Asp Asp Pro Arg Ser     770               #   775               #   780 Glu Glu Asp Lys Arg Phe Glu Ser His Ile Gl #u Cys Arg Lys Pro Tyr 785                 7 #90                 7 #95                 8 #00 Lys Glu Leu Arg Leu Glu Val Gly Lys Gln Ar #g Leu Lys Tyr Ala Gln                 805   #               810   #               815 Glu Glu Leu Ser Asn Glu Val Leu Pro Pro Pr #o Arg Lys Met Lys Gly             820       #           825       #           830 Leu Phe Ser Gln Ala Lys Ile Ser Leu Phe Ty #r Thr Glu Glu His Glu         835           #       840           #       845 Ile Met Lys Phe Ser Trp Arg Gly Val Thr Al #a Asp Thr Arg Ala Leu     850               #   855               #   860 Arg Arg Phe Gly Phe Ser Leu Ala Ala Gly Ar #g Ser Val Trp Thr Leu 865                 8 #70                 8 #75                 8 #80 Glu Met Asp Ala Gly Val Leu Thr Gly Arg Le #u Ile Arg Leu Asn Asp                 885   #               890   #               895 Glu Lys Trp Thr Glu Met Lys Asp Asp Lys Il #e Val Ser Leu Ile Glu             900       #           905       #           910 Lys Phe Thr Ser Asn Lys Tyr Trp Ser Lys Va #l Asn Phe Pro His Gly         915           #       920           #       925 Met Leu Asp Leu Glu Glu Ile Ala Ala Asn Se #r Lys Asp Phe Pro Asn     930               #   935               #   940 Met Ser Glu Thr Asp Leu Cys Phe Leu Leu Hi #s Trp Leu Asn Pro Lys 945                 9 #50                 9 #55                 9 #60 Lys Ile Asn Leu Ala Asp Arg Met Leu Gly Le #u Ser Gly Val Gln Glu                 965   #               970   #               975 Ile Lys Glu Gln Gly Val Gly Leu Ile Ala Gl #u Cys Arg Thr Phe Leu             980       #           985       #           990 Asp Ser Ile Ala Gly Thr Leu Lys Ser Met Me #t Phe Gly Phe His His         995           #       1000           #      1005 Ser Val Thr Val Glu Ile Ile Asn Thr Val Le #u Cys Phe Val Lys Ser     1010              #   1015               #  1020 Gly Ile Leu Leu Tyr Val Ile Gln Gln Leu As #n Gln Asp Glu His Ser 1025                1030 #                1035  #               1040 His Ile Ile Gly Leu Leu Arg Val Met Asn Ty #r Val Asp Ile Gly Cys                 1045  #               1050   #              1055 Ser Val Ile Ser Cys Ala Lys Val Phe Ser Ar #g Met Leu Glu Thr Val             1060      #           1065       #          1070 Phe Asn Trp Gln Met Asp Ser Arg Met Met Gl #u Leu Arg Thr Gln Ser         1075          #       1080           #      1085 Phe Ser Asn Trp Leu Arg Asp Ile Cys Ser Gl #y Ile Thr Ile Phe Lys     1090              #   1095               #  1100 Asn Phe Lys Asp Ala Ile Tyr Trp Leu Tyr Th #r Lys Leu Met Asp Phe 1105                1110 #                1115  #               1120 Tyr Glu Val Asn Tyr Gly Lys Lys Lys Asp Il #e Leu Asn Ile Leu Lys                 1125  #               1130   #              1135 Asp Asn Gln Gln Lys Ile Glu Lys Ala Ile Gl #u Glu Ala Asp Lys Phe             1140      #           1145       #          1150 Cys Ile Leu Gln Ile Gln Asp Val Glu Lys Se #r Glu Gln Tyr Gln Lys         1155          #       1160           #      1165 Gly Val Asp Leu Ile Gln Lys Leu Arg Thr Va #l His Ser Met Ala Gln     1170              #   1175               #  1180 Val Asp Pro Asn Leu Met Val His Leu Ser Pr #o Leu Arg Asp Cys Ile 1185                1190 #                1195  #               1200 Ala Arg Val His Gln Lys Leu Lys Asn Leu Gl #y Ser Ile Asn Gln Ala                 1205  #               1210   #              1215 Met Val Thr Arg Cys Glu Pro Val Val Cys Ty #r Phe Tyr Gly Lys Arg             1220      #           1225       #          1230 Gly Gly Gly Lys Ser Leu Thr Ser Ile Ala Le #u Ala Thr Lys Ile Cys         1235          #       1240           #      1245 Lys His Tyr Gly Val Glu Pro Glu Lys Asn Il #e Tyr Thr Lys Pro Val     1250              #   1255               #  1260 Ala Ser Asp Tyr Trp Asp Gly Tyr Ser Gly Gl #n Leu Val Cys Ile Ile 1265                1270 #                1275  #               1280 Asp Asp Ile Gly Gln Asn Thr Thr Asp Glu As #p Trp Ser Asp Phe Cys                 1285  #               1290   #              1295 Gln Leu Val Ser Gly Cys Pro Met Arg Leu As #n Met Ala Ser Leu Glu             1300      #           1305       #          1310 Glu Lys Gly Arg His Phe Ser Ser Pro Phe Il #e Ile Ala Thr Ser Asn         1315          #       1320           #      1325 Trp Ser Asn Pro Ser Pro Lys Thr Val Tyr Va #l Lys Glu Ala Ile Asp     1330              #   1335               #  1340 Arg Arg Leu His Phe Lys Val Glu Val Lys Pr #o Ala Ser Phe Phe Lys 1345                1350 #                1355  #               1360 Asn Pro His Asn Asp Met Leu Asn Val Asn Le #u Ala Lys Thr Asn Asp                 1365  #               1370   #              1375 Ala Ile Lys Asp Met Ser Cys Val Asp Leu Il #e Met Asp Gly His Asn             1380      #           1385       #          1390 Val Ser Leu Met Asp Leu Leu Ser Ser Leu Va #l Met Thr Val Glu Ile         1395          #       1400           #      1405 Arg Lys Gln Asn Met Thr Glu Phe Met Glu Le #u Trp Ser Gln Gly Ile     1410              #   1415               #  1420 Ser Asp Asp Asp Asn Asp Ser Ala Val Ala Gl #u Phe Phe Gln Ser Phe 1425                1430 #                1435  #               1440 Pro Ser Gly Glu Pro Ser Asn Ser Lys Leu Se #r Gly Phe Phe Gln Ser                 1445  #               1450   #              1455 Val Thr Asn His Lys Trp Val Ala Val Gly Al #a Ala Val Gly Val Leu             1460      #           1465       #          1470 Gly Val Leu Val Gly Gly Trp Phe Val Tyr Ly #s His Phe Ser Arg Lys         1475          #       1480           #      1485 Glu Glu Glu Pro Ile Pro Ala Glu Gly Val Ty #r Tyr Gly Val Thr Lys     1490              #   1495               #  1500 Pro Lys Gln Val Ile Lys Leu Asp Ala Asp Pr #o Val Glu Ser Gln Ser 1505                1510 #                1515  #               1520 Thr Leu Glu Ile Ala Gly Leu Val Arg Lys As #n Leu Val Gln Phe Gly                 1525  #               1530   #              1535 Val Gly Glu Lys Asn Gly Cys Val Arg Trp Va #l Met Asn Ala Leu Gly             1540      #           1545       #          1550 Val Lys Asp Asp Trp Leu Leu Val Pro Ser Hi #s Ala Tyr Lys Phe Glu         1555          #       1560           #      1565 Lys Asp Tyr Glu Met Met Glu Phe Tyr Phe As #n Arg Gly Gly Thr Tyr     1570              #   1575               #  1580 Tyr Ser Ile Ser Ala Gly Asn Val Val Ile Gl #n Ser Leu Asp Val Gly 1585                1590 #                1595  #               1600 Phe Gln Asp Val Val Leu Met Lys Val Pro Th #r Ile Pro Lys Phe Arg                 1605  #               1610   #              1615 Asp Ile Thr Gln His Phe Ile Lys Lys Gly As #p Val Pro Arg Ala Leu             1620      #           1625       #          1630 Asn Arg Leu Ala Thr Leu Val Thr Thr Val As #n Gly Thr Pro Met Leu         1635          #       1640           #      1645 Ile Ser Glu Gly Pro Leu Lys Met Glu Glu Ly #s Ala Thr Tyr Val His     1650              #   1655               #  1660 Lys Lys Asn Asp Gly Thr Ser Val Asp Leu Th #r Val Asp Gln Ala Trp 1665                1670 #                1675  #               1680 Arg Gly Lys Gly Glu Gly Leu Pro Gly Met Cy #s Gly Gly Ala Leu Val                 1685  #               1690   #              1695 Ser Ser Asn Gln Ser Ile Gln Asn Ala Ile Le #u Gly Ile His Val Ala             1700      #           1705       #          1710 Gly Gly Asn Ser Ile Leu Val Ala Lys Leu Va #l Thr Gln Glu Met Phe         1715          #       1720           #      1725 Gln Asn Ile Asp Lys Lys Ile Glu Ser Gln Ar #g Ile Met Lys Val Glu     1730              #   1735               #  1740 Phe Thr Gln Cys Ser Met Asn Val Val Ser Ly #s Thr Leu Phe Arg Lys 1745                1750 #                1755  #               1760 Ser Pro Ile Tyr His His Ile Asp Lys Thr Me #t Ile Asn Phe Pro Ala                 1765  #               1770   #              1775 Ala Met Pro Phe Ser Lys Ala Glu Ile Asp Pr #o Met Ala Val Met Leu             1780      #           1785       #          1790 Ser Lys Tyr Ser Leu Pro Ile Val Glu Glu Pr #o Glu Asn Tyr Lys Glu         1795          #       1800           #      1805 Ala Ser Ile Phe Tyr Gln Asn Lys Ile Val Gl #y Lys Thr Gln Leu Val     1810              #   1815               #  1820 Asp Asp Phe Leu Asp Leu Asp Met Ala Ile Th #r Gly Ala Pro Gly Ile 1825                1830 #                1835  #               1840 Asp Ala Ile Asn Met Asp Ser Ser Pro Gly Ph #e Pro Tyr Val Gln Glu                 1845  #               1850   #              1855 Lys Leu Thr Lys Arg Asp Leu Ile Trp Leu As #p Glu Asn Gly Leu Leu             1860      #           1865       #          1870 Leu Gly Val His Pro Arg Leu Ala Gln Arg Il #e Leu Phe Asn Thr Val         1875          #       1880           #      1885 Met Met Glu Asn Cys Ser Asp Leu Asp Val Va #l Phe Thr Thr Cys Pro     1890              #   1895               #  1900 Lys Asp Glu Leu Arg Pro Leu Glu Lys Val Le #u Glu Ser Lys Thr Arg 1905                1910 #                1915  #               1920 Ala Ile Asp Ala Cys Pro Leu Asp Tyr Thr Il #e Leu Cys Arg Met Tyr                 1925  #               1930   #              1935 Trp Gly Pro Ala Ile Ser Tyr Phe His Leu As #n Pro Gly Phe His Thr             1940      #           1945       #          1950 Gly Val Ala Ile Gly Ile Asp Pro Asp Arg Gl #n Trp Asp Glu Leu Phe         1955          #       1960           #      1965 Lys Thr Met Ile Arg Phe Gly Asp Val Gly Le #u Asp Leu Asp Phe Ser     1970              #   1975               #  1980 Ala Phe Asp Ala Ser Leu Ser Pro Phe Met Il #e Arg Glu Ala Gly Arg 1985                1990 #                1995  #               2000 Ile Met Ser Glu Leu Ser Gly Thr Pro Ser Hi #s Phe Gly Thr Ala Leu                 2005  #               2010   #              2015 Ile Asn Thr Ile Ile Tyr Ser Lys His Leu Le #u Tyr Asn Cys Cys Tyr             2020      #           2025       #          2030 His Val Cys Gly Ser Met Pro Ser Gly Ser Pr #o Cys Thr Ala Leu Leu         2035          #       2040           #      2045 Asn Ser Ile Ile Asn Asn Val Asn Leu Tyr Ty #r Val Phe Ser Lys Ile     2050              #   2055               #  2060 Phe Gly Lys Ser Pro Val Phe Phe Cys Gln Al #a Leu Lys Ile Leu Cys 2065                2070 #                2075  #               2080 Tyr Gly Asp Asp Val Leu Ile Val Phe Ser Ar #g Asp Val Gln Ile Asp                 2085  #               2090   #              2095 Asn Leu Asp Leu Ile Gly Gln Lys Ile Val As #p Glu Phe Lys Lys Leu             2100      #           2105       #          2110 Gly Met Thr Ala Thr Ser Ala Asp Lys Asn Va #l Pro Gln Leu Lys Pro         2115          #       2120           #      2125 Val Ser Glu Leu Thr Phe Leu Lys Arg Ser Ph #e Asn Leu Val Glu Asp     2130              #   2135               #  2140 Arg Ile Arg Pro Ala Ile Ser Glu Lys Thr Il #e Trp Ser Leu Ile Ala 2145                2150 #                2155  #               2160 Trp Gln Arg Ser Asn Ala Glu Phe Glu Gln As #n Leu Glu Ile Ala Gln                 2165  #               2170   #              2175 Trp Phe Ala Phe Met His Gly Tyr Glu Phe Ty #r Gln Lys Phe Tyr Tyr             2180      #           2185       #          2190 Phe Val Gln Ser Cys Leu Glu Lys Glu Met Il #e Glu Tyr Arg Leu Lys         2195          #       2200           #      2205 Ser Tyr Asp Trp Trp Arg Met Arg Phe Tyr As #p Gln Cys Phe Ile Cys     2210              #   2215               #  2220 Asp Leu Ser 2225 

What is claimed is:
 1. An isolated DNA molecule encoding a hepatitis A virus adapted to growth in MRC-5 cells, said molecule having a nucleotide sequence which corresponds to the cDNA sequence of HAV HM-175 Pass 35 (SEQ ID NO: 3) except for nucleotide positions 591 and 687 which have guanines as bases, nucleotide position 646 which has an adenine as a base and nucleotide position 669 which has a thymine as a base, and optionally at least one nucleotide selected from the group consisting of: (a) T at position 2750; (b) A at position 3027; (c) A at position 3196; (d) G at position 3934; (e) I at position 4418; (f) G at position 4563; (g) T at position 4643; (h) G at position 5145; (i) T at position 5745; (j) C at position 6908; (k) T at position 7032; (l) T at position 7255; wherein the nucleotide numbers shown above are those assigned to positions of the wild-type HM-175 sequence.
 2. The DNA molecule of claim 1, wherein the additional nucleotide is at least one of the nucleotides (e) through (g).
 3. The DNA molecule of claim 1, wherein the additional nucleotides are (e) through (g).
 4. The DNA molecule of claim 1, wherein no additional nucleotides are selected.
 5. An expression vector comprising the DNA molecule of any one claim selected from claims 1-4.
 6. A host cell containing the DNA molecule of any one claim selected from claims 1-4.
 7. An RNA transcript of the DNA molecule of any one claim selected from claims 1-4.
 8. A host cell containing the RNA transcript of claim
 7. 9. A method of producing a hepatitis A virus comprising transfecting cells with the DNA molecule of any one claim selected from claims 1-4.
 10. A method of producing a hepatitis A virus comprising transfecting cells with the RNA transcript of claim
 7. 